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ABSTRACT 
Nuclear pre-mRNA splicing occurs within a multicomponent complex, the 
spliceosome, which is formed by the ordered assembly of small nuclear 
ribonucleoprotein particles (snRNPs), and a host of other protein factors. The PRP2 
protein of Saccharomyces cerevisiae is a non-snRNP factor required for the first 
cleavage-ligation step of the nuclear pre-mRNA splicing reaction. It is not required 
for early stages of complex assembly, but associates transiently with spliceosomes 
prior to and throughout step 1. PRP2 is a member of the DEAD/DEAH box family 
of putative RNA helicases and has been shown to possess RNA-dependent ATPase 
activity. The highly transient association of PRP2 with spliceosomes has hindered 
biochemical studies of the interactions of this protein, and therefore a genetic 
approach, which has been used successfully to study protein-protein interactions in 
other systems, was adopted. The principle behind this approach is that mutations in 
the PRP2 gene that confer a dominant negative phenotype (ie. causing a dominant 
inhibitory effect over the wild-type) may do so by preventing release of PRP2 from 
splicing complexes. Stalled spliceosomes containing non-functional PRP2 would 
accumulate, facilitating genetic and biochemical analyses of this interaction. 
From a pool of randomly generated PRP2 mutants, one dominant negative 
allele, PRP2-dnl, was isolated that caused a decline in cell growth rate when 
overexpressed in a wild-type yeast strain. Cell growth inhibition was presumably the 
result of the observed defect in pre-mRNA splicing, and was partially alleviated by 
simultaneous co-overexpression of wild-type PRP2. Analysis of cell-free splicing 
extracts demonstrated that overproduction of the mutant protein, PRP2dI,  inhibited 
splicing in vitro, causing the progressive accumulation of inactive splicing complexes. 
Immunoprecipitation with anti-PRP2 antibodies confirmed that, in contrast to WT 
PRP2, PRP2` protein was indeed strongly associated with spliceosomes. The results 
are consistent with a scenario in which PRP2 dn' protein competes with its wild-type 
counterpart for entry into spliceosomes, with which it remains associated, 
sequestering essential splicing factors. Use of this system to trap PRP2 within its 
spliceosomal "pocket" provides a powerful genetic tool for the identification of factors 
with which PRP2 interacts. 
In addition to this exciting result, the PRP2-dnl mutation was shown to cause 
a single amino acid change within the highly conserved helicase motif, SAT, known 
to be required for RNA unwinding in the prototype helicase eIF-4A. This is the first 
time that the functional importance of these residues has been demonstrated in any 
U 
other member of the DEAD/H putative helicase family. In order to assess the effect 
of the PRP2-dnl mutation on the RNA-dependent ATPase activity of PRP2, a simple 
2-step procedure for the purification of wild-type and mutant forms of PRP2 protein 
was developed. RNA-dependent ATPase activity of purified PRP2` protein was 
reduced but not abolished. By analogy with the helicase eIF-4A, the dominant 
negative phenotype of PRP2dI may be due to a primary defect in RNA unwinding, 
reduced ATP hydrolysis being a secondary effect. 
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1.1 RNA Splicing. 
The revolutionary discovery that many eukaryotic transcripts are 
interrupted by non-coding sequences, led to the suggestion in 1977 that these regions, 
termed introns, were removed by a process of RNA splicing (reviewed by Witowski, 
1988). At the Cold Spring Harbour Symposium on Quantitative Biology in that year, 
investigators of viral transcription presented direct evidence for the existence of 
introns. Viral early transcripts, previously noted to be longer than the late mRNAs, 
were shown to form large RNA displacement loops when hybridised to the 
corresponding cDNA. To explain this, it was proposed that these intervening 
sequences were excised accurately from the precursor RNA via a series of cleavage 
and ligation reactions; the joining of adjacent coding regions (exons) forming the 
mature transcript. This was shown to be the case, and the accepted phenomenon of 
pre-mRNA splicing soon led to the explanation of a variety of systems with non-
coding regions including the chick ovalbumin gene, mouse and rabbit globin genes, 
and genes encoding yeast tRNAs. 
Research to elucidate the actual mechanism, sequence requirements, and trans-
acting factors involved in splicing led to the definition of four distinct classes of 
introns: 
tRNA introns - Spliced by a unique mechanism, unlike any of the other 
classes (Peebles et al., 1979). 
Group I introns - The mechanism by which this class is spliced was first 
elucidated for the pre-rRNA of Tetrahymena. Splicing of this highly structured intron 
was found to be RNA catalysed, occurring in the absence of proteins or ATP; only 
magnesium ions and guanosine were necessary. Later, other members of this group 
were found in Physarum and mitochondnal pre-mRNA of several species of fungi 
(reviewed in Cech and Bass, 1986). 
Group II introns - Also include highly structured autocatalytic introns, 
differing from group I introns with respect to secondary structure and sequence. This 
class has been found in fungal mitochondrial and chloroplast genes. The splicing 
mechanism of both groups I and II is discussed in Cech and Bass 1986. 
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4) Nuclear pre-mRNA introns - Despite basic mechanistic similarities between 
groups I, II, and nuclear pre-mRNA intron splicing, the process by which nuclear 
introns are removed is by far the most complex, and in contrast requires energy 
derived from ATP hydrolysis. It involves the association of the pre-mRNA with an 
array of trans-acting components including small nuclear ribonucleoprotein particles 
(snRNPs), and a host of other protein factors to form a multicomponent complex, the 
spliceosome, within which the reaction takes place (for reviews see Padget et al., 
1986; Sharp, 1987; Green, 1991). Extensive participation of trans-acting factors 
provides important implications for the use of RNA splicing in the post-translational 
control of gene expression through the employment of alternative splicing factors. 
Nuclear pre-mRNA splicing has been studied most extensively in 
mammals and S. cerevisiae (yeast), therefore results obtained through analyses of these 
systems will be the subject of this review. The development of in vitro splicing 
systems which reliably splice a well defined substrate (Kramer et al., 1984; Lin et 
al., 1985), and the use of sophisticated yeast genetics (reviewed in Beggs and 
Plumpton, 1992) has led to rapid progress in our understanding of this highly 
complex and stringently regulated process. Perhaps the most striking advances during 
the last two years of research, have been in the elucidation of dynamic RNA:RNA 
interactions that form the framework of the catalytically active spliceosome (reviewed 
in Moore et al., 1993). Predicted to be responsible for driving these interactions are 
a group of putative RNA helicases required at distinct stages of the reaction 
(Wasserman and Steitz, 1991). Although a number of important questions remain 
unanswered, the continuous elucidation of physical and functional links between 
components of the spliceosome is yielding a detailed portrait of the pre-mRNA 
splicing process. 
1.2 The Mechanism of Splicing. 
Branched RNA molecules detected in poly-adenylated RNA from Hela nuclei 
(Wallace and Edmonds, 1983) were later shown to be amongst the intermediates and 
products generated during the splicing process both in vitro (Padgett et al., 1984; 
Ruskin etal., 1984; Lin etal., 1985) and in vivo (Domdey etal., 1984; Zeitlin and 
Efstradiatis 1985). This evidence, and the discovery that cleavage at the 5'end of the 
intron (the 5' splice-site) preceded cleavage at the 3' end (the 3' splice site) (Kramer 
et al., 1984), led to the formulation of a two-step splicing pathway (figure 1.1) now 
believed to be responsible for the removal of all nuclear pre-mRNA introns. 
In the first step of the reaction, the pre-mRNA is cleaved at the 5' splice site 
to generate the intermediates; free exon one with a 3' hydroxyl group, and intron-
exon two in the form of a branched structure. This "lariat" intermediate is the result 
of an unusual 2'- 5' phosphodiester bond formed between the 5' end of the intron and 
an adenosine residue near the 3' end. In yeast, this branch-point is formed at the most 
3' A residue of an invariant UACUAAC sequence (Domdey et al., 1984). Step two 
involves cleavage at the 3' splice site and simultaneous ligation of the exons giving 

















Figure 1.1: The Pre-mRNA Splicing Reaction: The reaction occurs via two 
sequential transesterification reactions, step 1 and step 2. Reactive phosphates (p) and 
hydroxyl groups (OH) are shown, dotted arrows indicate nucleophilic attack. 
Conserved yeast intron sequences at the 5' and 3' splice sites and branch point are 
shown. El and E2 represent the 5' and 3' exons, IVS indicates the intron. 
Although nuclear pre-mRNA splicing is an ATP requiring process, none of 
the phosphates present in the reaction products are derived from exogenous AT?; the 
splice site phosphates are conserved in the products (Padgett et al., 1984; Lin et al., 
1985). For this reason, and the fact that phosphodiester bond cleavage and formation 
K. 
are never uncoupled, the reaction is believed to occur via two sequential 
transesterification reactions. Thus, step one involves nucleophilic attack by the 2'-OH 
of the branch point adenosine residue on the phosphate of the 5' splice site. Step two 
then occurs via nucleophilic attack on the phosphate of the 3' splice site by the 3'-OH 
of the linear exon one. The observation that autocatalytic group II introns are 
removed via the same two-step pathway as that of nuclear introns led to the proposal 
that the two are evolutionarily and mechanistically related (Cech, 1985; Sharp, 1985). 
This link between self-splicing and nuclear introns, and the importance of small 
nuclear RNA-containing snRNPs in splicing, forms the basis of the widely held belief 
that pre-mRNA splicing is also RNA catalysed. In this view, the ATP requirement 
of nuclear splicing is solely required for the spliceosome assembly cycle; the snRNPs 
and other trans-acting factors "replacing", in an evolutionary sense, the cis-acting, 
highly structured group II intron. Indeed, a number of essential splicing factors are 
known, or are presumed to be, RNA dependent ATPases (Schwer and Guthrie, 1991; 
Kim et al., 1992 and references therein. 
1.3 Splicing in Yeast and Mammals. 
Mammalian and yeast introns differ with respect to size, conserved primary 
sequence elements, and prevalence within genes, and their respective genomes. 
S.cerevisiae introns are generally much smaller than those of mammals; they are 
usually less than 400bp (Rymond and Rosbash, 1993) and no examples of the gigantic 
introns commonly seen in metozoa have been found in yeast. Mammalian genes often 
contain multiple introns whereas all the known yeast intron-containing genes harbour 
only one, and this is usually located at the 5' end of the primary sequence. The 
MATa1 gene, which contains two small introns (Miller, 1984) is an exception. 
Cis-acting sequences at the 5' splice site, and in particular, at the branch 
point, are less stringently conserved in mammalian introns. Presumably, this sequence 
degeneracy provides a more flexible system permitting the use, by mammals, of 
alternative splice sites which can be differentially selected in a tissue- or sex-specific 
manner. Thus splicing is an important factor in cell differentiation and development 
in higher eukaryotes. No examples of alternative splice site usage in yeast are known. 
The flexibility of the mammalian splicing system has been demonstrated in vitro; 
mammalian splicing extracts will remove introns from yeast and plant transcripts 
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(Ruskin et al., 1986; Brown et al., 1986). Yeast however, will not splice mammalian 
transcripts (Beggs et al., 1980; Langford et al., 1983). 
The frequency of introns in the S. cerevisiae genome is significantly lower than 
that in many other eukaryotes. Even the fission yeast S.ponthe has at least half of its 
genes interrupted (Potashkin et al., 1989) whereas a recent survey of nuclear encoded 
S. cerevisiae gene sequences revealed that only 3-5% of these were intron-containing 
(Rymond and Rosbash, 1993). There are two possible explanations for this lack of 
introns, and this relates to the unresolved arguement concerning the origin and 
evolution of introns: either the early progenitor of yeast and other eukaryotes 
contained many introns, and in the case of S. cerevisiae these have been lost, or, the 
progenitor contained few introns (similar to the modern S.cerevisiae), and higher 
eukaryotes have acquired their present complement through intron gain, perhaps by 
the insertion of transposable elements (Cavalier-Smith, 1985). The former model of 
intron loss as the principal mechanism is supported by the strong selection pressure 
on unicellular organisms for a short cell cycle; superfluous transcript length, and 
unnecessary RNA processing would be disadvantageous. Indeed, unicellular 
organisms generally possess fewer introns than higher eukaryotes. If S. cerevisiae has 
"lost" its original introns, then those that remain must either provide a selective 
advantage, or be difficult to remove. The first possibility has been investigated by 
testing the function of a cDNA version of the S. cerevisiae actin gene (Ng,R., et al., 
1995). A strain constructed to contain an intronless actin gene grew normally, 
suggesting that the intron served no essential function. In addition, only a few yeast 
introns have been shown to serve a regulatory function (Reviewed in Rymond and 
Rosbash, 1993). That the "remaining" yeast introns might prove "difficult to remove" 
was suggested by Fink (1987) to be due to their strong tendency to lie at the 5' end 
of transcription units, and the high level of reverse transcriptase activity in yeast. 
Fink (1987) proposed that yeast introns have been "removed" by homologous 
recombination events with cDNA copies of mature transcripts. Thus, incomplete 
cDNA synthesis and/or inefficient homologous recombination (due to insufficient 
complementarity at the 5' end) would lead to the persistence of intervening sequences 
at the 5' end of these genes. 
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1.4 Cis-acting Determinants of Splicing. 
In contrast to group I and group II introns, nuclear introns lack conserved 
structural features; minimal cis-acting sequences are sufficient for their definition and 
accurate excision. Identified through sequence comparisons of both yeast and 
mammalian introns, the role of these cis-acting elements has been further illuminated 
through the introduction of mutations, and the testing of mutant constructs in the 
appropriate in vivo or in vitro system. 
Three sequence elements that define the intron have been distinguished; the 
5' and 3' splice sites, and the branch point sequence (BPS) at which the 2'-5' 
phosphodiester link of the lariat is formed. Initial comparisons of mammalian intron 
sequences (Breathnach, 1978) revealed invariant dinucleotides GT and AG at the 5' 
and 3' ends respectively. Later it was shown that these sequences could be extended 
(Mount, 1982). The yeast consensus sequences differ slightly to those found in 
mammals, and are more highly conserved (Guthrie et al., 1986). A recent sequence 
comparison of these conserved regions from mammalian and S. cerevisiae introns is 
shown below (figure 1.2). 
1.4.1 The 5' Splice Site. 
Extensive comparison of viral and nuclear protein encoding genes (Mount, 
1982) led to the formulation of a 5' splice site concensus; AG/GURAGU (I denotes 
cleavage site). In higher eukaryotes, mutations within this sequence not only affect 
the activity of the authentic site, but also lead to the activation of 'cryptic' or 
alternative sites (Green, 1986). This phenomenon is frequently caused by naturally 
occurring mutations in globin genes, leading to the production of aberrant or 
truncated globins resulting in Thalassemias (reviewed in Treisman, 1983). Analyses 
of the effects of mutations at the invariant GU nucleotides of a (3-globin intron, both 
in vivo and in vitro (Aebi et al., 1986, 1987) demonstrated that many changes were 
compatible with 5' splice site cleavage, however would completely abrogate step two 
leading to the accumulation of lariat intermediates. 
Mutation of the yeast 5' splice site, which as demonstrated in figure 1.2 is 
more highly conserved, generally abolishes splicing, however, as observed in 
mammalian systems, some mutations, particularly at the GU dinucleotide, cause 
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5' Splice Site Consensus 
S. cerevisiae 	R74 I G100 T98 A% T89 G loo T94  
Mammalian 	(379 / G100 T100 R93 A74 G85  Y66  
Branch Point Consensus 
S.cerevisiae 	T 	A98 C100 T100 A1  Aioo C100 A74 
Mammalian 	Y89 N Y83  T69 R79 Aoo C72 N 
3' Splice site consensus 
S.cerevisiae 	Y98 A100 G100  
Mammalian 	C76  A100 G100  
Note: N= A,C,G,T; R= A,G; Y= CJ 
Subscripts refer to the percent representation of the indicated nucleotide in 
each position. The presumptive site of lariat formation is underlined in the 
branch point consensus. The S.cerevisiae consensus sequences were derived 
from the comparison of 54 introns. Consensus sequences for Mammalian 
introns were derived from sequence collections of between 50 and 170 
introns compiled in a recent study by Rymond and Rosbash, (1993). 
Figure 1.2: Comparison of Intron Consensus Sequences or 
S.cerevisiae and Mammals. 
aberrant cleavage events leading to the accumulation of 'dead-end' lariat intermediates 
(Newman et al., 1985; Fouser and Friesen, 1986; Jacquier and Rosbash 1986; 
Vijayraghaven et al., 1986). The importance of the conserved G5 nucleotide has been 
demonstrated as changes at this position can lead to aberrant 5' cleavage at 
nucleotides residing either upstream or downstream of the authentic 5' splice site 
(Parker and Guthrie, 1985; Fouser and Frieson, 1986). 
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1.4.2 The Branch Point and 3' Splice Site. 
Deletion analysis revealed the requirement for an element in the 3' portion of 
yeast introns (Pikielny, 1983), leading to the identification of the absolutely conserved 
branch point sequence (BPS), TACTAAC, located 20-60 bps upstream of the 3' splice 
site. Most mutations at this sequence abolish splicing completely, however, some 
changes have been shown to cause aberrant cleavage events leading to the 
accumulation of lariat intermediates (Fouser and Friesen, 1986; Jacquier and Rosbash, 
1986; Vijayraghaven et al., 1986). The high frequency with which mutations at either 
the 5' splice site (Aebi et al., 1986, 1987), or at the branch site, allow lariat 
formation to proceed but effect a total block of the second step in splicing, relates to 
the ability of the spliceosome to 'proof-read' the branch structure of the lariat prior 
to the second step. 
Initial searches for an analogous 'branch point' sequence in mammalian 
introns yielded a much less stringently conserved version (YNYIJRAY), (Keller and 
Noon, 1984; Reed and Maniatis, 1984). Later however, a more extensive sequence 
comparison revealed a mammalian BPS consensus matching much more closely to 
that of yeast; UNCURAC, (a current edition of this is shown in figure 1.2.) That the 
mammalian branch site also appears to be conserved is in keeping with the fact that 
both mammalian and yeast branch sites base pair with a complementary sequence in 
the snRNA component of the trans-acting U2 snRNP (section 1.5.2.3). Despite this, 
deletion of the human (-globin intron BPS activated the use of cryptic branch sites 
with few sequence constraints other than the branch site always formed at an 
adenosine residue, which was positioned within 22-37 nucleotides upstream of the 3' 
splice site (Ruskin et al., 1985). The importance of sequence context surrounding the 
adenosine branch residue has been demonstrated however, by conducting cis-
competition assays using an RNA precursor carrying a duplicated BPS/3' splice site 
region and from which all other cryptic branch sites had been removed (Reed and 
Maniatis, 1988). Deletions and single base changes at the internal BPS dramatically 
decreased the efficiency of splicing in vitro, and altered 3'splice site selection in vivo. 
These effects on splicing efficiency are paralleled by analogous mutations in yeast 
suggesting that the branch site plays a similar role in both systems. 
Although the 3' splice site in yeast simply consists of the final AG 
dinucleotide of the intron (figure 1.2), in mammals, it was initially defined as a run 
of pyrimidine nucleotides, (the polypyrimidine tract), followed by NYAG (Mount et 
al., 1982). The distance from the branch site to the 3' splice site AG is typically 20- 
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40 nucleotides in both yeast and mammals (Green, 1986; Padgett et al., 1986), and 
if the 3' splice site dinucleotide is mutated, the next downstream AG is recruited 
(Reed and Maniatis, 1985; Aebi a al., 1986; Reed, 1989). 
Due to the position of the polypyrimidine tract in mammalian introns, it was 
originally assumed that it played a role in 3' splice site selection. Contrary to this 
belief, analysis of the functional organisation of the sequences at the 3' end of 
mammalian introns by Reed (1989) has clarified its influence on branchpoint 
definition; maximum efficiency of lariat formation was only achieved when a 
pyrimidine stretch was located immediately downstream of the BPS. Interestingly, 
when the yeast actin intron was spliced in a Hela cell nuclear extract, a cryptic 
branchsite adjacent to a pyrimidine rich sequence was used (Ruskin et al., 1986). In 
addition, adenosine residues in a mammalian intron which had suitable polypyrimidine 
stretches downstream and yet were not used as branch points, were activated when 
converted to the strong yeast branchpoint consensus (Smith et al., 1989). These 
observations underline the strong influence of the polypyrimidine tract on branch site 
selection, and therefore, at first glance, demonstrate a major difference between 
mammalian and yeast splicing, as the latter does not require a polypyrimidine tract. 
The studies by Reed, (1989) combined with more recent work by Patterson and 
Guthrie (1991) shed some light on this difference between systems. From her in vitro 
analyses of intron sequence requirements, Reed (1989) was able to define two distinct 
classes of mammalian introns. The first class consists of introns that absolutely 
require the 3' AG for the first step to proceed, and these possess a polypyrimidine 
tract shorter than 14 nucleotides. The second class have longer pyrimidine stretches 
adjacent to the BPS and can undergo the first step in the absence of the 3' 
dinucleotide. Thus, these have been termed AG-dependent and AG-independent 
introns respectively. This phenomenon might be explained by the fact that in 
mammals, a number of splicing factors have been isolated that bind to the 
polypyrimidine tract, and require an adjacent 3' splice site for efficient binding (see 
section 1.5.2.2). Thus a long pyrimidine tract may stabilise the interaction of these 
factors with the pre-mRNA, compensating for the distal location of the 3' AG. 
Patterson and Guthrie (1991) demonstrated that in yeast, U-rich tracts can increase 
usage of a distal 3' splice site suggesting a role for pynmidine rich sequences in 
yeast. Therefore, polypyrimidine binding proteins analogous to those in mammals 
may also be present in yeast. 
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1.5 Trans-acting Factors - The Spliceosome Cycle. 
Broadly, the trans-acting factors involved in pre-mRNA splicing can be 
divided into two categories, the snRNPs, which form the main body of the 
spliceosome, and other protein factors that are not stably associated with a particular 
snRNP. A large variety of biochemical and genetic methods (and powerful 
combinations of these approaches) have been employed to identify, and understand 
the role of these factors in splicing (for reviews see LUhrmann et al., 1990; Guthrie, 
1991; Green, 1991; Ruby and Abelson, 1991; Brown et al., 1992), These will be the 
focus of this main section of the review. Finally, a model to summmarise our current 
knowledge of the cyclic interaction of these factors with the pre-mRNA to effect the 
process of RNA splicing is shown diagrammatically in figure 1.8. For clarification, 
it may be advantageous to refer to figure 1.8 throughout this section of the review. 
1.5.1 The Involvement of sñRNPs in Splicing. 
The four snRNPs involved in splicing, Ui, U2, U4/U6, and U5 are the best 
studied of the trans-acting factors and are considered the major determinants of intron 
definition. SnRNPs have been most extensively studied in mammalian cells in which 
they are highly abundant(10 5-106 copies per cell) (reviewed in LUhrmann, 1990). Each 
snRNP is composed of a characteristic set of proteins associated with one, or, in the 
case of U4/U6, two uradil-rich small nuclear RNAs after which the particle is named. 
Within the single U4/U6 particle, the U4 and U6 snRNAs are directly associated 
through Watson Crick base-pairing (Bringmann et al., 1984). In addition to proteins 
that are specifically associated with a particular snRNP, a core set of structural 
polypeptides are common to all snRNPS. To date, nine mammalian core proteins 
designated B, B' ,D 1 , D2 , D3 , E, F, G and G' have been identified. Several of the core 
snRNP proteins possess "Sm" epitopes; antigenic determinants of antibodies produced 
by patients with the autoimmune disorder systemic lupus erythematosis (Lerner and 
Steitz, 1979). Using 'anti-Sm' sera produced by these patients, immunoprecipitation 
assays demonstrated that yeast snRNPs contain cross- reactive polypeptides (Siliciano 
et al., 1987; Tollervey and Mattaj, 1987). This implies that at least some of the core 
peptides are conserved in yeast, however, only one yeast core protein has been 
identified to date. The yeast SMD1 gene, cloned by virtue of its close proximity to 
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the PRP38 locus, encodes a protein predicted to be 40% identical to the mammalian 
D1 protein. In vivo depletion of the yeast protein abolishes the first step of splicing 
and results in reduced levels of Ui, U2, U4, US but not U6 snRNAs (Rymond, 
1993). 
With the exception of U6, characteristic features of the mammalian snRNA 
molecules are a conserved single stranded sequence motif (RAUGR) termed the Sm-
binding site with which the core proteins interact (Mattaj, 1986), and a unique 2,2,7-
trimethyl guanosine (M3G) cap structure present at their 5' ends. 
Yeast spliceosomal snRNAs evaded identification for a number of years due 
to their low abundance, (only 10-500 copies per cell; Wise et al., 1983) and the 
relatively large number of distinct snRNA species (many of which are non-essential) 
that exist in yeast compared to mammalian cells (reviewed in Guthrie, 1986). 
Eventually, the essential, single copy genes encoding homologues of the mammalian 
Ui, U2, U4, U5 and U6 snRNAs were cloned and identified by virtue of their limited 
primary sequence and secondary structural similarity to the corresponding metazoan 
RNAs. Like their mammalian counterparts, the yeast Ui, U2, U4 and U5 snRNAs 
were shown to be M3G-capped (Wise et al., 1983), and to possess an Sm-binding site 
consensus motif. The anti-Sm precipitabiity of the yeast snRNAs demonstrated their 
association with proteins in the form of snRNPs. 
Mammalian snRNP specific proteins have been identified by purification of 
snRNPs from Hela extracts using either biochemical or immunological fractionation 
methods (reviewed in Lührmann, 1990). Ui snRNP possesses three specific peptides 
A, C and 70k; U2 possesses five, A' and B', and U2 factors with apparent molecular 
weights of 60, 66, and i20kD have recently been identified (Behrens et al., 1993). 
For US at least eight have so far been identified; one of the US specific proteins, 
p220, is the presumptive homologue of the yeast US specific protein PRP8 (Anderson 
et al., (1989); Garcia-Blanco et al., 1990). 
The yeast SNP1 gene, which encodes the putative homologue of the 
mammalian U1-70k protein was randomly identified through sequencing of the yeast 
chromosome IX (Smith and Barrell, 1990). Regions of greatest identity between SNP  
and U1-70k include glycine rich regions and an RNA recognition motif (RRM); the 
overall amino acid identity is 30%. Significantly, Kao and Siliciano (1992) 
demonstrated that an SNP1-fusion protein produced in E.coli specifically binds to a 
47 nucleotide region of the metozoan Ui snRNA that corresponds to the U1-70k 
binding site. Using a genetic screen to identify yeast factors that interact with the Ui 
snRNA, Liao et al. (1993) cloned the MUD1 gene which encodes a protein with 
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significant similarity to the mammalian U1A protein. The MIJD1 and WA proteins 
each contain two RRMs separated by a spacer region of similar length, and their 
functional similarity was revealed by the demonstration that Ui snRNA was co-
immunoprecipitated using a monoclonal antibody directed against epitope-tagged 
MUD  protein. Surprisingly, the MUD1 gene is non-essential, and is not required for 
splicing in vitro. Six additional snRNP specific proteins have been identified using 
other genetic screens in yeast (PRP8, PRP3, PRP4,PRP6 and PRP18), and are 
described in section 1.5.3.1. 
The initial proposal for snRNP involvement in splicing stemmed from the 
observed compiementarity between the 5' terminus of the U  snRNA and the 5' splice 
site (Lerner, 1980; Rogers and Wall, 1980). This gave rise to the hypothesis that Ui, 
and the other snRNPs might contribute to splice site definition. Such an important 
proposal fuelled experiments to confirm the requirement of the snRNPS in splicing, 
including targeted nuclease digestion and antibody inhibition experiments. Initially, 
anti-Sm and anti-M3G antibodies were shown to abolish the activity of mammalian 
splicing extracts (Padgett et al., 1983; Kramer et al., 1984). Kramer (1984) also 
demonstrated that removal of the 5' end of the Ui snRNA using a complementary 
oligodeoxynucleotide to target RNase H cleavage, abolished splicing in vitro. An 
essential role for the yeast homologue of the mammalian Ui snRNA was 
demonstrated by Kretzner, (1987); incubation of yeast splicing extracts (which possess 
endogenous RNase H activity (Rymond and Rosbash, 1986)) with oligonucleotides 
complementary to the 5' end of the metozoan Ui snRNA abolished splicing activity 
in vitro. Similar targeted nuclease digestion experiments demonstrated the requirement 
for the U2, U4 and U6 snRNAs in both yeast and mammalian systems. This method 
could not be applied to the US snRNA as it is resistant to nucleases (Chabot et al., 
1985). However, this problem was overcome by using the powerful approach of in 
vivo depletion employing a yeast strain containing a single copy of the U5 gene 
(SNR7), under the control of the GALl repressible/inducible promoter (Patterson and 
Guthrie, 1987). Growth of this strain under repressing conditions led to the 
accumulation of unspliced pre-mRNAs in vivo indicating the requirement for US 
snRNA in splicing. 
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1.5.2 Spliceosome Assembly. 
An ordered pathway of spliceosome assembly was originally defined by 
observing the kinetics of complex formation during mammalian and yeast in vitro 
splicing reactions. Distinct complexes were resolved using various native gel 
electrophoresis systems, and analysed to identify the RNA species that they contained 
(Konarska and Sharp, 1986, 1987; Pilcielny et al., 1986, Cheng and Abelson, 1987). 
In both yeast and mammalian in vitro systems, the order in which the snRNPs 
assemble onto the pre-mRNA is conserved; initially Ui binds at the 5' splice site, 
followed by U2 which interacts at the BPS. Finally U4/U6 and U5 snRNPs enter in 
the form of a pre-assembled tri-snRNP. 
A vast array of experimental techniques have been applied to understand the 
composition, structure and function of the spliceosome. Biochemical approaches 
include inhibition of splicing in vivo and in vitro using antibodies, oligo-directed 
RNase H cleavage of snRNAs, and biochemical fractionation and complementation. 
Genetic approaches, described in section 1.5.3 have been particularly fruitful, leading 
to the identification of splicing factors and providing clues concerning dynamic RNA 
interactions within the fully assembled spliceosome. 
1.5.2.2 Association of the Ui snRNP - Commitment Complex Formation. 
The interaction of Ui snRNP at the 5' splice site was first verified through 
RNase Ti protection experiments demonstrating that the 5' splice site was selectively 
protected by Ui snRNP in an ATP-independent fashion (Mount et al., 1983). Since 
this interaction, which occurred readily even at 0 °C, was protease sensitive, Ui 
snRNP protein components were also implicated in 5' splice site recognition. Indeed, 
more recently Heinrichs et al., (1990) showed that the 5' splice site binding activity 
of purified Ui snRNPs that had been chromatographically depleted of the Ui specific 
protein C, could only be restored by the addition of purified protein C. 
Consistent with original proposals, a Watson Crick base pairing interaction 
between the 5' end of the Ui snRNA and the 5' splice site has been demonstrated 
through elegant genetic experiments in both mammalian and yeast cells (Figure 1.3B; 
Zuang and Weiner, (1986); Seraphin et al. ,(i988); Siliciano and Guthrie (1988). 
They showed that the splicing defect caused by certain single point mutations at the 
5' splice site of suitable intron-containing transcripts could be suppressed by the 
introduction of compensatory changes in the 5' end of the Ui snRNA, which restored 
the postulated snRNA-pre-mRNA base pairing. Interestingly, not all of the 5' splice 
site mutations could be rescued by compensatory changes in the Ui snRNA, 
suggesting that although the base pairing interaction of Ui snRNA with the 5' splice 
site is essential, it is not sufficient for 5' splice site selection. This implies that 5' 
splice site specificity is determined in at least two steps: (i) by an initial base pairing 
with the Ui snRNP that determines a recognition "window" within which the splice 
site is specified; (ii) this is followed by a second interaction, with another factor (or 
factors) that precisely defines the exact phosphodiester bond to be cleaved. It is 
possible that the Ui snRNP may have already departed at the time of the second 
interaction (see below). Newman and Norman (1991, 1992) have produced impressive 
evidence that the highly conserved loop I of US snRNA may contribute to this second 
interaction (section 1.5.4.1). 
Surprisingly, the ATP-independent association of the Ui snRNP with pre-
mRNA, originally demonstrated by Mount et al., (1993), could not be detected during 
initial studies of spliceosome assembly using native gel electrophoresis and affinity 
chromatography. The first splicing specific complex to appear in the systems of 
Grabowski and Sharp, (1986), Konarska and Sharp, (1986), and Pikielny et al., 
(1986), contained only U2. This was soon explained by Bindereif and Green (1987), 
who showed that the interaction of Ui with splicing complexes is extremely sensitive 
to salt concentration. Using low stringency conditions, they isolated functional 
splicing complexes containing Ui, together with U2, U4/U6 and U5 snRNPs. The 
altered native gel electrophoresis conditions of Zillman et al., (1988), also 
demonstrated that Ui is a stable component of spliceosomes. The observed lability 
of the interaction between Ui and the spliceosome may represent a weakened 
association, perhaps following a conformational change caused by an ATP-dependent 
RNA unwinding event resulting in the melting of the bonds between Ui snRNA and 
the 5' splice site region. An excellent candidate for this activity is the PRP5 protein, 
a putative RNA helicase (see section 1.5.5) which is required for U2 binding, the first 
ATP-requiring step of splicing. Indeed Liao et al., (1992) have demonstrated that in 
yeast, a mutation in the 5' end of the Ui snRNA which disrupts its base pairing with 
the pre-mRNA 5' splice site allows some U2 snRNP addition to bypass the ATP 
requirement. The simplest interpretation of this phenomenon is that complexes 
containing the mutant Ui snRNA have a reduced requirement for the ATP-dependent 
helicase activity. Thus the Ui mutation may permit a conformational change that 
normally requires ATP (Liao et al., 1992). 
In yeast, several studies to investigate the early requirements for spliceosome 
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assembly led to the conclusion that the interaction of Ui snRNP with pre-mRNA 
precedes the entry of all other snRNPs. Legrain et al., (1988) demonstrated the 
formation of a stable complex containing labelled pre-mRNA substrates in extracts 
depleted of U2 snRNP through oligonucleotide-directed RNAse H cleavage of U2 
snRNAs. These were dubbed "commitment complexes", as entry of pre-mRNA into 
these structures could not be reversed by subsequent addition of excess unlabelled 
pre-mRNA, and they could be chased into active spliceosomes by the addition of fully 
active extract. Confirmation that the Ui snRNP plays a major role in commitment 
was demonstrated by Seraphin and Rosbash (1989). They used yeast splicing extracts 
depleted in vivo, (through transcriptional regulation), of either Ui or U2 snRNAs. In 
extracts depleted of Ui snRNA and incubated under splicing conditions, complex 
formation could not be detected. In extracts depleted of U2 snRNA however, two 
distinct complexes (CC1 and CC2) formed in an ATP-independent manner and were 
resolved using native gel electrophoresis. Both complexes were shown to contain Ui 
snRNP, and were commitment competent; upon addition of Ui-depleted extract, they 
were chased into active spliceosomes containing spliced mRNA product even 
following the addition of excess competitor RNA. 
The formation of commitment complexes described by Legrain et al., (1988) 
required not only an intact 5' splice site but also a UACUAAC sequence. Consistent 
with this observation, formation of CC2 in the system of Seraphin and Rosbash 
(1989) was dependent on the presence of both an intact 5' splice site, and BPS. These 
data in combination, suggest that early acting factors, other than the U2 snRNP, 
interact with the branchpoint region prior to U2 snRNP binding. Like Ui snRNP, 
these must be required to commit a pre-mRNA molecule to the splicing pathway. 
Alternatively, Ui itself might recognise the BPS prior to U2 addition. 
In mammals, ATP-independent complexes proposed to be analogous to the 
yeast commitment complexes have also been identified. Michaud and Reid (1991), 
purified an ATP-independent complex (designated "E" for early) from mammalian 
extracts using gel filtration chromatography. Complex E, which could form on 
substrates lacking either a 5' or 3' splice site, was shown to be a functional 
intermediate of in vitro spliceosome assembly, and w4 commitment competent. In 
contrast to yeast CC1 and CC2 however, complex E was shown to contain both Ui 
and U2 snRNPs, although U2 was not bound as stably as the Ui snRNP. More 
recently, an additional ATP-independent commitment complex containing only bound 
Ui snRNP has been characterised by Jamison et al,. (1992). In order to test which 
of the pre-mRNA cis-acting elements were required for formation of this complex, 
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they developed an assay involving the pre-incubation of Hela cell nuclear extracts 
with excess unlabelled mutant or WT competitor pre-mRNAs. The ability of the cis-
acting sequences, present in competitor RNAs, to sequester essential early factors, 
and thus prevent commitment complex formation upon subsequent addition of labelled 
WT pre-mRNA was then determined. If the ability of mutant competitor RNAs to 
bind early factors was abolished, then commitment complexes would form on the WT 
labelled RNA. They demonstrated that extracts pre-incubated with competitor RNAs 
carrying mutations in either the 3' splice site, 5' splice site, or to a lesser extent, 
within the polypyrimidine tract, formed stable commitment complexes on a labelled 
WT substrate, whereas extracts pre-incubated with excess WT RNAs did not. This 
indicated a role for the 5' splice site, 3' splice site, and polypyrimidine tract in the 
formation of mammalian commitment complexes. 
The proposed requirement for the 3' cis-acting elements in mammalian 
commitment complex assembly can, as with yeast, best be explained by the 
interaction of protein factors at these regions prior to U2 snRNP addition. Several 
likely candidates for this role include a number of mammalian factors shown to 
specifically bind the polypyrimidine tract with varying requirement for an adjacent 
3' splice site in an ATP-independent manner. These include U2 accessory factor 
(U2AF; Ruskin etal., 1988), pyrimidine tract binding protein (PTB; Gerke and Steitz, 
1986; Tazi etal., 1986), and hnRNP proteins Al, C, and D (Swanson and Dreyfuss, 
1988). 
Another explanation, would be the interaction between Ui snRNA and 
nucleotides not only at the 5' splice site but also at the 3' intron terminus. This would 
provide a simple method to juxtapose the two cleavage sites at an early stage. Genetic 
evidence to support such a model has recently been reported by Reich et al., (1992), 
using an engineered intron in the fission yeast Schizosaccharomyces ponibe which 
requires a 3'AG dinucleotide to facilitate lariat formation, thus typifying the AG-
dependent class of mammalian introns (defined in section 1.4.2). They demonstrated 
that the first step block in splicing exhibited by strains carrying mutations within the 
3'AG dinucleotide of the AG-dependent intron, was partially suppressed by the 
introduction of compensatory base changes at the conserved nucleotides C 7 or U8 in 
the S. pombe Ui snRNA. This led to th' attractive hypothesis shown in figure 1.3A 
in which U  acts as a bridge to physically hold together the two splice sites. In yeast 
and mammals, the corresponding positions of the conserved C7 U8 nucleotides of 
S.ponibe Ui are C9 and UlO, due to a 2 nucleotide truncation at the 5' end of the 
molecule. Although this model fits perfectly the original observations of 
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FIGURE 1.3 
A Model for Base Pairing Between Ul snRNA and the 3' Splice Site During 
Commitment of an AG-Dependent intron of Schizosaccharomyces pombe. 
An AG-independent intron of S.pombe is depicted (IVS). 5' and 3' splice site 
consensus motifs (lower case) of the intron (IVS) and their proposed base pairing to 
nucleotides 1-8 of S.pombe Ui (upper case) are shown. 
Interactions of Ui and U2 with Pre-mRNA. 
Ui and U2 snRNAs interact directly with the pre-mRNA. Base pairing interactions 
Ui to 5' splice site and U2 to branch point are indicated, the consensus intron and 
snRNA sequences are those of S.cerevisiae. Interaction of U2 effectively bulges out 
the branch site adenosine residue A whose 2' hydroxyl initiates the reaction. The 
phylogenetically conserved stem loop I of U2 snRNA is depicted. The dotted arrow 
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complementarity, between Ui snRNA and the 5' and 3' termini of introns thus 
juxtaposing the presumed reactive elements (Lerner et al. 1980; Rogers and Wall 
1980), a very recent study has shown that this U1-3' splice site interaction is not 
phylogenetically conserved (Kandels-Lewis and Seraphin, 1993). These investigators 
demonstrated that in S.cerevisiae the conserved Ui residues C9 and UlO were not 
required for viability, and analysis of a variety of pre-mRNAs in vivo indicated that 
accurate 3'splice site recognition did not require this base pairing event. 
1.5.2.3 Formation of the Pre-spliceosome - Association of U2 snRNP. 
Subsequent to the formation of a commitment complex, the U1 snRNP 
promotes binding of the U2 snRNP to form a complex commonly referred to as the 
pre-spliceosome. The precise mechanism by which this takes place is not fully 
understood, however, whereas the formation of commitment complexes is slow and 
ATP-independent, transition to the pre-spliceosome (or complex "A" in the 
mammalian native gel system of Konarska and Sharp, 1986), is fast and ATP-
dependent (Liao et al., 1992). Thus, U2 snRNP addition is the first ATP-requiring 
step in spliceosome assembly. 
In yeast, addition of the U2 snRNP requires both the 5' splice site and Ui 
snRNP (Ruby and Abelson, 1988; Seraphin and Rosbash, 1989), however in 
mammals, pre-spliceosome formation can occur in the absence of an intact 5' splice 
site (Frendeway and Keller, 1985; Konarska and Sharp, 1986; Bindereif and Green, 
1987) but does require Ui snRNP (Zillman, 1988). This phenomenon was 
investigated by Barabino et al., (1990) using Hela extracts that were either depleted 
of Ui snRNP, or contained Ui snRNPs "masked" at the 5' end of the snRNA using 
antisense oligoribonucleotide probes. Pre-spliceosomes were not formed in Ui-
depleted extracts, however in extracts in which the interaction of Ul snRNP with the 
5' splice site was blocked, complex formation was observed. Thus, an ill-defined 
chemical interaction between Ui and U2 snRNPs is required to promote stable 
association of the latter with complexes. 
The original proposal by Keller and Noon (1984) that U2 snRNP base pairs 
with the conserved intron BPS was confirmed in both yeast and mammals. Initially, 
RNase protection studies conducted by Black et al., (1985) demonstrated an 
association between U2 snRNP and the BPS-containing region of the intron. 
Additional evidence for this interaction was presented by Barabino et al., (1989) who 
demonstrated that an anti-sense oligoribonucleotide probe directed against the region 
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of U2 that is complementary to the intron BPS inhibited splicing. Evidence that the 
interaction involved direct base pairing was gained through in vivo suppression 
experiments in both mammalian and yeast systems (Parker et al., 1987; Zhuang and 
Weiner, 1989; Wu and Manley, 1989). 
Since not all compensatory mutations in U2 snRNAs were able to suppress the 
splicing defect caused by respective BPS mutations, the requirement for other entities 
in addition to Watson and Crick base pairing was indicated. Indeed, a number of 
mammalian factors required for U2 snRNP additon have been identified. Partially 
purified U2 snRNP was shown to be unable to interact with its target RNA sequence 
(Ruskin et al., 1988) leading to the identification of a U2 snRNP auxiliary factor 
required for the specific interaction of U2 snRNP with the mammalian BPS. Other 
mammalian factors required for U2 snRNP binding include SC-35, originally 
identified as an antigenic determinant of purified spliceosomes (Fu and Maniatis 1990, 
1992), and factors SF1 and SF3 (Kramer et al., 1987; Kramer, 1988; Kramer and 
Utans, 1991). Yeast factors so far demonstrated to be required for U2 addition are 
the putative RNA helicase PRP5 (whose possible role at this point is described 
above), and the PRP9 protein (Abovich et al., 1990; Ruby and Abelson, 1991). 
Abovich et al. (1990) demonstrated that in a mutant pip9 yeast strain, commitment 
complexes accumulated at the expense of spliceosomes. 
1.5.2.4 Formation of the Mature Spliceosome - Addition of U4/U6 and U5 snRNPs. 
Transition of the pre-spliceosome to a mature complex within which the 
splicing reaction is catalysed involves entry of the U4/U6 and US snRNPs. Several 
lines of evidence suggest that they enter in the form of a U41U6.U5 tri-snRNP. In 
both yeast and Hela extracts, U5 and U4/U6 snRNPs exist in a single complex, 
independent of the spliceosome, as observed by native gel electrophoresis, (Cheng 
and Abelson, 1987; Konarska and Sharp, 1987), and formation of the tri-snRNP 
requires the addition of ATP (Lossky et al., 1987). More recently it has been shown 
that in vivo depletion of U5 snRNA in yeast, prevents the association of U4/U6 with 
other spliceosomal components (Seraphin et al., 1991). The same effect is observed 
in vitro when mammalian extracts are depleted of US snRNA (Lamm et al., 1991). 
Several RNA-RNA interactions have been proposed to occur upon entry of the 
tri-snRNP and include those between U2 and U6 snRNAs (section 1.5.4.2), and 
between US nucleotides and exon sequences adjacent to both 5' and 3' splice sites. 
The latter interaction may persist following step 1 and could be important for actually 
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specifying the 5' cleavage site (section 1.5.4.1). The most well studied RNA-RNA 
interaction is the extensive base pairing between the U4 and U6 snRNAs resulting in 
a structure comprising of two helices, stems I and II (figure 1.4A; Shannon and 
Guthrie, 1991). 
Various native gel electrophoresis systems demonstrated that the assembly of 
the complex containing Ui, U2, US and U4/U6 snRNPs was followed by the 
formation of an active complex which did not contain U4 snRNA (Pikielny et al., 
1986; Cheng and Abelson, 1987; Lamond et al., 1988). This suggested that the U4 
snRNP but not U6 dissociates prior to step 1. Yean and Lin (1991) utilised a 
temperature-sensitive prp2 yeast mutant, which is defective for the first step of 
splicing, to isolate stalled complexes which lacked U4. These complexes could be 
chased into active spliceosomes only upon addition of PRP2 protein in the absence 
of U4, demonstrating that U4 is not required for the splicing reaction itself. In other 
systems however, analysis of purifed spliceosomes has shown that U4 may be 
associated with active complexes (Reed et al., 1988; Ruby and Abelson, 1988; 
Whittaker et al., 1990). Indeed, using a modified antisense oligoribonucleotide probe 
specifically directed against U4 snRNA, Blencowe et al., (1989) affinity selected 
complexes containing excised intron product indicating the presence of U4 in post 
splicing complexes. Together these results imply that the U4-U6 interaction is 
destabilised prior to step 1, and that like Ui, U4 is 'lost' under certain fractionation 
conditions. 
The destabilisation of U4 from U6 has been proposed to play a role in the 
catalytic activation of the spliceosome (Brow and Guthrie, 1989; Guthrie 1989). In 
this model, the U4 snRNA acts as a negative antisense regulator 'of U6 snRNA 
preventing catalysis at inappropriate times. This catalytic role of U6 in splicing is 
supported by its extreme phylogenetic conservation (it has the most highly conserved 
primary sequence of all spliceosomal snRNAs; Brow and Guthrie, 1988). In additon, 
extensive mutagenesis has defined two invarient sequences of U6 (ACAGAGA and 
ACG; figurel .4A) in which deletion or mutation cause either lethal, or conditional 
lethal phenotypes in vivo (Madhani et al., 1990) or differentially block the first or 
second step of splicing in vitro (Fabrizio and Abelson, 1990). Madharn et al., (1990) 
also demonstrated that the deleterious effects of certain mutations in U6 cannot be 
complemented by predicted compensatory changes in U4 snRNA suggesting additional 
functions for certain nucleotides of the U6 snRNA. 
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FIGURE 1.4 
The U4-U6 Complex. 
The U4 and U6 snRNAs are shown base paired together at stem I and stem II as in 
the U4/U6 particle. For simplicity, only those bases mentioned in the text are shown. 
Sequences and numbering are according to the S.cerevisiae snRNAs. Suppression of 
the cold sensitive U4 G14 to C mutation by mutations in prp24 is indicated by the 
dotted arrow. C38, G40, G43 and G91 are recessive mutations in U6 which suppress 
the U4 G14C cold sensitive mutation, and have been postulated to define binding sites 
for the PRP24 protein (Shannon and Guthrie, 1991). Mutations affecting boxed 
residues in U6 result in conditional lethal phenotypes in vivo, and block in vitro 
splicing reactions at either the first or second step (Fabrizio and Abelson, 1990) 
Interaction of U5 Stem loop I with exon nucleotides. 
Bases of loop I that are absolutely conserved between S. cerevisiae and the known 
sequences of other organisms are shown. Interactions with exon nucleotides are 
indicated by dotted lines, and the exon nucleotide demonstrated to crosslink to U5 
snRNA loop I residue U5 when changed to the crosslinking reagent 4-thiouridine is 
depicted. The loop I mutation U6 to A was isolated by Newman and Norman (1991) 
as a suppressor of the intron mutation Gi to A. El and E2 represent the 5' and 3' 
exons, P/S the intron. 
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1.5.3 Yeast Genetics - Identifying and Linking up the Components of the 
Spliceosome. 
Due to the complexity of the splicing apparatus, the most rapid progress in our 
understanding of eukaryotic pre-mRNA splicing has undoubtedly been achieved 
through the application of molecular and classical yeast genetics. The isolation of a 
wide spectrum of splicing mutants has provided the opportunity to arrest the 
spliceosome cycle at many distinct stages which can then be analysed biochemically. 
This has been particularly valuable for assessing the activities occurring within the 
fully assembled spliceosome; these subtle, final adjustments which allow both steps 
of the reaction to proceed, cannot be resolved using native gel electrophoresis 
systems. 
As splicing is an essential process, conditional (such as heat- or cold-sensitive) 
mutations have been most commonly sought, facilitating propagation at the permissive 
temperature. Once the affected genes have been cloned and characterised (with 
relative ease in yeast), they have often been used as the basis for other genetic screens 
to identify components which physically or functionally interact. The most widely 
used method is the isolation of trans-acting extragenic suppressor mutations. Others 
include the isolation of high copy-number or dosage suppressors, and the 
identification of synergistic mutations. These genetic approaches offer alternatives to 
biochemical studies which may not easily identify low abundance factors, especially 
where interactions are only transient. Suppressors of mutations in cis-acting elements 
(conserved intron sequences), or in genes encoding trans-acting factors (SNR and PRP 
genes) have provided exciting new insights into the mechanism of splice site 
recognition, and spliceosome composition and assembly. 
1.5.3.1 Isolation and Characterisation of Conditional Splicing Mutants. 
Astonishingly, the first conditional pre-mRNA splicing mutants were 
fortuitously isolated ten years preceding the discovery of splicing itself. In a genetic 
screen which isolated temperature-sensitive mutants thought to be defective in RNA 
metabolism, ten complementation groups (ma 2-11) were shown to specifically block 
ribosome biosynthesis (Hartwell, 1967; Hartwell et al., 1970). Later it was revealed 
that this phenotype was in fact a secondary effect of a primary defect in pre-mRNA 
splicing as a result of the disproportionally large number of intron-containing 
ribosomal protein genes in S.cerevisiae (Rosbash et al., 1981; Lustig et al., 1986). 
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Therefore, these mutants were re-named prp for precursor RNA Processing. Lustig 
et al., (1986) demonstrated that splicing extracts prepared from prp2, p,p3,  p,p4, 
prp5, prp8, and prpll mutants could be heat-inactivated in vitro. This defect could 
be alleviated by the addition of inactivated extracts prepared from a different mutant 
strain, indicating that the heat lability was due to the specific inactivation of an 
exchangeable splicing factor, the product of the particular PRP gene (Lustig et al., 
1986). In a companion study, Lin et al., (1987) analysed complex formation during 
incubations of labelled pre-mRNA with these heat-inactivated extracts. They 
demonstrated that in all except the prp2 extract, spliceosomes were not formed, 
therefore an involvement of these PRP factors in early stages of spliceosome assembly 
was indicated. In contrast, complexes containing unspliced pre-inRNA were 
assembled in p,p2  heat-inactivated extracts, and the transcript could be chased into 
products and intermediates by the addition of heat-treated extracts derived from other 
mutant strains. Thus, PRP2 is required for the first cleavage ligation step, but is not 
involved in the early stages of complex assembly (Lin et al., 1987). 
Vijayraghavan et al., (1989) identified another set of genes whose products 
are involved in pre-mRNA splicing. They screened a pool of 750 temperature-
sensitive yeast strains by Northern blot analysis using an intron-containing probe, and 
isolated a further eleven complementation groups (prpl 7-27) that affect various stages 
of the splicing pathway. In an attempt to identify novel splicing mutants, Strauss and 
Guthrie (1991) sought cold-sensitive splicing mutants. Mutational defects affecting 
macromolecular assembly are often enhanced at low temperature, possibly because 
assembly processes involve largely hydrophobic interactions and therefore are 
particularly sensitive to cold (Cantor and Schimmel, 1980). From a pool of 18 cold-
sensitive mutants, one was isolated that accumulated pre-mRNA at the restrictive 
temperature of 16 °C. Thus the PRP28 gene was identified. 
Sequence Analysis: 
Many of the PRP genes have been cloned by complementing the temperature 
sensitivity of the mutant strains with yeast genomic plasmid DNA libraries, all are 
single-copy, essential genes that encode proteins (for references and current complete 
list see Moore et al., 1993). DNA sequence analysis of the PRP genes has revealed 
a variety of protein motifs shared by these factors, helping to shed some light on 
possible roles played by certain PRP proteins during splicing. The most prevalent 
collection of motifs, common to five PRP factors (PRP2, PRP5, PRP16, PRP22 and 
PRP28) are those that are shared by related families of putative ATP-dependent RNA 
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helicases (see section 1.5.5). As will be revealed in section 1.5.4, the dynamic nature 
of the spliceosome provides ample opportunity for the action of ATP-dependent RNA 
helicases at various stages of spliceosome assembly, and the splicing reaction itself. 
Zinc finger-like sequences have been found in PRP2, PRP6, SLU7 (see below) 
PRP1 1 and PRP9. Variants of this structure are commonly found in nucleic acid 
binding proteins (Berg, 1986), and for the PRP factors, may facilitate either 
protein:protein or protein:RNA interactions. The gene products of PRP4 and PRP1 7 
bear a striking resemblance to /3-subunits of G proteins (Dalrymple et al., 1989; Ruby 
and Abelson, 1991). Since G proteins are involved in association/dissociation cycles, 
catalysed by GTP hydrolysis, it is tempting to speculate that these PRP factors are 
involved in similar cyclical stabilisation and destabilisation events throughout splicing. 
Alternatively, this sequence motif may play a general role in protein-protein 
recognition (Dalrymple et al., 1989). Another readily identifiable sequence motif 
repeated three times in the PRP24 protein, is an RNP-consensus motif commonly 
found in many RNA binding proteins from yeast to man (Bandziulis et al., 1989). 
snRNP-specific factors: 
Biochemical studies have identified some PRP factors as components of 
specific snRNPs. PRP8, is a U5 snRNP protein (Lossky et al., 1987) and more 
recently, the PRP18 protein has also been shown to be associated with U5 snRNP 
(Horowitz and Abelson, 1993). Interestingly, although PRP8 is required early, for the 
accumulation of U4/U6.U5 tri-snRNPs (Brown and Beggs, 1992), PRP18 is required 
only at step 2 of the reaction (Vijayraghavan and Abelson, 1990). PRP3 and PRP4 
are both U4/U6 associated (Banroques and Abelson, 1989; Peterson-Bjorn et al., 
1989; Ruby and Abeleson, 1991). PRP4 protein associates with the U4/U6 particle 
by binding directly to the 5' stem loop of U4 RNA (Banroque and Abelson, 1989; 
Bordonne et al., 1990; Xu et al., 1990), and is required for the stability of the U6 
RNA, and of all U6-containing particles (Blanton et al., 1992; Galisson and Legrain, 
1993). These biochemical data and the demonstration that PRP3 and PRP4 genetically 
interact (see 1.5.3.2) are consistent with their observed association with U4/U6. 
Recently, analysis of complexes formed in pip6-1 heat-inactivated extracts 
demonstrated that the PRP6 protein is required for the accumulation of U4/U6. U5 tn-
snRNPs (Galisson and Legrain, 1993). Originally PRP6 was believed to be part of 
the U4/U6 snRNP (Abovich et al., 1990), however, Gallison and Legrain (1993) 
found no evidence for this; its association with U4/U6 was dependent on the US 
snRNA. PRP6 is therefore the only U4/U6.U5 specific factor yet identified. The final 
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snRNP specific PRP factor identified to date is PRP24 which associates with free U6 
snRNPs (Shannon and Guthrie, 1991). 
Other early acting factors: 
Several factors which are not associated with a particular snRNP, are also 
required early during spliceosome assembly. These include factors required for U2 
snRNP binding; PRP5 and PRP9, (Abovich et al., 1990; Ruby and Abelson, 1991), 
and the more recently characterised non-snRNP factor PRP19. PRP19 has been shown 
to associate with complexes following or concommitent with U6 entry, but prior to 
the activation of the spliceosome (Cheng et al., 1993; Tarn et al., 1993). The PRP19 
protein was not associated with complexes in extracts depleted of either U2 or U6 
snRNAs, however it was associated with inactive spliceosomes formed inprp2-1 heat-
inactivated extracts (Tarn et al., 1993). 
Late acting factors: 
A number of pip mutants arrest the spliceosome cycle following assembly of 
the mature spliceosome. PRP2, as already mentioned, is required for step one, both 
this yeast factor and its potential mammalian homologue, SF4, act after formation of 
the spliceosome but prior or concommitent with step one (Kramer et al., 1987; Utans 
and Kramer, 1990). Both proteins are also approximately the same size (100 and 
1 lOkD). Several other yeast splicing factors are required for completion of the second 
catalytic step. These include PRP16, PRP17/SLU4, SLU7 (see later), and PRP18 
(Schwer and Guthrie, 1991; Vijayraghavan et al., 1989; Ruby and Abelson 1991; 
Frank et al., 1992). Interestingly, Horowitz and Abelson (1993) have presented 
evidence suggesting that PRP18 acts very late during step 2, and that its activity is 
ATP-independent. Extracts immunodepleted of PRP18 accumulated splicing 
intermediates. Following ATP-depletion of these PRP18A extracts, splicing 
intermediates could be chased into reaction products upon additon of purified PRP18 
protein alone, without addition of ATP (Horowitz and Abelson, 1993). This supports 
the belief that splicing proceeds via transesterification. Alternatively, the remaining 
3jM ATP following ATP depletion during their experiments may be sufficient for 
completion of the second step in this system, or ATP used for the final step might be 
stably bound to spliceosomes. 
Three factors which act following the splicing reaction have been identified. 
These are PRP22, PRP26 and PRP27, and their activities are described in sections 
1.5.5 and 1.5.6. 
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1.5.3.2 Suppressors of Defects in Trans-acting Factors. 
The classical approach of isolating extragenic suppressor mutations has been 
particularly productive, not only in analysing interactions between components, but 
also in identifying novel splicing factors. The general principle of the approach is as 
follows: under non-permissive conditions, a mutation results in a conformational 
change in factor X preventing an essential association with a second component, 
factor Y; suppression of this defect may be achieved by a mutation in the gene 
encoding factor Y which alters its conformation such that the interaction is restored. 
In practice, conditional-lethal (usually temperature-sensitive) splicing mutants are 
incubated under non-permissive conditions to select for growth of pseudorevertants. 
Cloning and further analysis of suppressor genes is facilitated if they confer an 
additional phenotype that is linked to suppression. Subsequent analysis must 
distinguish between the sought-after interactive suppressors, and other classes of 
suppressors which could be present in a pool of pseudorevertants. These include 
translational suppressors, suppressors which act by modulating the level of expression 
of the mutant protein, and by-pass suppressors i.e. unrelated factors that substitute for 
the mutant activity. 
In order to explain the cold-sensitivity of certain mutations in the region of U4 
snRNA that base pairs with U6, Shannon and Guthrie (1991) proposed the existence 
of an alternative complex that would be hyperstabilised in the cold-sensitive mutants. 
According to this model, mutations which destabilise the competing complex might 
suppress the cold sensitivity of these U4 defects. Such mutations were sought by 
selecting for recessive suppressors of the U4 mutation G14C. One class of suppressor 
mutations mapped to the U6 gene outwith the U4/U6 interaction domain (Figure 
1.4A). This suggested that U6 snRNA might form part of the competing complex in 
association with other trans-acting factors. They therefore sought mutations in these 
putative factors, and to prevent isolation of U6 mutants, suppressors were selected in 
U4-G14C haploids that contained an extra copy of SNR6 on a plasmid. Three 
recessive suppressors were isolated that mapped to the same gene, and one of these, 
by virtue of it having a temperature-sensitive phenotype, permitted complementation 
analysis. The factor was characterised as the previously identified PRP24 protein, and 
the recessive mutations in U6 were proposed to define possible binding sites for this 
factor (see figure 1.4A). 
Consistent with the existence of RNP-concensus motifs in PRP24, 
immunoprecipitation experiments using antibodies raised against the protein 
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demonstrated a strong association between this factor and the U6 snRNA in wild-type 
extracts (Shannon and Guthrie, 1990). However, in extracts prepared from U4-G14C 
mutants, PRP24 was found to be associated with both U4 and U6, whereas it was not 
associated with either snRNA in extracts from cells carrying snr6 or prp24 recessive 
suppressor mutations. Thus molecular evidence was obtained for a model in which 
PRP24 protein binds strongly to U6 RNA, stabilising the unwound form, and binds 
transiently to the destabilised form of U4/U6 in an alternative complex involved 
perhaps in reformation of the U4/U6 snRNP. This study demonstrates the immense 
power of suppressor analysis in identifying factors which interact. 
The interaction of the U5 snRNP protein PRP8 with a putative RNA helicase 
has been suggested by a suppressor approach; spp8l is one of several cold-sensitive 
suppressors of a mutation in the PRP8 gene (Jamieson et al., 1991). This spp8l 
mutation maps to the DED1 gene which encodes a member of the DEAD-box family 
of putative RNA helicases. A direct interaction between the spp8 1 and PRP8 proteins 
was suggested by the observation that increased copy-number of the wild-type PRP8 
gene impairs the growth of spp8l cells, indicating that excess PRP8 protein may 
sequester the essential DED1 protein, thus limiting growth. Strauss and Guthrie 
(199 1) have genetic evidence for PRP8 interacting with another RNA helicase protein 
PRP28; a mutant allele of the PRP8 gene was isolated as a suppressor of a cold-
sensitive mutation in PRP28. It is known that the PRP28 protein is essential for 
splicing, however it remains to be seen whether DED1/SPP81 is normally involved 
in splicing, or is recruited to this role under special circumstances. 
During attempts to clone the wild type SPP811DED1 gene by complementation 
of the cold-sensitive spp8l mutation, another gene was cloned by virtue of its ability, 
when present on high copy-number plasmids, to suppress the spp8l defect (Jamieson 
and Beggs, 1991). This gene encodes yet another member of the DEAD box family, 
and was designated DBP1 (Dead Box Protein). The predicted DBP1 protein sequence 
is very closely related to that of DED1 (82% similarity, 72% identity) and so 
presumably suppresses spp8l mutations by substituting for the activity that is 
defective at low temperatures. This is an example of dosage suppression, models for 
which are discussed by Last et al., (1987). 
Dosage suppression has also identified a novel factor, SPP2, which may 
interact with the PRP2 protein (Last et al., 1987). When present at elevated copy-
number, the SPP2 gene complements prp2 mutations. This does not occur simply as 
a bypass of PRP2 function, because elevated levels of SPP2 will not suppress a null 
allele of PRP2. Importantly, temperature-sensitive alleles of SPP2, created by in vitro 
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mutagenesis, show that SPP2 protein is itself essential for splicing. The dosage 
suppression is reciprocal; overexpression of the PRP2 gene can suppress temperature 
sensitive alleles of SPP2, providing strong evidence for a direct interaction between 
these splicing factors (Kim and Woolford, pers. comm.). 
Multiple copies of the PRP3 gene have been shown to suppress the 
temperature sensitivity of several pip4 alleles, but not a pip4 null allele (Last et al., 
1987). In this case, dosage suppression is not reciprocal; extra copies of PRP4 do not 
suppress pip3 mutations. However, certain prp4 mutants specifically suppress 
temperature-sensitive prp3 mutants Woolford (1989). These observations, which on 
a genetic level suggest a specific interaction between the PRP3 and PRP4 proteins, 
are consistent with molecular evidence for the association of both proteins with 
U4/U6 snRNPs (Banroques and Abeleson, 1989; Peterson-Bjorn et al., 1989; 
Anthony and Woolford, pers. comm.). 
1.5.3.3 Suppressors of Defects in as-acting Sequences. 
Mutations in the conserved yeast intron sequences generally cause severe 
splicing defects providing an ideal system for the genetic identification of splicing 
factors that interact with these cis-acting elements of the pre-mRNA. A strong 
selection for suppressors of intron mutations can be achieved by the use of a reporter 
construct that consists of a defective intron. 
This approach was adopted by Couto et al., (1987) using constructs containing 
an A to C branch point mutation (designated C259, figure 1.3B) which blocks the 
first step in the splicing reaction. They isolated a dominant suppressor by its ability 
to overcome the splicing defect conferred by the C259 mutation in an actin-HIS4 gene 
fusion. Growth on the histidine precursor histidinol was not possible unless the intron 
was accurately spliced, so pseudorevertants could be selected by growth on histidinol. 
The screen employed diploids to allow the recovery of recessive lethal mutations, and 
also because this results in the isolation of dominant suppressors which are likely to 
represent a gain of function. To establish that the suppressors were indeed extragemc 
and trans-acting, they were tested for the ability to suppress a second, independent 
C259 mutation present in another reporter gene. Only one of the dominant 
suppressors satisfied these criteria and this mapped to the PRP16 gene. The mutant 
protein encoded by this allele, prp16-1, was thus identified as being able to influence 
the fidelity of branch point recognition, however, as pip16-1 haploids are viable, the 
mutant protein must still fulfil its normal role. Although pip16-1 seems to influence 
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the recognition of the branch point in the pre-mRNA (i.e. before step 1), PRP16-
depleted extracts carry out the first cleavage-ligation step (Schwer and Guthrie, 1991). 
Thus the prpl6-1 mutation may confer an extra property on the PRP16 protein. The 
prp16-1 mutation causes a single amino acid change in the putative ATP binding 
domain of the protein (Burgess et al., 1990), supporting a role for PRP16 at one of 
the ATP-requiring steps in splicing. A kinetic proof-reading model was proposed in 
which the aberrant function of the prp 16-i protein was due to a relaxation in the 
fidelity of recognition of its target, caused by a change in the rate of ATP binding 
and/or hydrolysis (Burgess et al., 1990). This model was based on an analogy with 
mutations in translational components which are postulated to increase GTP 
hydrolysis rate causing an increase in wrongly incorporated amino acids during 
translation. Recently however, the pip16-1 mutation has been shown to confer a 
dramatic, 10-fold, reduction in ATP hydrolysis rate (Schwer and Guthrie, 1992). 
They reconcile this disparity by pointing out that the reduced ATP hydrolysis rate of 
prpl6-1 protein may slow down the scanning process resulting in reduced fidelity 
(Schwer and Guthrie, 1992). 
A similar approach was used with great success by Newman and Norman 
(1991, 1992), revealing possible interactions between U5 snRNA and exon sequences 
adjacent to both the 5' and 3' splice sites. This study is described in section 1.5.4.1. 
1.5.3.4 Synergistic mutations. 
In a multisubunit complex, the activity of one component may be dependent 
on the integrity/stability of another. Thus interacting factors may be identified by 
screening combinations of known mutations for those which are lethal when present 
together in a haploid cell under conditions which are permissive for the individual 
mutations. This phenomenon, termed synthetic lethality, has been demonstrated for 
mutations in PRP3 and PRP4 (Woolford, 1989). Such a genetic interaction between 
prp3 and prp4 mutants in vivo agrees with in vitro complementation studies in which 
prp3 and prp4 heat-inactivated splicing extracts complement only wealdy compared 
to many other combinations of mutant extracts (Lustig et al., 1986), and with the 
discovery that the PRP3 and PRP4 proteins are both associated with the U4/U6 
snRNP. Synthetic lethality has also been shown for certain alleles of PRP24 and 
PRP28 (Strauss and Guthrie, 1991). As PRP28 is a putative RNA helicase, and 
PRP24 is a U6 binding protein, Strauss and Guthrie (1991) proposed that these 
proteins both act in the U4/U6 cycle of unwinding and reannealing (see section 
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1.5.5.1). 
The phenomenon of synthetic lethality has been used recently to identify 
factors that functionally interact with U5 snRNA. Frank et al., (1992) screened for 
trans-acting mutations that exacerbate the phenotypes of conditional mutations in the 
phylogenetically conserved loop I of US snRNA. These genes were named SLU, for 
synergistically lethal with US snRNA. A starter strain was generated containing a 
genomic deletion of the SNR7 gene which encodes U5, a WT copy of the SNR7 gene 
on a URA3-containing plasmid, and a mutant copy of the snR7 gene on a HIS3-
containing plasmid. Following UV mutagenesis of this strain, genomic mutants were 
identified that prevented cell growth when the strain was plated on medium which 
selected against the plasmid carrying WT SNR7 gene. The slu mutants were also 
required to confer an additional temperature-sensitive phenotype to facilitate further 
genetic and biochemical characterisation of the loci. Out of 13 mutants, unlinked to 
the snR7 gene, four were found to confer splicing defects under non-permissive 
conditions in vivo and/or in vitro. These were the slul-1, slu2-1, slu4-1 and slu7-1 
alleles. Further analysis demonstrated that whilst SLU1 and SLU2 are required for 
step 1 of splicing, SL U7 and SL U4 (allelic with PRP1 7) are required only for step 2, 
and there is evidence to suggest that SLU7 influences 3' splice site choice (Frank and 
Guthrie, 1992). Interestingly, slu7-1 and slu4-1 were found to be lethal in 
combination with mutations in PRP16 and PRP18 which are also required for the 
second catalytic step. From these data Frank et al., proposed that SLU7, SLU4, 
PRP 16 PRP 18 and US snRNA interact functionally, and that US may act to 
coordinate this group of factors that are required for completion of the second step. 
1.5.3.5 Dominant Negative Mutations. 
Another genetic approach well suited to the analysis of multicomponent 
splicing complexes is the generation of dominant negative mutations. Usually a cloned 
gene is mutated in vitro, and alleles are selected in vivo which, when overexpressed 
from an inducible promoter, compete with and disrupt the activity of the 
corresponding wild-type factor (either RNA or protein). Several models have been 
proposed for the way in which these mutations may cause their phenotype 
(Herskowitz, 1987). Changes in a specific, overexpressed factor may permit its entry 
into complexes in preference to the wild-type version, but prevent subsequent activity 
and/or turnover of the complex. Production of these 'frozen', dead-end complexes 
could facilitate biochemical analysis of normally transient events. 
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In a study to test the function of variant U2 RNAs, the first example was 
isolated of a dominant negative mutation affecting a yeast splicing factor (Miraglia 
et al., 1991). A chimeric yeast U2 gene was constructed in which the branch point 
interaction region (Figure 1.3B) was replaced by the corresponding sequence from a 
trypanosome U2 snRNA gene. Overexpression of this gene caused a severe splicing 
defect, and a model was proposed in which the mutant snRNA was not released from 
complexes, thus sequestering essential limiting factors. 
Production of dominant negative mutations may also provide an excellent basis 
for the isolation of dosage suppressors, as overexpression of an interacting factor may 
titrate out the toxic mutant RNA or protein. This approach, although not yet applied 
to splicing has been used in other systems (eg. Powers et al., 1991). 
1.5.4 A Network of Spliceosomal RNA:RNA Interactions. 
Exciting research data, first communicated at the 1992 RNA Processing 
Meeting, described the elucidation of a complex network of RNA:RNA interactions 
predicted to form the scaffold of the catalytically active spliceosome. For the first 
time, a model of the internal RNA structure of the spliceosome could be assembled. 
Strong interest in this area has been fuelled by the theory that the process might be 
RNA catalysed, indeed several models predicting similarities between the structures 
of autocatalytic introns (group I and group II), and the structures formed through 
interactions between RNA components of the nuclear spliceosome have been 
compiled. 
These novel interactions have been elucidated through the use of either yeast 
genetics or biochemical crosslinking methods, and in some cases the evidence has 
been strengthened through the attainment of similar observations using both 
approaches. To summarise these findings, a simplified and highly schematic 
representation of proposed RNA interactions is shown in figure 1.5. These include 
the well established interactions between Ul snRNA and the 5' splice site (and 3'ss 
in S.pombe), U2 snRNA with the BPS, and the well studied extensive base pairing 
between U4 and U6 snRNAs. The more recently described interactions include that 
between U5 snRNA and exon sequences adjacent to both 5' and 3' splice sites, U6 
snRNA to the pre-mRNA S'splice site region (overlapping the Ui interaction 












Figure 1.5: An RNA:RNA Network. Highly schematic 
representation of proposed spliceosomal RNA network. El and 
E2 indicate 5' and 3' exons flanking intron respectively. 
snRNAs are marked. See text for details and references. 
1.5.4.1 Intermolecular snRNA:pre-mRNA interactions. 
Extensive biochemical and genetic evidence for the interactions of Ui and U2 
snRNAs to the pre-mRNA 5' splice site and BPS respectively has been described in 
previous sections. More recent are the proposals that U5 and U6 directly interact with 
regions of the pre-mRNA. 
Aiming to identify factors involved in 5' splice site recognition Newman and 
Norman (1991) sought suppressors of a 5' splice site mutation in which the invariant 
G residue at position 1 was substituted by an A (Gi to A). Expression of a G1A 
mutant (3-galactosidase reporter construct was blocked with the accumulation of intron 
exon 2 lariat intermediates as dead-end products. A dominant trans-acting suppressor 
mutant was isolated that activated a cryptic splice site 12 nucleotides upstream of the 
authentic 5' splice junction. This resulted in the production of an in-frame mRNA 
with a short deletion. Cloning and sequencing identified the suppressor as a mutant 
form of the U5 snRNA with a single U to C base change in a phylogenetically 
conserved 9-nucleotide loop (loop I U6 to C6; Figure 1.4B). During further studies 
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(Newman and Norman 1991, 1992), other mutations within this loop were shown to 
1) activate several cryptic 5' splice sites around the Gi to Al mutant site 2) allow 
step 2 to proceed from the A-A 2'-5'phosphodiester bond produced in step 1 from the 
Gi to A substrate 3) permit step 2 to occur when the 3' splice site is mutated from 
GA to AA, which normally blocks the second step. Taken together these observations 
suggest interactions of the U5 loop with both 3' and 5' ends of the intron. 
Astonishingly, the activating mutations in U5 increased the complementarity between 
the loop sequence and the exon nucleotides adjacent to the activated splice site, and 
through examination of mutants causing particular splicing events, it was proposed 
that suppression was the result of direct base pairing to exon sequences upstream of 
5' splice site and immediately downstream of the 3' splice site (Newman and 
Norman, 1992). The model was greatly strengthened by their ability to correctly 
predict which U5 loop mutants should lead to the activation of specific aberrant 
cleavage events. Since U residues can base pair with either A, G or C within helices 
(Holbrook et al., 1991), Newman and Norman (1992) proposed that the U-rich US 
loop would be able to base pair with non-conserved exon sequences (see figure 1.4B, 
and figure 1.6). It remains to be seen whether these direct interactions occur in a wild 
type situation. 
In addition, striking parallels were made between this base pairing and that 
found in group 11 autocatalytic introns between the D3 loop and exon sequences 
adjacent to the splice sites, known to be important for splicing (see Newman and 
Norman (1992) for further discussion and references). This adds weight to the view 
that nuclear and self-splicing introns may have evolved from a common group 11-like 
ancestor, and together with the revealed proximity of the conserved US loop and the 
5' and 3' splice sites, suggests that this sequence may play an important role in the 
actual transesterification reactions themselves. Alternatively the interactions of the US 
loop may act to hold free exon 1 in position following step 1 of the reaction (See 
figure 1.6 for this interaction in the context of the assembled spliceosome). 
Significantly, the same conserved US snRNA loop sequence has been shown 
by specific photocrosslinking to interact with exon nucleotides adjacent to the 
5' splice site (Wyatt et al., 1992). Pre-mRNA substrates containing a labelled 4-
thiouridine residue 2 nucleotides upstream of the 5' splice site, were synthesised and 
incubated in Hela nuclear extracts under splicing conditions. 4-thiouridine is 
specifically photoactivated by UV irradiation to form RNA crosslinks usually 
detecting non Watson Crick interactions (Lemaigre Dubreuile, 1991). US snRNA 
became crosslinked, as detected by oligonucleotide directed RNAse H cleavage, prior 
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FIGURE 1.6 Currently Defined Interactions Between U2, US, U6 snRNAs and 
the Pre-mRNA. 
Conserved intron and snRNA sequences are those of S. cerevisiae. Nucleotides of 
snRNAs that are involved in interactions are shown, those in upper case are 
absolutely conserved between S. cerevisiae and the known sequences of other 
organisms excluding trypanosomes. Dashed bonds indicate possible base pairs 
between U2 and U6 nucleotides that could not be proven by compensatory mutations 
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to step one. Primer extension blockage experiments revealed that the crosslink was 
formed within the U5 loop I. More specifically, the strongest primer extension block 
was the result of a crosslink to loop I nucleotide US proposed by Newman and 
Norman (1992) to base-pair with the exon 1 nucleotide at position -2 relative to the 
5' splice site (see figure 1.4B). 
A further snRNA:pre-mRNA interaction has been proposed involving a region 
of the U6 snRNA and the pre-mRNA 5' splice site region. Sawa and Abelson (1992) 
obtained UV induced crosslinks which mapped to the sequence GAAACA in U6 
snRNA, and nucleotides downstream of the 5' splice site (Helix C, Figure 1.6), 
partially overlapping the region of Ui snRNA interaction (represented in figure 1.5). 
1.5.4.2 Intermolecular snRNA: snRNA Interactions. 
The best characterised intermolecular snRNA:snRNA interaction is that which 
exists between the U4 and U6 snRNAs (Figure 1.4A) and evidence suggesting a role 
of this structure in catalysis has been discussed previously. Two separate interactions 
between U2 and U6 snRNAs have been revealed, and the structure formed by one of 
these bears a resemblence to conserved regions of both group I and group H 
autocatalytic introns. 
The first U2-U6 interaction was initially demonstrated by }{ausner et al., 
(1990) using psoralen induced photocrosslinking in Hela nuclear extracts (psoralen is 
specific for base paired nucleotides (Hausner et al., 1990)). The covalent crosslinks 
mapped to a sequence at the 5' end of U2 snRNA and nucleotides at the 3' end of U6 
(Helix A, figure 1.6). As this region was phylogenetically conserved, Hausner et al., 
(1990) proposed that this direct interaction might play an important role in 
mammalian splicing. This phylogenetic and biochemical evidence was later confirmed 
independently by Wu and Manley (1991), and Datta and Weiner (1991) who 
demonstrated that this base pairing interaction is indeed required for mammalian 
splicing in vivo. Mammalian cells were cotransformed with constructs expressing a 
mutant reporter transcript, a mutant U2 snRNA which facilitated splicing of the 
reporter transcript, and U6 snRNA. This provided an elegant system in which 
mutations in U2 that reduced the proposed base pairing between U2 and U6 could be 
analysed for their effect on splicing of the reporter transcript without interference 
from WT U2 snRNA molecules. Such U2 mutations were shown to decrease splicing, 
and this was alleviated by the introduction of compensatory mutations in U6 snRNA, 
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demonstrating the requirement for direct base pairing. 
This U2-U6 interaction (Helix A, figure 1.6) has also been shown to be 
important for spliceosome assembly. Using an in vitro system in which endogenous 
U6 snRNA was degraded and replaced by exogenously supplied U6, Wolff and 
Bindereiff (1992) showed that mutations in U6 that reduced the complementarity with 
U2 at this region did not prevent assembly of U6 into snRNP complexes, but did 
abolish spliceosome assembly. Surprisingly, despite its conservation, this region of 
U6 snRNA is not essential for viability in S.cerevisiae (Fabrizio et al., 1989; 
Madhani et al.,(1990), suggesting that this interaction does not occur in yeast. 
A second region of U2-U6 interaction has been demonstrated by Madhani and 
Guthrie (1992) through a combination of "sequence-gazing" and mutational analysis 
in yeast (Helix B, figure 1.6). Significantly, this bulged helix between U2 and U6 is 
mutually exclusive with the U4/U6 interaction. It involves nucleotides 53-61 of U6 
snRNA that were originally in stem I of the U4/U6 structure (Figure 1.4A), and 
nucleotides in U2 that formed the intramolecular U2 stem loop I (Figure 1.3B; 
McPheeters and Abelson, 1992). All but two mutations in one pairing partner of helix 
B (Figure 1.6) could be rescued by a compensatory base change in the other, 
indicating the functional importance of base pairing rather than sequence. Interestingly 
two potential base pairs in helix B (dashed bonds) could not be proven by 
compensatory mutations (Madhani and Guthrie, 1992) suggesting that these 
nucleotides of either the U2 or U6 have additional roles. It is possible that the U2 
nucleotides retain their interactions within the upper half of U2 stem loop I (Figure 
1.3B; McPheeters and Abelson, 1992). Significantly virtually all of the nucleotides 
involved in helix B are extremely phylogenetically conserved, being present in all 
organisms for which sequence is available (Madhani and Guthrie, 1992). 
The U2 nucleotides involved in helix B are immediately adjacent to those U2 
bases that interact with the BPS. Similarly, the U6 nucleotides involved in this 
structure are adjacent to U6 bases thought to interact with nucleotides downstream of 
the 5' splice site.. This would position the U2-U6 structure in close proximity to both 
the 5' splice site and the branch site; the two chemical protagonists of the reaction. 
Interestingly, parallels have been drawn between the configuration of helix B and 
specific secondary structures formed by autocata.lytic introns. This issue is however 
somewhat controversial; Madhani and Guthrie (1992) liken helix B together with the 
U2:BPS helix to Domains 5 and 6 of Group IIA introns respectively, whereas 
McPheeters and Abelson argue that helix B resembles P7 helix in group I introns. 
Both parties use these observations to argue a case for common ancestry between 
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nuclear introns and the unrelated group I introns (McPheeters and Abelson) or group 
II introns (Madhani and Guthrie). An interesting alternative, which effectively 
resolves this arguement is that the apparent similarities between the structure of 
nuclear introns and the two autocatalytic intron classes is a result of evolutionary 
convergence due to common functional constraints rather than common ancestry (see 
Weiner 1993 for review). 
1.5.4.3 Dynamic Structural Rearrangements. 
The proposed RNA-RNA network shown in figure 1.6 emphasises the dynamic 
nature of the spliceosome. The interaction between U2 and U6 cannot form unless U4 
dissociates from U6 and the stem loop I of U2 has been melted. Perhaps the 
interaction of U6 upstream of the 5' splice site requires destabilisation of the Ui 
snRNA from the 5' splice site region. Unfolding of pre-mRNA secondary structure 
may also occur to aid precise juxtaposition of the 5' splice site and the branchpoint 
prior to the first cleavage-ligation step. Such a complex cascade of RNA-RNA 
stabilisation and destabilisation events must demand stringent regulation. The only 
candidates identified to date, whose action is likely to be responsible for monitoring 
and driving these interactions, are members of a specific class of RNA-dependent 
ATPases, the RNA helicases. Such an activity is consistent with the observed high 
melting temperature of the U4-U6 helix (53 °C; Brow and Guthrie, 1988), implying 
that destabilisation within the spliceosome requires an active process. Thus the role 
of RNA helicases in splicing might explain the ATP requirement of the splicing 
process. 
1.5.5 Putative RNA Helicases. 
Although RNA unwinding activity remains to be demonstrated for any of the 
yeast splicing factors, five of the PRP genes (PRP2, Chen and Lin, 1990; PRP5, 
Dalbadie-McFarland and Abelson, 1990; PRP16, Burgess et al., 1990; PRP22, 
Company et al., 1991 and PRP28, Strauss and Guthrie, 1991) encode members of a 
rapidly expanding class of putative RNA helicases referred to as the DEAD\DEAH 
family. Three other members of this evolutionarily diverse family have been shown 
to possess ATP-dependent RNA helicase activity in vitro; the eukaryotic translation 
initiation factor eIF-4A (Rozen et al., 1990), the human p68 protein (Hiring et al., 
37 
1989), and the cylindrical inclusion (CI) protein of plum pox virus (Lain et al., 1990). 
Therefore, considering the strong conservation of sequence motifs required for this 
activity (see below), it is likely that other family members, including the PRP 
proteins will (under the correct in vitro conditions) unwind double stranded RNA 
substrates. Indeed, both PRP2 and PRP16 have been shown to possess RNA-
dependent ATPase activity (Kim et al., 1990; Schwer and Guthrie, 1991). 
Recent elucidation of essential, highly defined tertiary structure in certain 
RNA molecules, has led to a provocative new theory suggesting the existence of 
proteins required to catalyse the correct folding of such elaborate species (Fuller-Pace 
and Lane (1992). These RNA chaperonins would possess the ability to alter the 
conformation of RNA molecules, and therefore the DEAD/DEAH proteins are 
excellent candidates. In the light of this hypothesis, the PRP helicase-like proteins 
might act to ensure the correct conformation of certain, possibly catalytic, 
spliceosomal RNAs. 
The new and rapidly expanding helicase gene family was discovered following 
sequence comparisons of the eukaryotic translation initiation factor eIF-4A, and the 
human p68 protein (Ford et al., 1988). Large blocks of absolute amino acid identity 
unveiled a core region containing seven sequence motifs, which are now the hallmark 
of currently more than 22 members involved in a wide variety of cellular processes 
(reviewed in Schmid and Linder, 1992). 
Detailed functional analysis of the sequence motifs remains limited to the 
prototype of the group, eIF-4A. Four of the most highly conserved motifs are given 
in figure 1.7 together with their functions for eIF-4A deduced by Pause and 
Sonenberg (1992) from biochemical analysis of purified mutant forms of this 
translation factor. The most N-terminal motifs are special forms of the previously 
defined ATPase motifs A and B (Walker, 1982; Linder et al., 1989), variants of 
which are found in many nucleic acid-dependent ATPases (Gorbalenya et a!,. 1989). 
X-ray crystallographic studies have shown that residues of these motifs are in close 
proximity and act to bind the ATP molecule through interactions with Mg 2 which 
is complexed with the ( and 7 phosphates of the nucleotide (Story and Steitz, 1992). 
It was no surprise therefore that mutations within these domains of eIF-4A affected 
ATP binding and/or hydrolysis (Pause and Sonenberg, 1992). The C-terminal 
domains are much less well characterised, and the only information concerning their 
function is from this study of eIF-4A. Thus for eIF-4A, whereas the most C-terminal 
motif is involved in ATP hydrolysis, the SAT motif is believed to be essential for 
RNA unwinding. It remains to be seen whether these correlations hold for other 
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FIGURE 1.7 Highly Conserved Sequence Motifs of the Related DEAD and DEAH 
Putative Helicase Families. 
Schematic representation of the highly conserved amino acid regions in the DEAD 
and DEAH families (Schmid and Linder, 1992). Conserved regions are boxed and 
numbers between the boxes indicate distance in amino acids. The functional activity 
of the motifs in the DEAD helicase eIF-4A as deduced by mutational analysis (Pause 
and Sonenburg, 1992) are indicated above the boxes. 
DEAD FAMILY - PRP5, PRP28, prototype eIF-4A. 
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members of the group, however, the observations of Pause and Sonenberg provide 
an extremely valuable comparison for interpretation of mutagenesis studies of other 
putative helicases. 
The ATPase B motif has been used to identify members of this family, and 
the existence of the variants DEAH and DEXH define subfamilies of proteins sharing 
related but not identical sequences (compare the DEAD and DEAH motifs in figure 
1.7). Three of the helicase-like splicing factors, PRP2, PRP16 and PRP22 are 
members of the DEAH subfamily, whereas PRP5 and PRP28 represent DEAD box 
proteins. It is worth noting that although the DEXH motifs are less conserved than 
those of the DEAH and DEAD proteins, the CI protein of the plum pox virus (a 
DEXH protein) is known to possess helicase activity. Indeed the failure to 
demonstrate RNA unwinding for the DEAH proteins PRP2 (Kim et al., 1992) and 
PRP16 (B.Schwer pers.comm.) both of which are known to have RNA stimulated 
ATPase activity, may be due to stringent substrate specificity, or the requirement of 
additional factors (eIF-4A requires the auxiliary factor eIF-4B for example). 
1.5.5.1 The DEAD-box Splicing Factors. 
Functional PRP5 protein is required for the first ATP-dependent step of 
splicing, binding of U2 snRNP to the pre-mRNA, but not for Ui snRNP binding 
(Dalbadie-McFarland and Abelson, 1990). Therefore PRP5 may mediate its proposed 
helicase activity on a component of the U1-pre-mRNA commitment complex (as 
described in section 1.5.2.2), or on the U2 snRNA itself, perhaps ensuring the correct 
U2 snRNA secondary structure or removing such structures from the pre-mRNA to 
facilitate U2 binding. 
Genetic evidence implicates the activity of PRP28 in the most notorious RNA 
unwinding event in splicing, the destabilisation of U4/U6, proposed to occur just 
prior to the initial icleavage ligation step. Yeast strains containing cold-sensitive 
pip28 alleles are defective for the first step of splicing in vivo (Strauss and Guthrie, 
1990). As previously described, prp28 mutations and mutant alleles of the U6 binding 
protein PRP24 are lethal in combination. In addition, suppression analysis has 
detected a genetic link between PRP28 and the US snRNP protein PRP8. These data 
prompted Strauss and Guthrie (1990) to propose a model in which PRP28 acts to 
unwind the U4/U6 helix, with PRP24 stabilising the unwound form. PRP8 would act 
in opposition, stabilising the base paired form of U4/U6 in the context of the 
U4/U6.U5 tri-snRNP. Thus the three factors may act in concert during the 
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stabilisation/destabilisation cycle, the balance between these activities determining the 
extent of unwinding. The role of PRP8 in this model is consistent with the more 
recent finding that PRP8 is required for stability of U4/U6.U5 tri-snRNPs, and also 
for the stability of the individual U4, U5 and U6 snRNAs (Brown and Beggs, 1992). 
1.5.5.2 The DEAH-Box Splicing Factors. 
Following spliceosome assembly, PRP2 PRP16 and PRP22 appear to play 
sequential roles in the splicing process; PRP2 acts after destabilisation of U4 and U6, 
but before or at the first step (Lin et al., 1987; Yean and Lin, 1991), followed by 
PRP16 which is essential for step 2 (Schwer and Guthrie, 1991), and finally PRP22 
is required for release of the mature message from complexes (Company et al., 
1991). It is the activity of these factors which is thought, at least in part, to account 
for the ATP requirement at these stages of the reaction. 
Distinct functional similitude between the RNA-dependent ATPases PRP2 and 
PRP16 is implied not only by their high sequence homology, within the 320 amino 
acid core domain encompassing the helicase motifs, but also by a number of other 
striking analogies. Both PRP2 and PRP16 have been shown to associate transiently 
with spliceosomes, at step 1 and step 2 respectively. (King and Beggs, 1991; Schwer 
and Guthrie, 1991). In pip2 heat-inactivated extracts, pre-mRNA-containing 
complexes accumulate. Also, using anti-PRP2 antibodies, King and Beggs (1990) 
demonstrated co-immunoprecipitation of pre-mRNA (and to a lesser extent 
intermediates) but not reaction products from WT splicing reactions. Thus PRP2 
interacts just prior to the first step, and is released either before or concomitant with 
step 2. A similar transitory association of PRP16 with complexes at step 2 has also 
been demonstrated by biochemical means. In extracts immunodepleted of PRP16 
protein (PRP16 extracts), the first step of splicing proceeds unhindered, but reaction 
intermediates accumulate. Following ATP depletion of reaction intermediate-
containing complexes formed in iPRP16 extracts, and subsequent addition of purified 
WT PRP16, intermediates are strongly co-immunoprecipitated with anti-PRP16 
antibodies. Release of PRP16, accompanied by the formation of reaction products 
occurs only upon addition of ATP. 
This suggests that ATP hydrolysis by PRP16 is required for the second step 
and for its release from complexes, perhaps through activation of a conformational 
change by this RNA-dependent ATPase. Recent evidence strongly implies that this 
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is the case. First, purified mutant prp 16-i protein hydrolyses ATP with only 10% of 
the efficiency of WT PRP16, and is dramatically reduced in its ability to complement 
the second-step splicing block in APRP16 extracts compared to WT PRP16 protein 
(Schwer and Guthrie, 1992a). In addition, release of prpl6-1 protein from 
spliceosomes, even in the presence of ATP, is severely retarded, correlating ATP 
hydrolysis by PRP16 with release from complexes (Schwer and Guthrie, 1992a). 
Secondly, Schwer and Guthrie (1992b) demonstrated that during incubations in 
APRP16 extracts, the pre-mRNA 3' splice site became protected from 
oligonucleotide-directed RNAse H cleavage following addition of PRP16 and ATP. 
Taken together, these results suggest that PRP16 utilises ATP hydrolysis to effect a 
conformational change within the spliceosome required for, or accompanied by, the 
second cleavage ligation step. 
Significantly, despite the fact that in vitro splicing is extremely inefficient 
when ATP is replaced by any of the other 4 NTPs (Lin et al., 1985), in the case of 
both the PRP2-dependent and PRP 16-dependent steps (5' splice site cleavage and 3' 
splice site cleavage, exon ligation respectively), GTP, CTP or UTP can efficiently 
substitute for ATP (Kim et al., 1992; Schwer and Guthrie 1992b). Intriguingly, a 
broad spectrum of nucleotide usage is also exhibited by the DEXH RNA helicase, CI 
protein of the potyvirus (Lain et al., 1990). 
Given the biochemical similarities between PRP2 and PRP16, it is likely that 
they will play a similar role in splicing at different points during the reaction. As 
described in section 1.5.3.3, the mutant prpi6-1 protein seems to take on an 
additional role as, in contrast to WT PRP16, it functions at step 1 (ie. at the same 
point as PRP2), facilitating increased usage of a mutant pre-mRNA branchsite (Couto 
et al., 1987). It is likely therefore, that the prp 16-i protein actually takes over the 
role of PRP2 at this step, and this infers that PRP2 and PRP16 have a very similar 
spliceosomal target. Perhaps they interact with the same RNA molecule (possibly a 
duplex), which adopts a different conformation at the two steps of the reaction. 
Currently, there are two working hypotheses which might explain the function 
of PRP2 and PRP16 in splicing. The first is based on the "reduced fidelity" 
phenotype of the prp 16-i protein, allowing this factor to overcome the splicing defect 
caused by a branch point mutation. This suggested to Couto et al., (1987) that PRP16 
might act to proof read the branch site residue, and by comparison with mutations in 
certain components of the translation apparatus, a change in ATP hydrolysis 
rate/affinity might relax the stringency of this process. Certain ribosomal factors 
appear to utilise NTP hydrolysis to direct a series of unidirectional conformational 
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changes (Weissbach, 1980), thus PRP2 and PRP16 might effect sequential 
conformational changes accompanied by fidelity checks and ensure unidirectionality 
of the splicing process. The second hypothesis which may account for the activity of 
these factors, involves an analogy with the prototype of the helicase family, eIF-4A, 
believed to utilise the energy derived from ATP hydrolysis to unwind RNA secondary 
structure to facilitate ribosome binding (Sonenberg, 1988). Perhaps the RNA-helicase-
like splicing factors combine characteristics of both models, utilising ATP hydrolysis 
to unwind RNA helices, effecting conformational changes thus ensuring 
unidirectionality. Rigid substrate specificity might account for their role in effecting 
fidelity of splicing. Biochemical analysis of the effects of certain mutations within 
these splicing factors holds the answer. 
Although less is known about PRP22, its sequence similarity within a central 
domain suggests that it too will function via a mechanism similar to that of PRP2 and 
PRP16. In extracts derived from mutant pip22 cells, mRNA is synthesised but it is 
not released from post splicing complexes (Company et al., 1991). Thus PRP22 may 
act on either pre-mRNA:snRNA interactions or snRNAs or the pre-mRNA alone, to 
potentiate a conformational change culminating in message release. 
1.5.6 Spliceosome Disassembly. 
Following the in vitro splicing reaction, whilst the pre-mRNA is released for 
transport to the cytoplasm, the intron lariat is retained within a post-splicing complex, 
as detected by native gel electrophoresis (Konarska and Sharp, 1987; Cheng and 
Abelson, 1987). Mutant p,p22 cells incubated at the non-permissive temperature 
accumulate large amounts of excised lariat intron (Vijayraghavan et al., 1989) 
suggesting that intron turnover is an active process. The in vivoprp22 defect is likely 
to reflect retention of the intron within a defective spliceosome preventing 
disassembly and consequent intron degradation by cellular nucleases. Two other prp 
strains accumulate mature lariat intron, and are thus also implicated in spliceosome 
disassembly and/or intron turnover. The pip26 gene encodes a 2'-5' 
phosphodiesterase (Chapman and Boeke, 1991), this debranching activity suggests a 
role in intron turnover. A debranching enzyme has also been purified from 
mammalian extracts (Ruskin and Green, 1985). The function of the PRP27 gene 
product is unknown, however pip27 mutants also super-accumulate the mature lariat 
intron. It is likely that the conditional lethal phenotypes of prp22 and prp27 mutants 
43 
are due to a block in the recycling of spliceosomal components, causing depletion of 
the pool of free splicing factors, preventing further rounds of processing at the non-
permissive temperature. 
1.5.7 A Model - The Spliceosome Cycle. 
The genetic and biochemical evidence for the highly complicated process of 
spliceosome assembly, catalysis, and disassembly discussed in this review can be 
summarised and simplified in the form of a diagrammatic model. Such a model is 
presented in figure 1.8, showing the proposed order of snRNP entry, and where 
known, the points of action of those PRP factors discussed. Several (but not all) 
mammalian factors are also included in the model, and it can be assumed that these 
yeast and mammalian splicing factors will have analogues in the other. 
Initially the pre-mRNA is bound by hnRNP proteins, and other factors 
including ]IBP, PTB, U2AF, and the Ui snRNP, leading to commitment of the 
transcript to the splicing pathway. The next to bind is U2 snRNP, dependent on Ui 
snRNP, U2AF, and other factors. The U4/U6.U5 triple snRNP then assembles onto 
the pre-spliceosome, and the activity of a helicase leads to the destabilisation of U4 
from U6. Other structural rearrangements, also involving ATP-driven RNA 
unwinding/modification events lead to the formation of the active site, and steps one 
and two of the reaction are catalysed. Spliced mRNA is released whilst the lariat 
intron is retained within a post-splicing complex. Disassembly of the post splicing 
complex leads to debranching and degradation of the lariat intron, and release of the 
free snRNPs and other splicing factors to enter another round of splicing. 
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FIGURE 1.8 A Model- The Spliceosome Cycle. 
The ordered assembly of the snRNPs is depicted. The points of action of many yeast 
and several mammalian splicing factors (in brackets) is shown. Points at which ATP 
is known to be required are indicated. 
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1.6 This Thesis. 
The original objective of the thesis was to analyse the interaction of PRP2 
protein with spliceosomes with a view to identifying its spliceosomal ligand(s). 
Genetic approaches in S. cerevisiae were utilised in order to overcome problems 
caused by the transient association of PRP2 with splicing complexes found previously 
to hinder biochemical studies. Following unsuccessful attempts to isolate interactive 
suppressors of pip2 mutations, a novel approach in the field of splicing, that of 
isolating dominant negative PRP2 mutants, was applied. In vivo and in vitro 
characterisation of dominant negative PRP2 mutants obtained in this study is 
described, and their potential use for the identification of splicing factors is discussed. 
I present: 
Isolation of a dominant negative PRP2 mutant, PRP2-dnl, that causes an 
in vivo splicing defect resulting in cell growth inhibition when overexpressed in a 
wild-type strain. 
Identification of the single amino acid change responsible for the dominant 
inhibitory phenotype; a serine to leucine substitution at the highly conserved putative 
helicase motif SAT. 
Use of site-directed mutagenesis to assess the effect of a number of other 
amino acid changes at the SAT motif. 
Demonstration that overproduction of the mutant protein inhibits splicing 
in vitro causing the accumulation of stalled inactive complexes. 
Use of immunoprecipitation to elucidate the molecular basis for 
dominance; mutant and WT forms of PRP2 compete for entry into spliceosomes, 
however, release of PRP2" is retarded, blocking admission of its WT counterpart. 
Development of a simple two-step procedure for the purification of 
functional WT PRP2 protein, and dominant inhibitory PRP26" protein. 
The finding that the ATPase activity of PRP2 1 ' is reduced but not 
abolished, possibly as a result of a primary defect in RNA unwinding, known to be 
coupled to ATP hydrolysis in the well characterised helicase prototype eIF-4A. 
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CHAPTER 2. 
Materials and Methods. 
2.1 MATERIALS. 
2.1.1 Suppliers of Laboratory Reagents. 
Standard laboratory reagents: Sigma, Fisons, BDH, Bio-Rad, Serva. 
Restriction endonucleases and other DNA modifying enzymes: Bethesda Research 
Laboratories, Boehringer Mannheim, New England Biolabs, Pharmacia. 
Radiochemicals: Amersham International. 
Deoxyribonucleotides and ribonucleotides: Pharmacia and Sigma. 
Acrylamide and NN'-methylene bisacrylamide: BDH Chemicals, "Electran" grade. 
Agarose: Bethesda Research Laboratories ultra-pure electrophoresis grade. 
Media reagents: Difco Labs, and Sigma. 
2.1.2 Growth Media. 
Unless otherwise stated quantities are for 1 litre volume. Solutions were 
autoclaved (section 2.2.2) and stored at room temperature. Antibiotics and amino 
acids were stored as filter sterilised, concentrated stocks and were added to growth 
media immediately prior to use. To make plates bacto-agar was added to 2% (w/v) 
prior to autoclaving. 
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2.1.2.1 E.coli Media. 
Luria-Bertarn medium (LB): lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 
adjusted to pH7.2 with NaOH. 
LB-amp: LB containing 0. lg/l ampiciffin. 
M9 medium: 6g Na2HPO4, 3g K}{2PO4 , 0.5g NaCl, ig NH4C1, 0.25g MgSO4 .7H20, 
2g glucose. Amino acids and/or other requirements were added after autoclaving to 
20mg/i. 
2X YT: lOg bacto-peptone, lOg bacto-yeast extract, 5g NaCl. 
2.1.2.2 Yeast Media. 
YPDA: lOg bacto-yeast extract, lOg bacto-peptone, 20g glucose, 20mg adenine 
sulphate. 
1MM: 6.7g yeast nitrogen base without amino acids, 20g glucose, supplemented with 
amino acids etc. as required to 20mg/i. 
YMMCas/YMGRCas: 1MM or YMGR plus lOg vitamin-free casamino acids. After 
autoclaving, tryptophan, adenine, and uradil, which are not supplied by the casamino 
acids, were added as required to 20mg/i. 
Pre-sporulation: 8g bacto-yeast extract, 3g bacto-tryptone, lOOg glucose. 
Sporulation: lOg potassium acetate, ig bacto-yeast extract, 0.5g glucose, 2mg each 
relevant amino acid. 
5-FOA: 6.8g yeast nitrogen base without amino acids, 20g glucose, ig 5-fluoro-
orotic acid, 2g casamino acids, and 50mg uradil were dissolved in 11 20 up to 500m1 
and filter sterilised. 5g of bacto agar was added to 11 20 up to 500m1, autoclaved and 
cooled to below 85°C. The two solutions were mixed together and poured into petri 
dishes to make plates. 
2.1.3 Bacterial Strains. 
Table 2.1 E.coli strains 
Strain Genotype Description Reference/Origin 
NM522 (i.(lac, pro), hsdi5, Used throughout for Messing et al., 
supE, tht, F (lacP, general purpose 1977. 
lacZM15, pro). cloning, sequencing 
etc. 
BW313 HfrKL16 P0/45 Used for site-directed G.Reid, 
[lysA (61-62)], duti, mutagenesis Edinburgh 
ungi, diii, relAl. 
2.1.4 Yeast Strains. 
Table 2.2 Yeast Strains. 
Strain Genotype Reference/Origin 
S150-2B a, ura3-52, leu2-3,412, trpl -289, FWellcome 
DJY85 ala, prp2-1, ura3, adel/ADEJ, ade2, D.Jamieson, 
trplITRPl, his3/HIS3, tyr11TYR1, lys2- (this lab.) 
801/LYS2, cani/CAN1. 
DJY36 a, pip2-1, ura3-52, ade. As above. 
EFY2 a/a, PRP2IPRP2:: URA3, adel/ADE1, E.Flirin, (this 
trpl/TRP1, lys2-801/LYS2, leu2- lab.) 
31LEU2, ura3-521ura3-52. 
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2.1.5 Plasinid Vectors and Constructs. 
Table 2.3 Plasmid vectors and constructs. 
Plasmid Description Reference/Origin 
pTZ18R, Phagemid vectors with multiple cloning Pharmacia 
pTZ19R sites in lacZ a-peptide fragment. Fl 
origin allows synthesis of single-stranded 
DNA; Wflp ' . 
pFL45 Yeast high copy number plasmid based Bonneaud et al., 
on 2,u and pUC19; TRP1. (1991). 
pY2016 Yeast integration plasmid YTP5 Lee et al., (1984) 
containing a 3.2kb EcoRI-Ba,nHI 
fragment encoding the entire PRP2 gene. 
pBM125 Yeast E.coli shuttle plasmid, (low copy Johnston and 
number) containing a 0.81kb EcoRI- Davis, (1984). 
BamHl fragment containing the GALl 
UAS and promoter region. ARS, CEN, 
URA3. 
pBMPRP2 The vector pBM 125 containing the 2.9kb King and Beggs, 
PRP2 gene (derived from pY2016) fused (1990). 
to the GALl inducible promoter. 
pBMP2H-X Deletion constructs based on pBMPRP2. S. Anderson, (this 
pBMP2X-P In each case, a single restriction lab.) 
pBMP2zP-S fragment has been removed from the 
PRP2 gene and replaced with a linker 
containing a unique Sacl restriction site. 
For constructs pBMP2zH-X, 
pBMP2X-P and pBMP2P-S 
restriction fragments deleted are: 
Hind ffl-XbaI XbaI-Pvull and Pvull-Saul 
respectively. 
50 
Plasmid Description Reference 
pT7rp8s Containing most of the yeast RP28 gene. M.Lossky, (this 
Used as template for in vitro lab.) 
transcription of most of El, WS and E2 
after linearisation with EcoRI. 
pSM8 Containing the entire DBP1 gene. Used S.Macallum, 
to make intronless in vitro transcripts of (this lab.) 
the first 780 nucleotides after 
linearisation with Bglll 
2.1.6 Antisera and Antibodies. 
Table 2.4 Antisera and Antibodies. 
Antiserum or Antigen Raised Against Origin 
Antibody 
Anti-55 Fusion 2.3 protein D.King, (this lab.) 
(see figure 2.1 below) 
Anti-140 Fusion 2.5 protein (see D.King this (lab.) 
figure 2.1 below.) 
Anti-M3G 2,2 ,7-trimethylguanosine R. LUhrmann (Marburg), 
L_ LUhrmann et al., (1982). 
2.1.7 Markers. 
Size markers for nucleic acid and protein electrophoresis were as follows: 1kb 
ladder markers (BRL; catalogue number 56155A) were used for agarose gel 
electrophoresis of DNA and RNA; Sigma pre-stained protein markers (catalogue 
number SDS-7B) or high molecular weight markers (SDS-6H) were used for SDS-
PAGE electrophoresis of proteins. 
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EcoRI 	Hindlll 	Xbal 	PvuIl 	BamHl Restriction map of 
the PRP2 gene 
2.3 
AfIl Hill 	2.5 
Regions present in 
3-gaIactosidase-PRP2 fusion 
proteins against which 
antibodies were raised. 
Figure 2.1: Anti—PRP2 antibodies used in this study. 
2.1.8 Buffers. 
1OXTAE: 	0.4M Tris-acetate pH7.5, 20mM EDTA. 
1OXTBE: 0.9M Tris-borate pH8.3, 20mM EDTA. 
1OXTB: 	0.9M Tris-borate pH8.3. 
1OXTBS: 0.5M Tris-HC1, 1.5M NaCl pH7.5. 
20XSSC: 	3M NaCl, 0.3M tn-sodium citrate pH7.0. 
2.2 GENERAL METHODS. 
2.2.1 General Guidelines. 
Unless otherwise stated: All procedures were carried out at room temperature. 
For small-scale procedures sterile 1 .5m1 polypropylene microfuge tubes (Treff) were 
used, larger scale procedures being carried out in either 15nil or 30m1 sterile Corex 
tubes, lOmi Sterilin tubes, or 50m1 Falcon tubes. For harvesting 3-41 cell cultures, 
Sorvall 500m1 plastic pots were used. 
Centrifugation of volumes greater than 50m1 was carried out in a Sorvall 
Superspeed centrifuge using either a GS-A or GS-3 rotor at 5000rpm, and volumes 
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between 1.5 and 50m1 were centrifuged in either a SS34 or HB-4 rotor at speeds 
between 10000 and 18000rpm as indicated, or in a JEC CENTRA-4X bench-top 
centrifuge at 4500 rpm in a 215A swing-out rotor. High speed centrifugation of 
volumes greater than 1.5m1 was performed in a Sorvall OTD50, 55 or 65B 
ultracentrifuge (Du Pont) with the appropriate Sorvall rotor and speed as indicated. 
Volumes less than or equal to 1 .Sml were centrifuged in an Eppendorf benchtop 
microcentrifuge at 1400 rpm. 
2.2.2 Sterilization Procedures. 
When necessary, plastics (such as microfuge tubes) and solutions were 
sterilized by autoclaving for 20mins. at 120 °C and 15 pounds/inch 2 . Solutions 
prepared in small volumes and those which could not be sterilized in this manner, for 
example DTF, tryptophan, SDS and antibiotics, were sterilized by filtration through 
a disposable Acrodisc filter unit (0.45 micron size; Gelman Sciences). 
In order to inactivate ribonucleases, Corex tubes, glass pipettes and other 
glassware used work with RNA were dry-sterilised by baking at 250 °C for 16hrs. 
2.2.3 Deionisation of Solutions. 
Formamide and acrylamide solutions were deionised by mixing with 0.1-0.2 
volumes of analytical grade mixed-bed resin (20-50 mesh; Bio-Rad Laboratories) for 
30mins. The resin was removed by filtration through Whatman No.1 filter paper. 
Acrylamide and formamide were stored at 4 °C. 
2.2.4 Photography. 
Photographs of agarose gels containing nucleic acids stained with lug/ml 
ethidium bromide were obtained by exposing Polaroid 667 professional film to the gel 
during visualisation of the nucleic acid by short-wave length ultraviolet light (254) 
from a transilluminator. 
2.2.5 Autoradiography. 
[32P]-labelled nucleic acids were detected by exposing pre-flashed X-ray film 
(Du Pont Cronex or Amersham Hyperfilm-MP) to gels and filters in a light-proof 
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cassette with a calcium-tungstate intensifying screen at -70 °C. 
[35S]-labelled DNA was detected by exposure of X-ray film (Du Pont Cronex) 
to gels at room temperature without an intensifying screen. 
2.2.6 Cerenkov Counting. 
Cerenkov counting of free [32P]-Pi released from ['y- 32P]ATP following 
hydrolysis during ATPase assays was performed in a Beckman LS1701 scintillation 
counter set at program 8. 
2.3 MICROBIOLOGICAL METHODS. 
2.3.1 Propagation and Storage of Bacteria. 
Growth and storage of E.coli were carried out as in Maniatis et al., (1982). 
2.3.2 Preparation of Competent E.coli, and Transformation. 
Based on the method of Hanahan, (1983). 
500mls of LB was inoculated with imi of a stationary phase culture of 
NM522 and grown to OD 6. 0.3-0.4. 
The culture was chilled by placing on ice. Cells were harvested at 4 0C, 
resuspended in lOOmls ice-cold 75mM CaC12 , and incubated on ice for 30mins. 
Cells were spun down again at 4 °C, resuspended in 20mls (4% original 
volume) TFBII, and incubated on ice for 30mins. 
Cells were either used immediately, (see below) or snap frozen in liquid 
nitrogen and stored at -70 0C. 
For transformation, cells were aliquoted into 2001il volumes, DNA added 
(about 50-10ng plasmid, or a portion of a ligation mixture) and incubated on ice for 
2Omins. 
Cells were heat shocked at 42 °C for 2-3 mins and placed on ice for Smins. 
imi of LB was added, and the cells incubated at 37 °C for lhr to allow 
expression of the antibiotic resistance gene. 
Aliquots were plated onto LB-amp plates, and if necessary IPTG and X-Gal 
54 
were included in the plates (50 and 60kg respectively per 10cm plate) to allow 
identification of 13-galactosidase minus colonies (containing recombinant plasmid) by 
their white rather than blue appearance. 
Buffers: 
TFBII - 10mM MOPS (pH6.8, adjusted with KOH), 10mM RbC1, 75mM CaC1 2 , 15% 
(v/v) glycerol. Sterilised by autoclaving. 
2.3.3 Propagation and Storage of Yeast. 
Yeast cells were grown and stored as described in Rose et al., (1990). 
2.3.4 Sporulation and Spore Recovery. 
Diploid strains to be sporulated were streaked onto presporulation medium, 
grown overnight, and cells then transferred to a sporulation plate being spread evenly 
over a 2cm2 area of the surface using a drop of sterile dH 20. The plate was incubated 
for between 3 and 7 days at 25 °C or 30°C to allow sporulation to take place. 
Asci were resuspended in 90l spore buffer (1.2M sorbitol, 10mM EDTA, 
100mM citric acid) to give a slightly turbid solution, and 1041 /3-glucuronidase 
(Boehringer Mannheim) added to digest the ascus walls. Dissection of asci was 
carried out using a Singer MSM microdissector (Singer Instrument Co.), the four 
haploid spores being placed separately in a row on a YPDA plate. The plate was 
incubated at the appropriate temperature to allow the growth of spores into discrete 
colonies. 
2.3.5 Transformation of Yeast. 
Yeast transformation was carried out either by the method of Ito et al., (1983; 
below), or by electroporation using a geneZAPPER (IBI) according to the 
manufacturer's instructions. 
A lOOml yeast culture was grown in the appropriate medium to OD 6. 0.4-
0.6. (mid-log phase). 
Cells were harvested, washed with 20m1 sterile TE, re-sedimented and 
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resuspended finally in 5m1 TB. 2081.d 2.5M lithium acetate was added and incubated 
with gentle mixing at room temperature for Mr. 
1-10g DNA in a volume of lOOil sterile dH20 was added to 200il cells 
and incubated at room temperature for 30mins. 
0.7m1 freshly prepared filter sterilised 50% (wlv) PEG-4000 was added, 
mixed and left for lhr at room temperature. 
Cells were incubated at 42 0C for 5mins, washed in imi sterile dH2O and 
plated onto medium selecting for cells that contained the plasmid. 
2.4 NUCLEIC ACID METHODS. 
2.4.1 General. 
Many standard DNA and RNA manipulations were carried out either 
according to Maniatis et al., (1982) or according to enzyme and equipment 
manufacturers' instructions. These included: quantitation of nucleic acids by 
spectrophotometric or ethidium bromide fluorescence; deproteinisation of nucleic acid 
solutions with phenol/chloroform (phenol was glass-distilled grade, water-saturated; 
Rathburn Chemicals); precipitation of nucleic acids with ethanol; restriction 
endonuclease digestion of DNA; agarose gel electrophoresis of DNA; isolation of 
DNA fragments from agarose gels (using the Geneclean kit; Bio 101); filling-in 3' 
recessed ends; dephosphorylation of DNA; ligation of DNA fragments. All DNA and 
RNA solutions were stored in sterile distilled water (dH 20) unless otherwise stated 
(DNA at 4°C, RNA at -200C). 
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2.4.2 Plasmid DNA Preparations. 
2.4.2.1 Small Scale. 
Based on the method of Birnboim and Doly, (1979). 
5mls LB-amp was inoculated with a single bacterial colony and incubated 
at 37°C with shaking overnight. 
1.5mls of the culture was harvested in an eppendorf tube by spinning in a 
benchtop microfuge for 1mm. 
The LB-amp was discarded, cells resuspended in 100d solution A and 
incubated at room temperature for 3-5mins. 
200d solution B was added, the lysed cells mixed by gentle inversion, and 
incubated on ice for 3-5mins. 
150.d solution C was added, the tube was vortexed briefly and placed on 
ice 3-5mins. 
Cell debris was removed by spinning for 5mins in a benchtop microfuge 
and transferring the supernate to a fresh tube. 
The supernate was extracted once with phenol/chloroform. 
DNA was precipitated by adding imi cold absolute ethanol (4 9C), mixing 
by inversion, and sedimented by spinning at 4 °C in a benchtop microfuge for 15mins. 
The pellet was washed once with 70% (v/v) ethanol, dried in a vacuum 
desicator and dissolved in 3041 sterile dH20. 
Buffers: 
50mM glucose, 25mM Tns-HC1 (pH8.0), 10mM EDTA, 1mg/mi lysozyme 
(Sigma) was added just before use. 
0.2M NaOH, 1 % (w/v) SDS (freshly prepared). 
3M sodium acetate pH5.3. 
2.4.2.2 Medium Scale. 
This is essentially a scaled-up version of the small scale plasmid preparation 
above. However, as this was used as the standard plasmid DNA preparation method, 
the DNA being stored at 4 °C for long periods of time, care was taken to extract as 
much protein as possible to remove DNases, and an RNase A step was included to 
remove RNA from the preparation. 
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Steps 1) - 8) as small scale preparation except: 
50mls LB-amp was inoculated and harvested in a 50m1 Falcon tube after growing 
to stationary phase. 
Volumes of solutions were: A - 2mls; B - 4mls; C - 3mls; 100% ethanol - l8mls. 
The single phenol/chloroform extraction was replaced with one phenol and two 
phenol/chloroform extractions. 
All sedimentations were carried out in an ]EEC CENTRA-4X benchtop centrifuge 
except the final DNA sedimentation which was in an HB-4 rotor at 12krpm in 30m1 
corex tubes. 
The DNA pellet was resuspended in 0.5m1 dH 20. 
RNaseA was added to a concentration of 0.2zg/il and incubated at 37 °C 
for lhr. 
RNase treated DNA was extracted once with phenol, then with 
phenol/chloroform until the interface was clear, and finally once with chloroform 
The DNA was precipitated with ethanol, the pellet washed with 70% (v/v) 
ethanol, dried in a vacuum desicator and dissolved in 2501d sterile dH 20. 
This method routinely yielded 100-200jLg of plasmid DNA. 
2.4.2.3 Large Scale. 
Large scale purification of plasmid DNAs to be used for in vitro transcription 
reactions (where the purity of the DNA was important to ensure that there was no 
contaminating RNase), and plasmids to be subjected to hydroxylamine mutagenesis 
or double-stranded sequencing was carried by centrifugation to equilibrium in caesium 
chloride-ethidium bromide gradients. An alkaline lysis method based on that of 
Maniatis et al., (1982) was used. 
500m1 LB-amp was inoculated with a fresh stationary bacterial culture and 
grown at 370C with shaking overnight to stationary phase. 
Cells were chilled on ice and harvested at 4 °C in 250m1 Sorvall pots at 
5krpm for 5 mins. in a GS3 rotor. 
Cells were resuspended in 7.5m1 25% sucrose, 50mM Tns/HC1 pH7.5, 
transferred to a SOml falcon tube and incubated on ice for 10 mins. 
2.5m1 lysozyme (10mg/nil made fresh in dH 20) was added to cells, mixed 
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by gentle inversion and incubated for 30 mins. at room temperature. 
3m! 0.25M EDTA pH8.0 was then added, mixed by inversion and 
incubated on ice for 30mins. 
12ml lysis buffer was added, mixed gently, incubated on ice for 10 mins, 
and centrifuged at 12krpm for 45mins. 
The supernate was transferred to a 50m1 Falcon tube, and the volume of the 
supernate was made up to 30m1 with dH20. CsC1 (30g) was added and gradually 
dissolved by gentle stirring. 
3m! 5mg/mi ethidium bromide was added and the solution transferred to the 
appropriate plastic ultracentrifuge tubes using a pasteur pipette and spun in a TV865B 
vertical rotor overnight at 10 °C (the temperature should not rise above 10 °C as the 
CsC1 will precipitate). 
DNA bands were visualised by exposure to shortwave U.V. light from a 
transilluminator and the plasmid DNA (running below the genomic DNA) was 
removed carefully with a #21 hypodermic needle. 
Ethidium bromide was removed by adding an equal volume butan-1-ol 
saturated with dH 20, vortexing for 2 mins. and spinning at Skrpm for 5mins. The 
ethidium bromide remains in the upper butanol phase therefore the lower aqueous 
phase was removed and transferred to a fresh tube. The washing procedure was 
repeated until all the ethidium bromide had been removed. 
The CsC1 was removed by dividing the solution into two 3m! samples (in 
30m1 Corex tubes), adding 8m1 TB and 8ml propan-2-ol to each, mixing and placing 
at -20°C for 10 mins (to precipitate the DNA). 
DNA was harvested by centrifugation at l0krpm for 30mins, and the pellet 
resuspended in 500d dH20. 
This method routinely yielded 1-2mg of plasmid DNA. 
Buffers: 
TB: 50mM Tris HC1 pH7.5, 20mM EDTA 
Lysis Buffer: 0.1% Triton xlOO, 60mM EDTA pH8.0, 50mM Tns HC1 pH8.0. 
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2.4.3 Sequencing. 
All sequencing reactions were carried out using the Sequenase version 2.0 kit 
(USB) according to the manufacturers instructions. Templates for the reactions were 
either single-stranded preparations of pTZ phagemids (pTZ18R and pTZ19R; 
Pharmacia), or "double-stranded" preparations of plasmids based on pBMPRP2 (see 
below for preparation of templates). Products of sequencing reactions were run on 6% 
(w/v) denaturing polyacrylamide gels in 1X TB buffer, fixed in 10% (v/v) methanol 
10% (vlv) acetic acid for 20mins. at room temperature and dried on a vacuum gel 
drier (Bio-Rad). 
2.4.3.1 Preparation of Single-Stranded pTZ Templates. 
A 5m1 culture of NM522 transformed with the recombinant pTZ was grown 
overnight in M9 medium plus thiamine and ampicillin. 
1 .5m1 2XYT was inoculated with 301Ll of the overnight and grown at 37 °C 
for 45mins. with vigorous shaking. 
4.51.d M13K07 helper phage was added and the culture grown for a further 
6hrs at 37°C with vigorous shaking. 
The cells were pelleted in a microfuge tube and imi of the supernate 
transferred to a fresh tube. 
150.d PEG/NaC1 was added and incubated at room temperature for 20mins. 
Phage were pelleted by spinning for lOmins, and any tubes with no visible 
pellet discarded. 
The supernate was removed, the tubes spun for a further 2mins. and any 
residual PEG removed. 
The pellet was resuspended in 1001Ll dH 20 and extracted twice with 
phenol/chloroform. 
DNA was precipitated with ethanol, the pellet washed in 70% (v/v) ethanol 
and vacuum dried. 
The pellet was dissolved in 25d sterile dH20 and 7d used in the 
annealing step of the Sequenase reaction. 
Buffer: PEG/NaC1: 20% (wlv) PEG 6000, 4M NaCl. 
Note: M13K07 1helper phage was prepared as recommended by the supplier 
(Pharmacia). 
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2.4.3.2 Preparation of Double-Stranded Templates. 
Plasmids to be used directly for "double-stranded" sequencing were treated 
as below before use in the sequenase reaction. 
2jtg of CsC1-purified plasmid DNA in a total volume of 241 was denatured 
by adding 6l 2M NaOH, mixing, and leaving at 37 °C for 5-15 mins. 
70ng primer was added and mixed well with a pipette tip. 
To "snap anneal" primer to template, the DNA was precipitated by the 
addition of 9jzl 3M NaAc pH5.2 followed by 240d cold ethanol, left on ice for 10 
mins, and sedimented by spinning in an Eppendorf rotor at 4 °C for 10 mins. 
The supernate was discarded, the pellet dried in a vacuum and the DNA 
resuspended in 7,ul dH20 for direct use in the labelling reaction (Step 7) of the 
Sequenase Version 2.0 sequencing protocol. 
2.4.4 Hydroxylanune Mutagenesis of Plasmid DNA. 
Random chemical mutagenesis of plasmid DNA was carried in vitro out by treatment 
with hydroxylamine as described by Rose et al., (1990; below). 
The hydroxylamine solution was prepared just prior to use and stored on 
ice until needed: 
Hydroxylamine Solution: 
Hydroxylamine HC1 	 0.35g 
NaOH 	 0.09g 
Ice cold dH20 	 5m1 
Solids were dissolved in the H20 (the pH should be approximately 7.0). 
Warning: Hydroxylamine is a mutagen and should be handled carefully. 
10kg of CsC1-purified plasmid DNA was added to 500d of hydroxylamine 
solution in a microfuge tube and incubated at 37 °C for 20 hrs. 
The reaction was stopped by adding 10d SM NaCl and 50d 1mg/mi BSA. 
The DNA was precipitated by the addition of lml cold 100% ethanol, 
placed at -70°C for 10 mins, and sedimented by spinning in a microfuge for 10 mins. 
The supernate was removed carefully and the DNA resuspended in 100d 
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dH2O. 
101 3M sodium acetate and 250zl 100% ethanol were added, the DNA 
precipitated at -70°C and sedimented as in step 4. 
The pellet was air-dried and resuspended in 10041 dH 20. 
The DNA was then used directly to transform either yeast or E.coli. 
2.4.5 Site-Directed Mutagenesis. 
For the directed introduction of point mutations in vitro into PRP2 DNA 
sequences present in the phagemid vector pTZ18R, a modified version of the method 
described by Kunkel et al., (1987) was used. The advantage of this procedure is the 
attainment of very high mutagenesis rates (routinely 65-85%), allowing clones to be 
screened directly by sequencing. The method involves 5 steps: 
Generation of Uracil-Containing Template DNA: 
The recombinant double-stranded pTZ DNA clone to be mutated was 
introduced into the mutant E. coil strain BW3 13, and a single transformant grown 
overnight in 5m1 M9 medium plus thiamine and ampicillin. This culture was used to 
inoculate fresh M9 medium, grown again to stationary phase, and used to prepare 
single stranded template DNA as described in section 2.4.3.1. Since BW3 13 lacks the 
enzyme dUTPase responsible for metabolising dUTP, DNA synthesis proceeds with 
dUTP incorporation. 
Kinasing the Synthetic Oligodxynuc1tide: 
The appropriate oligodeoxynucleotide carrying the desired mutation (listed in 
table 2.4) was kinased by assembling the kinase reaction as follows: 200pmol 
oligodeoxynucleotide, 3l 1M Tris/HC1 pH8.0, 1.5z1 0. 1M DTT, 1.01d 0.2M MgC12 , 
1 .0d 10mM ATP, 5 units polynucleotide kinase, and dH 20 to 30d. The reaction was 
allowed to proceed for lhr at 37°C, and subsequently the enzyme was inactivated by 
incubation at 68°C for lhr. 
62 
Annealing the Synthetic Oligodeoxvnucleotide to Template DNA: 
0.5pmol uracil-containing single-stranded DNA, lOpmol kinased oligo, 21d 
annealing buffer and sterile dH 20 to 10l were mixed together and heated for 10 
mins. to a temperature 20°C higher than the melting temperature of the synthetic 
oligo. The tube was then allowed to cool slowly, and placed on ice when below 30 °C. 
Polymerisation Reaction and Ligation: 
The annealed oligo was extended from the 3' terminus to copy the U-
containing template strand utilising the enzymes DNA polymerase and T4 DNA 
ligase. The reaction was assembled as follows: 10d annealed oligo/template, 1l 
buffer B, 4.d deoxynucleotide mix, 111 ATP, 2 units T4 DNA ligase, 2 units DNA 
polymerase 1 Klenow fragment (Boehringer) and dH 20 to 20d. The reaction was 
allowed to proceed for 20hrs at 15°C. 
Introduction into WT E.coli: 
To destroy the "non-mutated" uracil-containing strand in vivo the double-
stranded DNA produced as a result of polymerisation and ligation was used to 
transform NM522. To identify mutant clones, single transformants were grown 
overnight in M9 medium plus thiamine and ampicillin, single-stranded template DNA 
(described in section 2.4.3.1.) was isolated and analysed by sequencing. 
Buffers: 
Buffer B: 0.2M Tris/HC1 pH7.5, 0. 1M MgC1 2 , 0. 1M DTT. 
Deoxynucleotide Mix: 2mM each of dATP, dTT'P, dCTP, and dGTP. 
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2.4.6 Yeast Genomic DNA Preparation. 
1) A 20m1 yeast culture was grown in the appropriate medium to OD 6w 0.5- 
0.7. 
Cells were harvested and resuspended in 400d sorbitollNaPO 4 . 
100141 lyticase at 2500U/ml in sorbitol/NaPO4 was added and cells incubated 
for lhr at 37°C with gentle shaking. Cells were checked for sphaeroplast formation. 
Sphaeroplasts were pelleted and resuspended in 0.5m1 TE. 
5014120% SDS was added, mixed well and incubated at 65°C for 30mins. 
200/Li 5M potassium acetate was added and left on ice for lhr. 
Cell debris was pelleted by spinning for 5mins. in a microfuge, and the 
supernate transferred to clean tube. 
DNA was precipitated by the addition of an equal volume of isopropanol, 
mixing and leaving at room temperature for 5 mins. 
The DNA was harvested by spooling on a modified Gilson pipette tip 
(2001Ll size) which had been melted at the end to form a blob. 
The DNA was resuspended in 300d 'FE. 
Buffers: 
Sorbitoi/NaPO4 : 1.2M sorbitol, 50mM NaPO4 , 5mM DIT added immediately before 
use. 
TE: 50mM Tris/HC1 pH7.5, 20mM EDTA. 4 pH8.0 
2.4.7 Extraction of RNA from Yeast. 
A lOOml yeast culture was grown in the appropriate medium to OD 0.6. 
The culture was chilled on ice and harvested in Sorvall 250m1 pots at 
5krpm for Smins in a GS-A rotor at 4 °C. 
The cell pellet was washed in 9m1 TNE (cold), transferred to a 15ml corex 
tube spun down and finally resuspended in imi TNE. 
To fracture the cells, approximately 100d acid-washed glass beads were 
added and the tube vortexed vigorously for 2mins. 
Rapidly, 3m1 TNE, 0.2m1 20% (wlv) SDS, and 4m1 phenol were added and 
the tube vortexed again for 2mins. 
After spinning for 5mins. at 4.5krpm the aqueous phase was transferred to 
a fresh tube and re-extracted with 4m1 phenol/chloroform. This was repeated, 
transferring the aqueous phase to a fresh tube each time until the interface was clear. 
One chloroform extraction was performed and the RNA precipitated with 
ethanol. 
The RNA was sedimented by spinning at l2krpm in an HB-4 rotor at 4 °C 
for 15mins, the pellet washed with 70% (vlv) ethanol, air dried and dissolved in 
1501d sterile dH20. 
RNA was stored at -20°C as an aqueous solution. 
Buffers etc.: 
TNE: 50mM Tris-HC1 (pH7.5), 5mM EDTA, 100mM NaCl. 
Acid-washed glass beads (100 mesh; BDH) were prepared by boiling for 
20mins in 1M HC1, cooling, washing extensively in dH 20 drying and baking at 250°C 
for l6hrs. 
Note: 
If it was not convenient to extract RNA from cells immediately after 
harvesting they were stored at -20 °C in absolute ethanol and washed once in TNE 
before proceeding with the extraction. 
2.4.8 Labelling Restriction Fragments by Random Priming. 
Modified from Feinberg and Vogelstein, (1984). 
2-10/hg plasmid DNA was digested to completion and electrophoresed 
through an agarose gel to separate the fragments. 
The required block of agarose was cut out and the DNA fragment purified 
using the Geneclean procedure. 
The concentration of the fragment was assessed by running a small volume 
on an agarose gel and the DNA stored at 4 °C. 
The oligolabelling reaction was set up by adding together the following in 
this order: 50-100ng fragment made up to 35/hl with dH20 and denatured by boiling 
for 3-5mins and then cooling on ice; 10141 OLB; 2141 BSA at 10mg/nil; 3/hl 
[0132P]dCTP at lOmCi/ml; 2 units DNA polymerase 1 Kienow fragment. 
The reaction was incubated at room temperature for 6-8hrs or overnight. 
The labelled DNA was separated from the unincorporated nucleotides by 
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passing the reaction mix over a gel exclusion column (NAP-10 column, Pharmacia) 
equilibrated with 10mM sodium phosphate (pH7.0). 
Buffers: 
OLB was made from the following: 
*Solution 0: 1.25M Tris-HC1 (J)H8.0),0. 125M MgC1 2 . 
#Solution A: imi solution 0, 18d (3-mercaptoethanol, 5z1 each dATP, dTFP and 
dGTP at 0.1M. 
*Solution B: 2M Hepes (J)H6.6 with 5M NaOH). 
#Solution C: Hexadeoxyribonucleotides (Pharmacia) at 90 OD units/ml in dH 20. 
A:B:C were mixed in the ratio 1:2.5:1.5 to make OLB#. 
(* = stored at 4°C, # = stored at -200C) 
2.4.9 Denaturing Agarose Gel Electrophoresis of RNA. 
A 1.4% (w/v) agarose gel containing MOPS buffer and formaldehyde was 
used. Ethidium bromide was included to allow the visualisation of RNA following 
electrophoresis. Warning - formaldehyde releases a dangerous vapour, therefore the 
gel should be poured and run with care, and in a fume cupboard if possible. 
2. ig agarose was added to 15m1 lox MOPS buffer and 130.5m1 dH20, 
swirled to mix, and boiled until the agarose was dissolved. 
After cooling to below 65 °C, 7.65m1 formaldehyde (37%) and 7.5d 
5mg/mi ethidium bromide were added and the gel poured. 
2) RNA (30ig total yeast RNA is adequate for Northern analysis) was made 
up to 20/Ll with dH20, 201d Formamide Sample Buffer (FSB) was added and the 
samples were incubated at 65°C for 5 mins to denature and snap cooled on ice. 
10d gel loading buffer (FDE) was added to each RNA sample prior to 
loading into dry wells and samples were run in before covering the gel with running 
buffer. 
The gel was run at 1OV/cm using a pump to mix the buffer. Following 




FSB: 100d lOx MOPS, 200d formamide, 120l formaldehyde (37% w/v). 
FDE: 0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll. 
lOX MOPS: 25g MOPS, 8. inil 3M sodium acetate p115.0, 20m1 250mM EDTA up 
to 500m1 with dH2O (pH adjusted to 7.0 with NaOH). 
2.4.10 Capillary Blotting of DNA AND RNA. 
Southern and Northern blotting of agarose gels containing DNA or RNA was 
onto Hybond-N nylon membrane (Amersham) by drawing up 10XSSC through the gel 
into a stack of paper towels as shown in figure 2.2 below. Prior to assembling the 
blot, agarose gels were treated as follows: 
RNA-containing gels were washed twice, each for 20mins, in 10XSSC. 
DNA-containing gels were soaked twice in denaturation buffer (0.5M NaOH, 
1 .5M NaOH) each for 20 mins, followed by soaking twice in neutralisation solution 














Figure 2.2: Capillary transfer of RNA or DNA from agarose 
gels 
After transfer, RNA and DNA were fixed to the membrane by exposure to UV 
light in a UV Stratalinker 1800 (Stratagene) using the auto-crosslink setting. 
2.4.11 Hybridisation of Southern and Northern Blots with Random Primed 
Probes. 
Northern and Southern blots were hybridised in bottles in a Hybaid 
hybridisation oven used according to the manufacturer's instructions. Pre-
hybridisation, hybridisation and washing were as below, probes were made as in 
section 2.4.8: 
Pre-hybridisation was carried out at 42 0C for 6-8hrs in 1X"P" Buffer, 50% 
(v/v) formamide, 1M NaCl, lOjzg/ml denatured sonicated salmon sperm DNA 
(Stratagene). 
The probe was added following denaturation by boiling for 5mins and 
chilling on ice. 
Hybridisation was carried out overnight at 42 °C. 
The membrane was washed in the same bottle as follows: 
2X10mins. at 42°C with lOOmis. 2X SSC. 
2X30mins. at 65°C with lOOmis. 2X SSC + 0.5% (w/v) SDS. 
2X30mins. at room temperature with lOOmis. 0. lx ssc. 
The membrane was blotted on filter paper to remove excess liquid, covered 
in Saran Wrap and exposed to X-ray film. 
Buffers: 
5X "P" Buffer: 1% BSA, 1% PVP (MWt. 40kDa), 1% Ficoll (M.Wt. 400kDa), 
250mM Tns-HC1 pH 7.5, 0.5% (w/v) sodium pyrophosphate, 5% (w/v) SDS. 
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2.4.12 In vitro Transcription. 
T7 RNA polymerase-directed in vitro transcription reactions were performed 
essentially as described by Davanloo et al., (1984). Radiolabelled transcripts were 
produced using the plasmids pT7rp28s and pSM8 (described in table 2.3) as 
templates. 
0.2jLg linearised plasmid DNA (taken directly from a restriction 
endonuclease digest), ii lox reaction buffer, 1l nucleotide mix, 30Ci [01-32P]UTP 
(800Ci/mmol) and 10 Units RNasin (Promega) were made up to 9.541 with dH 20. 
0.5zl 17 RNA polymerase was added and the reaction mix incubated at 
37°C for 11 mins. 
The reaction was stopped on ice and used directly in splicing reactions. 
Buffers: 




Nucleotide mix: 5mM each ATP, GTP, CTP, 0.25mM UTP (Pharmacia, 17 Grade). 
2.4.13 Denaturing Polyacrylaunide Gel Electrophoresis of DNA and RNA. 
DNA and RNA were electrophoresed through 6% (wlv) acrylamide, 8M urea 
gels. Gels for running DNA samples contained 1X TB buffer, gels for running RNA 
samples contained lx TBE (recipes for buffers are given in 2.1.8). 
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2.5 PROTEIN AND IMMUNOLOGICAL METHODS. 
2.5.1 Quantitation of Proteins. 
Protein concentration was estimated using the Bradford assay (Bradford, 1976) 
with a dye concentrate purchased from Bio-Rad and used as recommended by them. 
To generate standard curves BSA was used. 
2.5.2 SDS-Polyacrylaniide Gel Electrophoresis of Proteins. 
Proteins were separated by SDS-discontinuous poylacrylamide gel 
electrophoresis (SDS-PAGE) as described by Laemmli, (1970). 7.5% gels were cast 
between 16xl6cm glass plates with 1.5mm spacers and 0.5cm wide wells, the 
stacking gel being at least as deep as the wells. Samples were prepared by adding an 
equal volume of 2X sample buffer (125mM Tris-HC1 (pH6.8), 200mM DTF, 4% 
(w/v) SDS, 40% (v/v) glycerol, 0.02% (w/v) bromophenol blue; stored at -20°C), 
heating to 100°C for 8mins and centrifuging for 3-5mins to remove any precipitated 
material. Gels were run in an ATTO electrophoresis tank at 30-150V in SDS-PAGE 
buffer (25mM Tris base, 192mM glycine, 0.1 % (w/v) SDS). 
2.5.3 Staining SDS-polyacrylaniide Gels. 
Polypeptides separated by SDS-PAGE were visualised either by staining with 
Coomassie Blue to detect proteins at concentrations at or above 0.5/4g/cm 2 of gel, or 
for the detection of proteins at concentrations below 0.5/hg/cm 2 of gel the more 
sensitive method of silver staining was used. 
2.5.3.1 Coomassie Staining of Protein Gels. 
SDS-PAGE gels were incubated at 37 0C for 30-60min in sufficient coomassie 
staining solution (50% (vlv) methanol, 10% (vlv) acetic acid, 0.1% (w/v) Coomassie 
Brilliant Blue G) to cover the gel. Following staining the gel was destained by 
incubating in destaining solution (10% (v/v) methanol, 10% (v/v) acetic acid) at 37 0C 
until the background was low. For storage, gels were incubated in 10% (v/v) glycerol 
for 30min before being placed between 2 sheets of acetate and dried in a vacuum gel 
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drier (Bio-Rad) at 800C. 
2.5.3.2 Silver Staining of Protein Gels. 
This highly sensitive silver staining method is taken from Ansorge, (1985) and 
was used for the detection of trace impurities during protein purification procedures. 
Prior to staining with silver, the method involves impregnation of polypeptides with 
a weak solution of KMnO4 and a copper salt. 
Gels were soaked in 200mls 10% (vlv) methanol 10% (v/v) acetic acid for 2 
hrs and then treated as shown in table 2.5. Unless otherwise stated, volumes of 
200mls and a platform shaker to agitate the solution (at about 40rpm) were used. 
Table 2.5 Silver Staining Procedure 
STEP TREATMENT TREATMENT 
TIME 
1 50% methanol, 12% trichioroacetic acid, 
2% CuC12 
20 mins. 
2 Solution A: 10% ethanol, 5% acetic 
acid 
10 mins. 
3 0.01% KMnO4 10 mins. 
4 Solution A 10 mins. 
5 10% ethanol 10 mins. 
6 dH20 10 mins. 




8 10% K2CO3 1 mm. 





10 solution A 1-2 mins. 
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2.5.4 Western Blotting. 
Following SDS-PAGE proteins were electrophoretically transferred to 
Nitrocellulose (Schleicher and Schuell) in a Trans-Blot Electroblotting Cell (Bio-Rad) 
with plate electrodes, stained with Ponceau S (Sigma) to visualise molecular weight 
markers and verify transfer, and probed for the presence of the protein of interest 
(PRP2) using antibodies as described below. 
The following were soaked in transfer buffer: gel, nitrocellulose sheet, two 
Scotchbrite pads and 4 pieces of blotting paper (cut to the same size as the gel). 
The gel was "sandwiched" between 1 Scotchbrite pad and 2 pieces of 
blotting paper on one side, the nitrocellulose followed by 2 pieces of blotting paper 
and the second Scotchbrite pad on the other in a Trans-Blot gel holder. Any air 
bubbles were carefully removed. 
The gel was placed in an Electroblotting Cell (Nitrocellulose towards the 
anode) with cooling coils, filled with transfer buffer and transferred for lhr at 100V. 
After transfer the filter was air dried, re-wet in dH 20 and stained in 
Ponceau S for 1-2mins. The filter was rinsed with dH 20 to remove excess stain. 
The filter was incubated in blocking solution for 1-2hr. 
Blocking solution was discarded, the filter rinsed in 1XTBS and incubated 
with primary antibody at the appropriate dilution in antibody solution overnight at 4 °C 
or at room temperature for 1-2hr (approximately imi per 10cm 2 of membrane). 
The filter was rinsed twice in wash buffer and washed 3 times in SOml 
wash buffer for 15min at room temperature. 
The filter was then incubated in 15m1 alkaline phosphatase-conjugated goat 
anti-rabbit antibodies (Promega Biotec) at the recommended dilution (1:7500) in 
antibody solution. 
As 7). 
The membrane was rinsed in development solution and then incubated in 
5-10mi development solution containing 0.33mg/ml NBT and 0. 165mg/nil BCIP (both 
Promega Biotec.) until the desired staining of bands was reached. 
The development reaction was terminated by washing the membrane in 
several changes of water. The membrane was blotted dry, covered in Saran Wrap 
and stored in the dark (to prevent the colour fading). 
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Buffers: 
Transfer buffer: 20mM Tns base, 150mM glycine. 
Blocking solution: 5% (w/v) BSA, 1X TBS. 
Wash solution: 1XTBS, 0.1% (v/v) NP-40. 
Antibody solution: 1% (w/v) BSA, lx TBS. 
Development solution: 100mM Tns-HC1 (pH9.5), 100mM NaCl, 50mM MgC1 2 . 
2.5.5 In vitro Splicing. 
2.5.5.1 Preparation of Yeast Splicing Extracts. 
Modified from Lin et al., (1985). 
The appropriate medium was inoculated with a fresh stationary yeast culture 
and grown overnight to OD 6. 0.5-0.7. (31 at OD6. 0.6 gave 4m1 extract). 
Cells were spun down at room temperature, resuspended in = 50mls 50mM 
potassium phosphate pH7.5, spun down again and resuspended in 40mls lyticase 
buffer. 1-1 .5mls lyticase (Sigma) at 2500U/ml was added and incubated for 30mins-
lhr at 30°C (23°C for temperature-sensitive strains). 
Cells were checked for sphaeroplast formation, spun down slowly, at 2-
3krpm and washed 2X in 1.2M sorbitol, resuspending gently and spinning down 
slowly. 
Cells were spun down slowly again, washed once with SB-3 (ice cold) and 
placed on ice. Everything was done at 4 °C from this point on. 
The cell pellet was weighed, resuspended in lml buffer A/g cells, 
transferred to a chilled Dounce homogeniser and homogenised with 10-13 SLOW 
strokes. 
The homogenate was transferred to a beaker on ice with a magnetic bar 
stirring. The volume was checked and 1/9th  volume of 2M KC1 was added dropwise. 
The extract was left stirring for 30mins. 
After transferring to a cold polycarbonate SS-34 tube, the cell debris was 
pelleted by spinning at l7krpm for 30mins. 
The supernate was transferred to a TiSO polycarbonate bottle avoiding the 
top (lipid) layer, and spun at 37krpm for lhr at 4 °C in a pre-cooled Ti50 rotor. 
The supernate was transferred to dialysis tubing, again avoiding the lipid 
layer and dialysed for 31irs against 11 buffer D with changes of buffer after each hour. 
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11) Finally the extract was spun for lOmins in microfuge tubes (at 4 0C) and 
snap frozen in aliquots. 
12) Extracts were stored at -70 °C, and were not thawed and refrozen more than 3 
times as this causes loss of activity. 
Buffers: 
Lyticase buffer: 1.2M Sorbitol, 50mM potassium phosphate pH7.5, 30mM Dfl' 
YPDAS: 1 %(w/v) Yeast Extract, 2% Peptone, 2% Glucose, .002% adenine sulphate, 
1.2M Sorbitol. 
SB-3: 50mM Tris-HC1 pH7.5, 10mM MgCl2 , 1.2M Sorbitol, 3mM DTT* 
Buffer A: 10mM HEPES-KOH pH7.5, 1.5mM MgC12 , 10mM KC1, 0.5mM DTT' 
Buffer D: 20mM HEPES-KOH pH7.5, 0.2mM EDTA pH8.0, 0.5mM D'F, 50mM 
KC1, 20%(v/v) Glycerol. 
DTT was added fresh immediately prior to use. 
2.5.5.2 In vitro Splicing Reaction. 
Assays for the production of splicing intermediates and products were carried 
out essentially as described by Lin et al., (1985). The standard reaction 10jd was 
assembled at room temperature as below. Splicing extract was thawed and incubated 
for 3-5mins at 25 °C before use. Substrates were produced by transcription in vitro 
(section 2.4.12). 
The splicing mix was prepared as follows: 101.d 30% (w/v) PEG 8000 
(Sigma), 61d 1M potassium phosphate (pH7.5), 141 0.25M MgC1 2 , 11d 0.225M ATP, 
- 0.5iCi substrate RNA from an in vitro transcription reaction, sterile dH 20 to 5041. 
The splicing mix was aliquoted into 5il volumes and 5d splicing extract 
added and incubated at 25 1C for the required time (2-30mins). 
The reactions were stopped on ice. 
To analyse the RNA, 2d lmg/ml proteinase K (in 50mM EDTA, 1% (w/v) 
SDS) was added and incubated at 37 °C for 30mins. 
100d "splicing cocktail" buffer was added and the sample extracted twice 
with phenol/chloroform and precipitated with ethanol. 
Samples were electrophoresed through a 6% (wlv) denaturing acrylamide 
gel and detected by autoradiography. 
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Buffers: 
"Splicing cocktail": 50mM sodium acetate p115.3, 1mM EDTA, 0.1% (wlv) SDS, 
25g/ml E. coli tRNA. 
2.56 Native Gel Electrophoresis of Splicing Complexes. 
Native gel electrophoresis was carried out according to Pikielny a al. (1986) 
except that the EDTA concentration in the gel was 10mM (1mM in Pikielny et al., 
(1986)). This system separates three splicing complexes designated I, II, and ffi, 
complex II (the final complex formed) being the active spliceosome, as verified 
previously by the analysis of the RNA species in the three complexes (Brown J.D. 
PhD. thesis). 
15cmXl5cmXl.5mm composite gels were made and run in an ATTO 
electrophoresis tank by dissolving 0.5g agarose in 40m1 dH 20 and cooling to 
approximately 50°C. 2.5ml 1OXTB, lml 0.5M EDTA, 5ml 30% (w/v) acrylamide 
(60:1 acrylamide:bis-acrylamide) were added quickly and the volume made up to 
50ml. 0.5m1 10% APS and 50d TEMED were added and the solution poured into 
warm plates (370C). A comb with 10 X 9mm slots was inserted and the gel allowed 
to set for at least Mr. 
The gel was pre-electrophoresed at 4 °C for lhr in 0.5X TB, 10mM EDTA 
at 80V. 
Splicing reactions were set up as in section 2.5.5.2 and stopped on ice. To 
51.d aliquots of the reactions 5d ice cold Q buffer was added and incubated on ice for 
5mins. 
2.5p.l 5X RNP load buffer was added to each sample,and they were loaded 
onto the gel and run at 4 °C for 8-10hrs at 80V. 
Buffers: 
Q buffer: 450mM KC1, 2.3mM Mg-acetate, 23mM EDTA, 18mM Tris-HCL (pH 
7.5), 1.2mg/mI yeast total RNA (prepared as in section 2.4.4). 5X RNP load buffer: 
5X TB, 50mM EDTA, 50% (v/v) glycerol, 0.25% (w/v) each bromophenol blue and 
xylene cyanol FE. 
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2.5.7 Immunoprecipitation. 
Immunoprecipitation of splicing complexes from splicing reactions or mock 
splicing reactions (splicing reactions with no ATP) was carried out essentially as in 
Lossky et al., (1987). Antibodies were pre-bound to protein-A sepharose (PAS) 
beads. In order to lower the background caused by nonspecific binding of labelled 
RNA to PAS, a blocking step was included following binding of antibodies to PAS. 
PAS beads (Sigma) were swollen in NTN for 20mins and washed 4 times 
with lml N1'N. The beads were aliquoted into appropriate volumes (50d per 
reaction) the antibody added (sufficient to give maximal precipitation of antigen), and 
incubated in 0.3m1 NTN with mixing for lhr. 
0.2m1 blocking buffer was added and the incubation continued for 45mins. 
The beads were washed 5 times with imi MN, and placed at 4 °C until the splicing 
reaction mix was ready. 
A 101d splicing reaction was added to lOjzl ice-cold buffer Q and incubated 
on ice for lOmins. The quenched reaction was diluted in NTN to give a final volume 
of 300d and was then added to the antibodies bound to PAS beads and incubated at 
4°C for 2hrs with mixing. 
The beads were washed 2X with lml NTN, lx with NT removing the final 
(NT) wash carefully. 
To analyse RNA 501d proteinase K solution was added and incubated at 
37°C for 30mins with mixing. 
SO/Ll dH20 was added and the sample phenol/chloroform extracted 3X. 
RNA was precipitated with ethanol adding 1l E.coli tRNA at 20mg/mi to 
each sample as a carrier. 
The samples were electrophoresed through a 6% (w/v) denaturing 
polyacrylamide gel, the gel covered with Saran Wrap and exposed to X-ray film. 
Buffers: 
Block buffer: BSA, Glycogen, E.coli tRNA each at lOOj.tg/ml. Freshly made. 
Q buffer: 450mM KC1, 2.3mM Mg-acetate, 23mM EDTA, 18mM Tns-HC1 (pH 
7.5), 1.2mg/mi yeast total RNA (prepared as in section 2.4.4). 
NTN: 50mM Tris-HC1 (pH7.5), 150mM NaCl, 0.1% (v/v) NP-40. 
NT: As NTN but with no NP40. 
Proteinase K solution: 50mM Tris-HC1 (pH7.5), 300mM NaCl, 5mM EDTA, 1.5% 
(w/v) SDS, 2mg/mi proteinase K (store as -20C). 
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2.5.8 Purification of Polyhistidine-Tagged PRP2 Protein from Yeast. 
This 2-step small-scale system was developed to purify soluble PRP2 protein 
from yeast extracts prepared from cells induced to overexpress polyhistidine-tagged 
PRP2. Extracts were passed sequentially over 2 columns: 
Ni2 -nitrilotriacetic acid agarose (NTA) column 
Polyuridylic acid agarose column. 
2.5.8.1 Preparation of Yeast Extracts For Purification of PRP2 Protein. 
The yeast strain S150-2B harbouring the GALl-regulated histidine-tagged 
PRP2 gene (present in pBMPRP2) was grown in 1.51 YMGCas (repressing 
conditions) to mid-log phase (OD6w 0.6). 
Cells were harvested using sterile 250m1 Sorvall pots, the glucose media 
discarded and the cells resuspended in 41 YMGRCas to give an OD NO of 0.12. 
Cells were grown under these inducing conditions to mid-log phase (0.6 
OD), for between 7 to 10 hrs. and harvested using 500m1 Sorvall pots. 
Cells were washed, sphaeroplasted, homogenised and subjected to 
centrifugation using essentially the same procedure as for the preparation of splicing 
extracts (section 2.5.5.1, steps 2-9). The only changes made to this protocol were as 
follows: 
DTT was not added to buffer A or to SB3, as reducing agents are not compatible 
with the use of nickel-chelating resin. 
The final dialysis in buffer D (step 10) was omitted, the extract being snap frozen 
following the 37krpm spin, and stored at -70C until required. 
A 41 culture gave 6-7mls of extract. 
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2.5.8.2 Assembling and Running Purification Columns: 
Columns were run at 4 °C, and all buffers were pre-cooled to 4 °C prior to use. 
A peristaltic pump was used to control the flow rate of extracts and buffers over the 
columns. The volume of each column refers to the volume of packed resin placed into 
Bio-Rad Econo-columns of the appropriate size: 4m1 packed nickel-chelating resin 
(Invitrogen) was placed into a 1.77cm 2 5cm length column cat. No. 737 1506; imi 
packed polyuridylic acid agarose (Sigma) was placed into a 0.2 cm 2 5cm length 
column cat. No. 737 0506. 
STEP I - Nickel-Chelating Column. 
Adapted from Hoffman and Roeder, (1991). 
A 4ml nickel-chelating column was equilibrated with 20mM Tris/HC1 
pH7.9, 0.5 M NaCl, by passing 40mls of buffer over the column at a rate of 
20mls/hr (all procedures were carried out at 4 0C). 
An equal volume of 2X sample buffer was added to yeast cell extract 
prepared from 41 of cells and imidazole.HC1 pH7.9 added to a concentration of 1mM 
before loading onto the NF'-NTA column. 
The extract was circulated over the column at a flow rate of approximately 
15mls/hr, for 2 hrs. 
The column was washed with 30mls BC 100 containing 20mM 
imidazole.HC1 pH7.9, followed by 20mls BC 100 containing 49mM imidazole.HC1 
pH7.9 at a flow rate of 15mls/hr. 
PRP2 protein was step-eluted with Smls BC100 containing 150mM 
imidazole.HC1 pH7.9 followed by 7mls BC100 containing 200mM imidazole.HC1 
pH7.9. passed over the column at a flow rate of 4mls/hr. imi eluate fractions were 
collected, numbered 1-12 and analysed by SDS-PAGE and silver staining to identify 
the peak elution fractions. Those containing the highest PRP2 protein concentration 
were reproducibly fractions 6-9. 
Buffers: 
2X Sample buffer: 20% glycerol, 20mMTris/HC1 pH7.9, 1M NaCl. 
BC100: 20% glycerol, 20mM Tns/HC1 pH7.9, 100mM KC1. 
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STEP II - Poly-U Agarose Column. 
Adapted from Kim et al., (1992). 
Peak fractions from the nickel-chelating column were pooled and dialysed 
against 31 BP containing 50mM KC1 for 2hrs with a change of buffer after one hr. 
During the dialysis, a imi poly-U agarose column was washed with 20m1 
BP containing 50mM KC1 at a flow rate of 15mlsIhr. 
The dialysed protein sample was circulated over the column at a flow rate 
of 15mls/hr for 2hrs. 
The column was washed with 20mls BP containing 100mM KC1, followed 
by lOmis BP containing 150mM KC1 at a flow rate of 15mls/hr. 
PRP2 was step eluted with 5m1 BP containing 200mM KC1 followed by 5m1 
BP containing 250mM KC1 passed over the column at a flow rate of 4m1/hr. 0.5m1 
eluate fractions were collected, numbered 1-20 and analysed by SDS-PAGE and silver 
staining to identify the peak PRP2 containing fractions. Essentially pure PRP2 was 
reproducibly eluted in fractions 11 and 12. 
Buffers: 





* DTT was added fresh just prior to use. 
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CHAPTER 3. 
Isolation and in vivo Characterisation of Dominant 
Negative PRP2 Mutants. 
3.1 INTRODUCTION. 
Rapid progress in our knowledge of the yeast spliceosomal components and 
their interactions has been achieved through genetic studies in Saccharomyces 
cerevisiae. The first pre-mRNA splicing mutants were isolated from a pool of heat-
sensitive mutants defective in RNA metabolism and fell into 9 complementation 
groups named rna2-10I11 (Hartwell, 1967; later renamed prp2 -1 0/11). Subsequently, 
these prp mutants have been shown to be defective in pre-mRNA splicing as indicated 
by the accumulation of unspliced precursor mRNAs when incubated at the restrictive 
temperature (Rosbash et al., 1981; Teem et al., 1983; Lustig et al., 1986). By 
genetic complementation of these defects, a number of genes encoding essential 
splicing factors were cloned. These original mutant strains have provided the basis 
for a number of other genetic screens specifically directed at the isolation of splicing 
factors which functionally or physically interact with the protein in question (see 
section 1.5.3). One such approach, the isolation of extragenic suppressors of 
conditional lethal mutations, has been of particular use in the multicomponent system 
of splicing, and it was this classical genetic approach which was initially chosen in 
this study to attempt to identify splicing factors which interact with PRP2. 
Three prp2 mutant strains available in this lab. (the alleles prp2-1 , prp2-2 and 
prp2-4) were mutagenised using U.V. radiation, and plated at the non-permissive 
temperature (34 °C) to select for pseudorevertants. In order to allow the putative 
suppressor gene(s) to be analysed and eventually cloned, pseudorevertants were 
screened for those which had the additional phenotype of cold-sensitivity. Cloning of 
the suppressor genes would be facilitated through screening a yeast genomic DNA 
library for functional complementation of the cold-sensitive defect. Unfortunately, 
genetic analysis of all stable cold-sensitive suppressors that were isolated, showed that 
cold-sensitivity and suppression were not linked ie. in each case, the mutation 
responsible for suppression of the heat-sensitive phenotype, and the cold-sensitive 
mutation resided in separate genes. Thus the suppressor genes could not be cloned by 
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complementation. It is likely that the failure of this method to produce informative 
mutants was linked to the nature of the mutant alleles used. For such a screen it is 
favourable to employ fully characterised mutants that are known to disrupt either a 
specific function of the protein, or to interfere with its interaction with other factors. 
Such information for these pip2 alleles was unavailable. 
Taking these considerations into account, an alternative approach was adopted; 
that of isolating conditional dominant negative PRP2 mutants whose overexpression 
causes a cessation of cell growth as a consequence of interference with wild-type 
(WT) PRP2 function. Such inhibition at the protein level is likely to provide potent 
agents for studying interactions between components of multiprotein systems 
(Herskowitz, 1987). In the case of PRP2, one way in which a dominant mutation 
might disrupt the function of its WT cellular counterpart, would be by competing for 
binding to a common spliceosomal binding site or 'pocket'. As the interaction of WT 
PRP2 with spliceosomes is a transient event, an inactive PRP2 molecule which forms 
a stable (non-transient) association with complexes would prevent access of WT PRP2 
and cause the accumulation of 'jammed' inactive splicing complexes containing 
mutant PRP2 protein. This hypothesis is described diagrammatically in figure 3.1. 
In addition to providing an excellent basis for a genetic screen for interactive 
suppressors, a mutant of this kind would also facilitate the biochemical technique of 
chemical or photo-crosslinking to specifically identify RNA species with which PRP2 
might interact. 
This chapter describes the use of a genetic screen to isolate dominant 
inhibitory PRP2 mutants generated by random mutagenesis of the entire PRP2 open 
reading frame fused to an inducible promoter. Initially, candidates possessing the 
required growth inhibitory phenotype were tested to determine whether the defects 
were plasmid-encoded. Experiments were subsequently carried out to explore the 
effects of the mutations in vivo, and to probe the mechanism of dominance. 
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FIGURE 3.1 Model to Explain how a Dominant Inhibitory PRP2 Mutation Might 
Interfere with the Activity of its Wild-Type Counterpart. 
Wild-Type PRP2 protein transiently associates with the assembled spliceosome 
eliciting its activity required for step one of the splicing reaction. 
A dominant negative form of PRP2 (dn) containing an amino acid substitution 
within a functionally important site (asterisk) is introduced. The mutation does not 
affect binding of dn to complexes therefore WT and mutant proteins compete for 
entry into spliceosomes. Once bound however, the mutant is unable to elicit the 
activity required for step one and release from complexes is inhibited, resulting in the 
formation of inactive "stalled" complexes. 
When expression of the dominant negative protein is repressed, the wild-type 
scenario prevails. If however the inhibitory molecules are overproduced, limiting 
spliceosomal factors may be sequestered; dominant negative protein will deny entry 






















3.2 METHODS AND MATERIALS. 
3.2.1 Preparation of Yeast Cell Extracts by Sonication. 
Cell extracts were prepared by sonication of S150-2B cells harbouring 
pBMPRP2 or pBMPRP2'. Cells were grown to mid-log phase in YMOCas, the 
cultures split, harvested, one half resuspended in lOOmi YMGCas (repressing 
medium), and the other in lOOml YMGRca5 (inducing medium) to an ODnm of 
0.12. The cultures were incubated at 30°C with shaking, grown to an ODnm of 0.6 
and harvested. Cells were washed in lOmls TBS, pelleted again, and finally 
resuspended in 1 m TBS plus 0.1 % (v/v) NP-40 in a microfuge tube. The tube was 
placed on ice and the cells sonicated three times for 30 seconds, with 30 second 
intervals. To remove cell debris, extracts were spun in a microcentrifuge for lOmins 
at 4°C and the supernate transferred to a fresh tube. The extracts were snap frozen 
in liquid nitrogen and stored at -70°C. 
3.2.2 Rescue of Plasmid DNA from Yeast Cells. 
The standard method used to isolate plasmid DNA from yeast involves the 
preparation of yeast total genomic DNA which is subsequently used to transform 
E. coli. As this method was found to be inefficient for the isolation of pBMPRP2-
derived plasmids from S150-2B, a more reliable procedure was developed consisting 
of, briefly, the initial cell lysis steps of the protocol for yeast genomic DNA 
preparation, followed by the Bimboim and Doly method of 1979 to isolate plasmid 
DNA which was then successfully introduced into E. coli. 
Cultures of the dominant negative mutants were grown in YMGCas and used 
in steps 1-5 of the yeast genomic DNA preparation procedure (section 2.4.6.). The 
resulting cell lysates were treated exactly as in steps 3-9 of the small scale plasmid 
DNA preparation (section 2.4.2.1), starting with the addition of 100d solution A. All 
301d of DNA was used to transform NM522, and in each case between 2 and 5 
transformants were obtained. 
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3.3 RESULTS. 
3.3.1 Isolation of Three Putative Dominant Negative PRP2 Mutants. 
An important requirement for the isolation and propagation of potentially 
dominant negative mutants is a stringently regulated expression system. This was 
provided by the plasmid pBMPRP2 which contains the entire PRP2 coding region 
fused to the GALl inducible promoter which provides tight carbon source-dependent 
regulation of expression at the level of transcription (Johnson, 1987). When cells 
containing this plasmid are grown in glucose-containing medium expression of the 
PRP2 gene from the GALl promoter is repressed, whereas when grown in galactose-
containing medium PRP2 is overexpressed, resulting in overproduction of the PRP2 
protein. As the inducer, galactose, is itself metabolised, the neutral carbon source 
raffmose was included in the galactose-containing medium (YMGRCas). 
pBMPRP2 was subjected to random chemical mutagenesis by treatment with 
hydroxylamine (section 2.4.4) which specifically introduces transition mutations (C-G 
to A-T). To test the efficacy of the mutagenesis procedure, the plasmid pFL45 which 
contains the c-peptide fragment of the lacZ gene was also treated with hydroxylamine 
and used to transform NM522 cells which were plated in the presence of IPTG and 
the chromogenic substrate X-gal. Clones carrying mutations affecting the activity of 
the LacZ gene product were readily identified as these produced white rather than 
blue colonies. The frequency of white transformants carrying mutagenised DNA was 
10-fold greater than that amongst transformants containing unmutagenised DNA. This 
indicated that treatment with hydroxylamine was indeed causing the introduction of 
mutations and therefore the screen for dominant mutants using mutagenised 
pBMPRP2 could proceed. 
The mutagen-treated DNA was introduced directly into the WT strain S 150-213 
and transformants selected on YMGCas (non-inducing medium). Transformants were 
screened for those which failed to grow when plated onto galactose-containing 
medium; 800 colonies were picked from the glucose plates, resuspended in sterile 
dH20, and spotted onto both selective YMGCas and YMGRCas plates. To permit 
propagation and identification of temperature-dependent dominant mutants which 
might be generated, all transformants were incubated at 23 °C, 30°C, 340C or 36°C for 
three days or 18°C for five days. Figure 3.2A shows the result of the screen; three 
independent isolates were obtained which were able to grow on glucose but failed to 
grow on galactose/raffmose at all temperatures. These strains were designated 
FIGURE 3.2.A Three Independent Isolates fail to grow on Galactose-Containing 
Medium. 
Following single colony purification, the three mutant isolates S150P2" (diii), 
S1502d 2  (dn2) and S15OP2"- (dn3) (identified in the screen for dominant negative 
mutants) and as a positive control S 150-213 harbouring pBMPRP2 (WT) were grown 
overnight in selective YMGCas (repressing conditions) at 30 °C, harvested by 
centrifugation, and resuspended in dH 20 to a concentration of approximately 10 6 
cells/mi. 15d drops of these cultures were spotted onto either selective YMGRCas 
(Galactose) or selective YMGCas (Glucose) plates. The plates were incubated for 60 
hours at 30°C. 
Figure 3.2B The effect on Cell Growth of Simultaneous Overproduction of WT 
PRP2 and PRP2"' in S150-2B. 
S150-213 cells co-transformed with either pBMPRP2' t" and pFL45::PRP2 (line A) or 
pBMPRP2' and pFL45 (line B), pBMPRP2 and pFL45: :PRP2 (line C) or pBMPRP2 
and pFL45 (line D) were grown overnight in YMGCas at 30°C, harvested by 
centrifugation and resuspended in dH 20 to a concentration of 2x10 5 cells/ml 
(measured in a haemocytometer). 15al drops of these cultures and of 10-fold serial 
dilutions were spotted onto selective YMGCas (Glucose) or YMGRCas (Galactose) 
plates from left to right. The plates were incubated for 60 hours at 30°C. 
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Sl5OP2', Sl5OP2' 2 and Sl50P2. Cells carrying WTpBMPRP2 were able to grow 
on both glucose and galactose-containing media implying that the galactose-sensitivity 
exhibited by the three isolates was due to the presence of mutant form(s) of 
pBMPRP2. Procedures carried out to test this are described in the following section. 
3.3.2 The Dominant Negative Mutations are Plasmid Encoded. 
To ensure that the phenotype of the three mutants isolated was caused by the 
presence of a toxic form of pBMPRP2, it was necessary to isolate plasmid DNA from 
the mutants, use it to retransform fresh S 150-2B cells, and demonstrate that the defect 
was inherited by these formerly WT cells. 
Initially, a rapid yet highly informative procedure was carried out: the mutant 
isolates were cured of the URA3 plasmid DNA by growth in the non-selective 
medium YPDA, and isolates auxotrophic for uracil (due to loss of the plasmid) were 
plated on both glucose and galactose/raffmose-containing media. In all three cases, 
the cured cells were able to grow on both types of media, therefore the dominant 
phenotype was indeed due to the presence of a toxic plasmid, rather than genomic 
defects fortuitously harboured by the yeast isolates. 
Meanwhile, plasmid DNA was recovered from Sl50P2, Sl50P2" 2 and 
S 150P2, (the plasmids obtained were named pBMPRP2' pBMPRP2 2 and 
pBMPRP2 respectively) and each was used to transform E. coli. In each case 
between 2 and 5 NM522 transformants were obtained. Using one of each of the 
E. coli transformants, CsCl-purified plasmid DNA derived from each of the dominant 
negative mutants was prepared (2.4.2.3.) and used to transform WT S150-2B cells. 
The resulting yeast transformants were plated onto both inducing and repressing 
media and as expected, the presence of plasmid DNA isolated from each of the 
dominant mutants conferred a galactose-sensitive growth phenotype. 
To confirm that the plasmids responsible for the defect were derived from the 
parental plasmid pBMPRP2, diagnostic restriction enzyme digests were performed 
and the DNA fragments electrophoresed through a 0.8% agarose gel. The restriction 
pattern produced by each of the three rescued plasmids was found to be identical to 
that of WT pBMPRP2 (data not shown). Further assurance that the mutant plasmids 
were pBMPRP2-derived, came from Southern blotting: the DNA fragments generated 
by restriction enzyme digestion were transferred from the agarose gel onto a 
nitrocellulose filter, and probed with a 32P-labelled DNA fragment containing the 
entire PRP2 coding sequence. As expected, the hybridisation pattern of WT 
pBMPRP2 was identical to that obtained from all three mutant plasmids. The 
sequence data presented later in section 4.2.3. confirm these results. The mutant 
PRP2 alleles obtained were named PRP2-dnl, PRP2-dn2 and PRP2-dn3 and the 
proteins that they encode will be referred to as PRP2' PRP212 and PRP2 
respectively. 
3.3.3 Galactose-Sensitivity of S150P2' 	is Rescued by Simultaneous 
Overexpression of WT PRP2. 
Genetic dominance is commonly explained in terms of gains of functions 
(neomorphism), or increases in activity (hypermorphism). A third mechanism for 
dominance, of great importance for studying interactions between proteins, involves 
competition between the mutant molecule and its WT counterpart for binding to a 
common cellular factor. This phenomenon termed antimorphism (after Muller, 1932) 
may be distinguished from other forms of dominance, as unlike neomorphs and 
hypermorphs the negative phenotype will be rescued by the co-overexpression of the 
WT protein (due to increased competition by the WT form). Therefore, in order to 
probe the mechanism for dominance exhibited by PRP2tI,  the strain S150-2B was co-
transformed with both pBMPRP2' and the construct pFL45: :PRP2, the latter 
providing constitutive overexpression of WT PRP2 from its own promoter by virtue 
of a high copy-number 2z origin of replication. pFL45: : PRP2 was constructed by 
cloning the 3.2 kb EcoRl-BamIll fragment of pY2016 (described in table 2.2), which 
contains the entire PRP2 coding region linked to its own promoter, into the polylinker 
of pFL45. The vector pFL45 (described in table 2.2) was chosen as it carries the 
TRP1 gene, and since pBMPRP2' contains the URA3 gene, simultaneous selection 
for both plasmids was possible in the trpl -289, ura3-52 auxotroph S150-213. Figure 
3.2B shows the growth of various cotransformants on glucose or galactose-containing 
media. To ensure that apparent differences in growth rate between strains was not 
simply an effect of inoculum size, a titration assay was used: cells were resuspended 
in dH20 to a concentration of 2x10 5/ml, and serial dilutions of this suspension spotted 
onto media and incubated at 30°C for three days. 
As expected, growth of cells harbouring pBMPRP2 plus pFL45 vector alone 
(Row B) exhibited the dominant phenotype, being unable to grow on inducing 
medium. In contrast, cells harbouring pBMPRP2 plus pFL45::PRP2 were able to 
grow on both non-inducing and inducing media (Row A). As the only difference 
between these strains is the presence or absence of the WT PRP2 gene in pFL45, 
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rescue of the dominant inhibitory phenotype must be due to the constitutive 
overexpression of WT PRP2 from pFL45: : PRP2. 
As an experimental control, S150-213 was also transformed with WT 
pBMPRP2 plus either pFL45 or pFL45: :PRP2. Both strains were able to grow on 
both types of media (rows C and D), and on YMGRCas produced colonies of a 
similar size (compare rows C and D at a dilution of 10-2)  demonstrating that even 
very high levels of WT protein have no apparent effect on cell growth. Comparison 
of the size of colonies in rows A and C on galactose-containing medium, (shown 
clearly at a dilution of 10.2),  shows that growth of cells containing pBMPRP2 ," and 
pFL45: :PRP2 on galactose is much slower than for cells harbouring pBMPRP2 and 
pFL45: :PRP2. This partial phenotype, exhibited by cells in row A, is indicative of 
competition between mutant and WT forms of PRP2. 
This result rules out the possibility of either neomorphism or hypermorphism, 
and provides evidence in favour of a competitive mechanism for dominance such as 
that described in figure 3.1. A fourth mechanism which is not ruled out by this 
experiment should also be considered; if PRP2 protein forms homodimers (or 
multimers) in order to function, a mutant PRP2 molecule still capable of binding WT 
PRP2 might cause the formation of functionally inactive dimers. Overproduction of 
the inhibitory polypeptide would block the formation of functional WT homodimers. 
This mechanism (known as internal dominance) will be considered in chapter 6. 
3.3.4 Overproduction of PRP2' causes a Decline in Cell Growth Rate and a 
Defect in Pre-inRNA Splicing. 
If, as the cotransformation experiment described above suggests, PRP2" 
competes with and functionally blocks its WT cellular counterpart, overproduction of 
the mutant form would be expected to cause a defect in pre-mRNA splicing. To test 
this theory, several in vivo characterisation experiments were carried out and are 
described in this section. These experiments were also carried out to analyse 
S150P2 2 and S150P2, however as similar results were yielded for all three 
mutants, only those obtained for S1501`2' are presented. An explanation for the 




To assess the time after induction at which the growth defect of the mutant 
becomes evident, S150-2B cells harbouring either pBMPRP2 or pBPRP2 dnl  were 
grown in liquid media and growth curves shown in Figure 3.3. were obtained. In 
YMGCas (repressing conditions), both strains grew with a constant doubling time of 
2 hours. In YMGRCas however, although the initial doubling time of both strains 
under these inducing conditions was slightly greater (2hrs 15 mins), after 5 hours the 
growth rate of cells carrying the mutant plasmid declined continuously whereas the 
growth rate of cells carrying WT pBMPRP2 remained constant. As the only 
difference between the two strains was the presence of pBMPRP2 rather than the 
WT form pBMPRP2, the growth defect of S15OP2" in YMGRCas was attributed to 
the presence of this mutagenised plasmid. 
Western Blotting 
To demonstrate that the growth defect after 6 hours induction was indeed due 
to the overproduction of a toxic form of the PRP2 protein from pBMPRP22I,  the 
levels of PRP2 protein in the strain S150-2B harbouring either pBMPRP2 or 
pBMPRP2 grown under inducing or repressing conditions were examined by 
Western blotting and probing with anti-PRP2 antibodies. The Western blot (Figure 
3.4A) shows that after 6 hours growth under inducing conditions both WT and mutant 
forms of PRP2 are strongly overproduced (tracks 2 and 4 respectively), and when 
grown under repressing conditions the signal is barely detectable (compare track 1 
with 2 and 3 with 4 respectively). In attempts to compare the levels of PRP2 
produced under inducing and repressing conditions using western blot analysis (data 
not shown), it was necessary to dilute overexpressing extracts 50-fold in order to 
completely lose the signal. Therefore the level of PRP2 in cells grown under inducing 
conditions for 6 hours was approximately 50-fold. 
Northern Blot Analysis 
To assess the effect on the splicing of intron-containing transcripts caused by 
overproduction of PRP2'' or WT PRP2, total RNA prepared from S150-211 cells 
carrying either pBMPRP2 or pBMPRP2' grown under inducing or repressing 
conditions (in YMGRCas or YMGCas respectively for 6 hrs after initial growth in 
YMGCas) was analysed by Northern blotting. Figure 3.4B shows the result of such 
an experiment in which transcripts from the RP28 and actin genes, each of which 
contain a single intron, were examined. As a positive control, RNA prepared from 
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FIGURE 3.3 In vivo analysis of the Dominant Negative Strain S150P2". 
Growth Curves. 
Mid-log phase cultures of S 150-2B cells carrying pBMPRP2 (WT) or pBMPRP2' 
(dnl) were spun down (time 0), and of half the cells were returned to the glucose 
medium YMOCas, (repressing conditions), while the other half were shifted into 
galactose-containing medium YMGRCas, (inducing conditions). The cultures were 
diluted to maintain logarithmic growth which was monitored by measuring OD 6 . 
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FIGURE 3.4 In vivo Analysis of the Dominant Negative Strain S150P2". 
Western Blot- Overproduction of PRP2 and PRP2!Iil. 
Extracts of S 150-2B cells carrying pBMPRP2 or pBMPRP2' grown under repressing 
conditions (WT GLU; dnl GLU, lanes 1 and 3 respectively), and under inducing 
conditions (WT GAL; dnl GAL, lanes 2 and 4 respectively) for 6 hours, were 
prepared by sonication. Extract equivalent to 100jg of protein was electrophoresed 
through a 7.5% SDS-polyacrylamide gel and Western blotted. The blot was probed 
with affinity-purified a-PRP2 antibodies (a-55; see figure 2.1). Affinity purification 
was against the PRP2-TrpE fusion peptide 2.6 which contains the entire PRP2 protein 
fused to a 33kD fragment of the E. coli TrpE protein (carried out by McGarvey M. 
this lab.). Lane M; marker proteins with sizes indicated in kD. 
Northern Analysis. 
Total yeast RNA was extracted from S150-213 cells carrying pBMPRP2 or 
pBMPRP2'' grown under repressing conditions (WT GLU; dnl GLU) or inducing 
conditions (WT GAL; diii GAL), and from a prp2-1 temperature-sensitive strain 
(DJY36) grown at the permissive temperature, 23 °C (2-1 23 °C), or shifted to the non-
permissive temperature 37 °C (2-1 36°C) for 2 hours. RNA (30g) was denatured, 
and electrophoresed through a 1.4% agarose gel, blotted onto Hybond-N and 
hybridised to P32-labelled DNA fragments encoding actin and rp28. The positions of 
unspliced precursor RNA (pre-mRNA), and spliced messenger RNA (mRNA) are 
marked. 
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a recessive heat-sensitive pip2-1 mutant (strain DJY36) grown at the permissive 
temperature (23 1C) or heat-shocked at the non-permissive temperature (37 °C) for 2 
hours was also analysed (lanes 1 and 2). For this recessive mutant a severe splicing 
defect is indicated as a consequence of heat shock; most of the actin transcripts 
remained unspliced (track 2). Unspliced pre-mRNA also accumulated in the dominant 
mutant grown under inducing conditions (lane 6) but not when grown under 
repressing conditions (lane 5), whereas overexpression of WT PRP2 had no effect on 
pre-mRNA splicing (lane 4). This indicates that the growth phenotype caused by 
overproduction of PRP2(bI  is the result of a defect in pre-mRNA splicing. 
The splicing defect is clearly more dramatic for the recessive mutant than the 
dominant mutant (compare lanes 2 and 6); the majority of actin transcripts being 
processed in the dominant mutant. This is likely to reflect temporal differences 
between the dominant and recessive mutations as a result of their contrasting 
mechanisms: the loss of function prp2-1 mutation is rapidly manifested whereas for 
the dominant mutant (if the model in figure 3.1 is correct) a lag period may be 
required during which interference of WT PRP2 function by PRP2' is increased. 
The splicing defect is shown more clearly using the rp28 probe rather than the 
actin probe as, in vivo, rp28 transcripts are less efficiently spliced than those 
produced by the actin gene. As a result, in track 2, the rp28 message is undetectable 
whereas for actin, although the ratio of spliced to unspliced RNA is increased, a 
substantial amount of mRNA remains. 
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3.4 DISCUSSION. 
This chapter describes the isolation and initial characterisation of three 
dominant negative PRP2 mutants generated by random chemical mutagenesis of a 
construct carrying the PRP2 gene fused to the GALl regulated promoter. Despite the 
success of this approach in studies of other multicomponent systems such as the cell 
cycle (Mendenhall et al., 1988; Fleig et al., 1992) and signal transduction, for 
example the interactions of cellular Ras proteins, (Feig and Cooper, 1988) and G-
protein signalling (Leberer et al., 1992), this is the first time that a screen directed 
at the isolation of dominant inhibitory splicing mutants has been carried out (although 
two previously existing splicing mutants fortuitously exhibit dominance when 
overexpressed: Miraglia et al., 1991; Schwer and Guthrie, 1992). 
To generate a random pool of PRP2 mutants, a rapid and simple in vitro 
mutagenesis procedure was chosen involving treatment of DNA with hydroxylamine. 
Under strongly acidic conditions hydroxylamine acts as a powerful hydroxyl donor, 
the overall result of which is to deaminate cytosine to uracil. Under the milder 
conditions used in this study (described by Rose et al., 1990), an intermediate in the 
deamination of cytosine, hydroxyaminocytosine, is formed. This is stable and can 
form a non-Watson-Crick base-pair with adenine giving rise to C-G to A-T transition 
mutations (Lawley, 1967). 
The conditions described by Rose et al. were optimised by them using a plasmid 
containing the URA3 gene (occupying 10% of the plasmid) which, following 
hydroxylamine treatment, was tested in E. coli for the formation of ura7 plasmids. The 
E. coli strain used was ung (therefore competent to repair U-A mismatches) and they 
obtained 4% urac colonies. Exactly these conditions were used to mutagenise 
pBMPRP2, and although no further optimisation procedures were carried out, a 
simple blue/white screen in E. coli following hydroxylamine treatment of a plasmid 
containing the lacZ a-peptide fragment was used to indicate that mutations were being 
introduced. 
From a pilot screen of 800 S150-2B transformants harbouring mutagen-treated 
pBMPRP2, three independent galactose-sensitive isolates were obtained. This high 
frequency is likely to be due to the tightly regulated expression system used 
(demonstrated by Western blotting), an appropriate mutation frequency attained by 
the mutagenesis procedure, and also the natural tendency of mutations present in the 
PRP2 gene to cause dominant phenotypes. Proteins containing multiple functional 
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sites which could be mutated independently would be particularly susceptible to 
dominant inhibitory mutations (Herskowitz, 1987). This should apply to the PRP2 
protein since it contains a number of discrete, highly conserved, and presumably 
functionally important sequence motifs common to the putative RNA helicase family. 
Conditionally dominant negative mutants of the p34 2 protein kinase have 
been generated at a high frequency (similar to that for PRP2 in this study) following 
hydroxylamine mutagenesis of either the CDC2 gene of S.pombe or the homologous 
CDC28 gene of S.cerevisiae (Fleig et al., 1992; Mendenhall et al., 1988). These 
mutants were shown to be catalytically inactive, and therefore the dominant inhibitory 
phenoype could best be explained if the defective molecules were still capable of 
binding polypeptides required for the function of WT p34 kinase; these essential 
factors would be sequestered when the mutant proteins were overproduced. It is likely 
that a similar mechanism accounts for the phenotype of the three dominant PRP2 
mutants obtained. 
Following initial isolation of the galactose-sensitive isolates, it was imperative 
to demonstrate that the defects were encoded by a plasmid related to the parental 
construct pBMPRP2. This was shown to be the case as plasmid DNA isolated from 
each of the mutants conferred the galactose-sensitive phenotype when introduced into 
fresh WT yeast cells. Subsequently, restriction analysis and Northern blotting 
identified the plasmids as pBMPRP2-derived. 
Experiments which followed demonstrated that the reduced growth rate 
exhibited by cells overproducing PRP2d1I  was the result of a pre-mRNA splicing 
defect and that this growth inhibition was alleviated by co-overproduction of WT 
PRP2. These observations are consistent with the following scenario: mutant and WT 
forms of PRP2 directly compete for binding to spliceosomes, hence the ratio of 
expression of the two proteins determines the growth properties of the cell; 
overexpression of the dominant mutant in a WT haploid cell inhibits the splicing of 
primary transcripts, terminating cell growth, however this may be rescued by co-
overproduction of WT PRP2. By virtue of a well established in vitro splicing system 
this hypothesis can, and will, be definitively tested. 
The unfavourable possibility that cannot ruled out by data presented in this 
chapter is that the dominant defect is simply due to a decrease in the levels of WT 




Mapping and Sequencing the Dominant Inhibitory 
PRP2 Mutations. 
4.1 INTRODUCTION. 
The principal reason for isolating dominant negative PRP2 mutants was to 
obtain a suitable genetic tool for investigating the interactions of PRP2 with other 
spliceosomal factors. In other systems however, the approach has been used 
effectively to provide information concerning structural requirements for the activities 
of certain proteins. For example, conditionally dominant negative mutations have 
identified two conserved regions within a G protein a-subunit required for 
downstream signalling, (Leberer et al., 1992) and there are many cases in which 
dominant negative mutations within NTP-binding domains affect protein function 
(Haber and Walker, 1991; Farnsworth and Feig, 1991). 
By determining the precise location(s) of the mutations responsible for the 
dominant phenotype of the PRP2 mutants isolated, important details concerning 
structure-function relationships of PRP2 maybe unveiled. Such information might 
extend to the other DEAH proteins with which PRP2 shares a number of highly 
conserved sequence motifs. 
This chapter describes the mapping and sequencing of dominant inhibitory 
mutations present in pBMPRP2' pBMPRP2 2 and pBMPRP2. The significance 
of the results are discussed. 
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4.2 MATERIALS AND METHODS. 
4.2.1 Synthetic Oligodeoxynucleotides. 
All oligonucleotides were synthesised at the OSWEL DNA service, Edinburgh. 
Table 4.1 Oligodeoxynucleotides used for Sequencing the Hindffl-XbaI Region of the 
PRP2 gene. 
Name Sequence (S'to 3') Information 
Reverse CAGGAAACAGCTATG Anti-sense strand, anneals upstream of 
primer AC and adjacent to 'F7 promoter of 
pTZ18R or pTZ19R, complementary 
to sequence within the lacZ gene. 
006P CCCACTFCCCCAAG Anti-sense strand, for sequencing 
upstream from nucleotide 1090 of the 
PRP2 gene within the Hind ffl-XbaI 
region. 
685P GCGTFCA'ITGTTGCTG Anti-sense strand, for sequencing 
upstream from nucleotide 1350 of the 
PRP2 gene within the Hindffl-XbaI 
region. 
385V GTTGCCTCCGGCTGC Anti-sense strand, for sequencing 
upstream from nucleotide 1441 of the 
PRP2 gene. Used for direct 'double- 
stranded' sequencing through the SAT 
motif within the Hind ffl-XbaI region. 
4.2.2 Sequencing Reactions. 
Sequencing reactions were carried out using the Sequenase version 2.0 kit 
(USB) according to the manufacturers instructions. Templates for the reactions were 
prepared as described in section 2.4.3. These were either single-stranded preparations 
of pTZ18R clones or 'double-stranded' preparations of pBMPRP2'''. 
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4.2 RESULTS. 
4.2.1 The PRP2-dnl Mutation(s) Map(s) to a central 777bp Region of the PRP2 
Gene. 
In order to approximately localise the PRP2-dnl mutation(s) and circumvent 
the task of sequencing the entire PRP2 gene, three chimeras were made between the 
dominant PRP2-dnl and WT PRP2 genes, each of which contained one of three non-
overlapping regions of the mutant gene. The chimaeric genes were then overexpressed 
in S150-2B to identify the region of PRP2-dnl responsible for the dominant 
phenotype. The construction of these "mapping plasmids" is described in figure 
4.1. A.  Use was made of three PRP2 deletion constructs based on pBMPRP2 from 
which a restriction fragment of the PRP2 gene has been deleted and replaced with a 
short linker containing a unique diagnostic SacI site. These have been named 
pBMP2H-X, pBMP2X-P, and pBMP2AP-S referring to the restriction fragment 
deleted (Hindffl-XbaI, XbaI-Pvull and Pvull-Saul respectively). The restriction 
fragments Hind ffl-XbaI, XbaI-Pvuil and Pvull-Saul from pBMPRP2" were cloned 
into the corresponding deletion constructs, replacing in each case the short Sac! 
linker. Prior to introduction into E. coli, the ligation products were cleaved with Sad 
to linearise any non-recombinant vector molecules (which would retain the Sacl site), 
thus increasing the efficiency of the cloning experiment. As an experimental control, 
the restriction fragments Hind ffl-XbaI , XbaI-Pvull and Pvull-Saul from the WT PRP2 
gene were also cloned into the appropriate deletion construct to produce three mock 
"WT mapping plasmids". 
Each of the three mutant and three mock WT chimaeric constructs were 
introduced into the strain S150-2B, and transformants plated onto both YMGCas and 
YMGRCaS to test for dominance. As expected, isolates carrying each of the WT 
control constructs grew on both types of media therefore any growth defect incurred 
by overexpression of mutant chimeras was not a fortuitous consequence of the cloning 
procedure. The growth of cells harbouring each of the PRP2-dnl mapping constructs 
on inducing and repressing media is shown in Figure 4.1 .B; cells carrying chimaeric 
constructs containing the XbaI-Pvull or Pvull-SauI fragments of the mutant gene grew 
on both types of media, however cells transformed with the mapping construct 
containing the Hindffl- XbaI fragment of the PRP2-dnl gene inherited the dominant 
growth defect on inducing medium. Thus the lesion(s) responsible for dominance 
mapped to within the Hindffl-XbaI region of the PRP2 gene. Significantly, it is this 
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FIGURE 4.1 Mapping the PRP2-dn1 mutation(s) present in pBMPRP2 1 . 
Three non-overlapping restriction fragments HindIII-XbaI , XbaI-PvuII and PvuII-
Saul from pBMPRP2' were subcloned into the corresponding pBMPRP2-derived 
deletion construct pBMP2zH-X, pBMP2zX-P, or pBMP2zW-S respectively, 
replacing in each case the short linker region containing a Sacl site. 
Each of the three chimaeric constructs produced was introduced into S 150-213 and 
transformants which had been selected on YMGCas were transferred onto YMGCas 
(GLU: repressing medium) or YMGRCas (GAL: inducing medium). The growth 
phenotypes of the transformants are indicated; + indicates growth; - indicates failure 
to grow. 
The PRP2 open reading frame (2.9kb) begins at the first BamHI site and ends 80 
nucleotides downstream of the Saul site. 
Mapping a Dominant Negative PRP2 Mutation 
Map of PRP2 gene 
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region which carries the conserved motif sequences common to the DEAH proteins. 
4.2.2 The PRP2-dnl Mutation Causes a Single Serine to Leucine Substitution 
Within the Highly Conserved SAT Motif. 
In order to identify the dominant mutation(s) located within the Hind ffl-XbaI 
region of the PRP2-dnl gene, this restriction fragment was cloned into the polylinker 
of pTZ18R, single-stranded template DNA was prepared, and the entire 777 base-pair 
region was sequenced using the three oligodeoxynucleotides 006P, 685P and M13 
reverse primer (table 4.1). Only a single transition mutation (G to A on the non-
coding strand) was identified which caused a serine to leucine substitution at amino-
acid 378 within the highly conserved SAT motif: SAT was changed to LAT. This 
is represented diagrammatically in figure 4.2, which shows the positions at which the 
sequencing primers anneal to the recombinant template DNA relative to the conserved 
sequence motifs. 
To confirm this exciting result, the original pBMPRP2 C5C1-purified DNA 
preparation was used as a template for direct "double-stranded" sequencing through 
the SAT motif using oligodeoxynucleotide 385V (Table 4.1). Oligonucleotide 385V 
was designed to prime close to the SAT motif (see fig.4.2) giving good quality 
double-stranded sequence data at this region. The sequence obtained is shown in 
Figure 4.3 (compare WT and PRP2-dnl sequences) and as expected the novel point 
mutation (G to A) was present. 
M13 
006P 	 685P 385V 	RP 
HThdIII 	
GEIGSGIC1 	 pt 	SAT 




(5' to 3 of 	 MUWW I 	I 006P,658P. 385V and 1i113 reverse Pre (RP) 
annealed to recornbaM 12 
Conseived motifs unZei 	
twçte - 	LAT 	 100ç) 
Figure 4.2: Nap of the central region of the PRP2 gene 
showing positions of conserved sequence motifs and sites at 
which the sequencing oligodeoxynucleotides anneal. 
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FIGURE 4.3 Sequencing the PRP2-(Inl PRP2-dn2 and PRP2-dn3 Mutations. 
The plasmids pBMPRP2, pBMPRP2 12  and pBMPRP2' and pBMPRP2 (dnl, dn2, 
dn3 and WT respectively) were used as templates for sequencing reactions using the 
primer 385V. The single transition mutation identified for all three mutants (G to A) 
on the non-coding strand is indicated (the mutated nucleotide is underlined). This 
causes a serine to leucine substitution within the highly conserved SAT motif of the 
putative helicase PRP2. 
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4.2.3 PRP2-dnl PRP2-dn2 and PRP2-dn3 Mutations are Identical. 
Prior to constructing mapping plasmids to locate dominant negative mutations 
within the PRP2-dn2 and PRP2-dn3 genes, it was decided to target the Hind ffl-XbaI 
region directly by sequencing through the highly conserved and presumably 
functionally important sequence motifs at the centre of this region. The Hind ffl-XbaI 
fragment of PRP2-dn2 and PRP2-dn3 were cloned into pTZ18R to facilitate 
preparation of single-stranded template DNA for sequencing. Surprisingly, from 
sequence data obtained using oligonucleotides 006P 658P and M13 reverse primer, 
only a single transition mutation (G to A) was identified, at exactly the same location 
as the PRP2-dnl mutation causing the serine to leucine substitution within the SAT 
motif. For confirmation, the original CsC1-purified DNA preparations of pBMPRP2 2 
and pBMPRP2 were used as templates for 'double-stranded' sequencing through the 
SAT motif using oligodeoxynucleotide 385V. The sequence data obtained are shown 
in figure 4.3: the mutation G to A on the non-coding strand is identical for all three 
mutants isolated. Therefore out of 800 transformants screened, three independent 
isolates were obtained that contain the same dominant inhibitory mutation. 
It is likely that this reflects a combination of the highly stringent phenotype 
demanded in the screen, and also the specificity of the chemical mutagen used. 
Hydroxylamine induces only transition mutations, thus the variety and number of 
amino-acid substitutions that can be induced by hydroxylamine in a given sequence 
will be significantly less than that obtained using a mutagenesis procedure that can 
produce all possible base substitutions. It will be demonstrated in the following 
chapter that a number of other substitutions at the SAT motif result in dominant 
inhibitory phenotypes, however none of these could be achieved through the use of 
hydroxylamine. In fact, the only possible amino-acid substitutions at S378 of PRP2, 
(the first residue of the SAT motif), which could be produced by a single transition 
mutation are S378L (that obtained in the screen) or S378P. If the latter change (serine 
to proline) does not induce the phenotype for which the screen was designed to 
identify, then the only dominant negative substitution which could be produced at this 
location is that which was obtained. In order to obtain other novel dominant inhibitory 
PRP2 mutants by extending this screen, it would be advisable to use a less biased 
mutagenesis procedure such as one based on the polymerase chain reaction. Such 
methods usually involve decreasing the fidelity of the Taq DNA polymerase either 
through addition of Mn" or by varying the concentration of nucleotides and Mg 2 
present during reactions (see Spee et al., (1993) and Lang et al., (1989) for various 
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methods). 
In light of the fact that the three dominant negative alleles were identical, no 
further mapping or sequence analysis of the PRP2-dn2 and PRP2-dn3 genes was 
carried out. The unlikely possibility that these genes harboured other dominant 
mutations which remain unidentified cannot be ruled out. 
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4.3 DISCUSSION. 
This chapter reports the mapping and sequencing of mutations responsible for 
the dominant inhibitory phenotype of the three randomly generated PRP2 mutants. 
The PRP2-dnl mutation was localised to within a central 700 base-pair fragment of 
the gene, spanning the region which contains 7 sequence signatures diagnostic of the 
DEAD/DEAH family of putative helicases. Sequence analysis of this entire region 
revealed a single G to A transition, consistent with the mutagen used, that caused a 
serine to leucine substitution within the highly conserved SAT motif. Surprisingly, 
the identical mutation was also found within the PRP2-dn2 and PRP2-dn3 genes, thus 
the SAT to LAT substitution was independently isolated three times. 
This exciting discovery attests to the functional importance of the SAT domain 
which, in conjunction with the six other helicase signatures, is found not only within 
the DEAD/DEAH proteins but more widely in members of a vast superfamily of 
demonstrated and presumptive DNA and RNA helicases delineated by Gorbalenya et 
al., (1989). The closely related DEAD and DEAH proteins form a subdivision of this 
superfamily (SF11) which includes proteins of E.coli, eukaryotes, RNA and DNA 
viruses. Gorbalenya et al. identified the 7 consecutively positioned sequence domains 
designated I, la through to VI, where la and 11 represented a special version of the 
bipartite purine NTP binding domain found widely in a large number of NTPases 
(ATPase motifs A and B respectively, Walker et al., (1982)). The SAT residues are 
housed within domain ifi positioned between the ATPase B sequence and domain V, 
as shown for the DEAD family in figure 4.4. 
Summary of the DEAD Family Helicase Domains 
ATPase 	 ATFase 
MOW A MOW B 
I AXXGXG KrI 	I PTRELA H DEAD F-I SATH ARG-D H H RIG RXXR I 
la 	II 	Ill 	\f 	VI 
Figure 4.4: Schematic representation of conserved amino-
acid regions of the DEAD family, variants of which are 
found in members of other related helicase families. 
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Schmid and Linder, (1992) presented a sequence alignment of 25 members of 
the DEAD or DEAH subfamilies which shows that the SAT residues in domain ifi 
are completely conserved except for the splicing factor PRP28 which encodes the 
variant TAT at this position. Figure 4.5 shows a comparison of domains II and ifi for 
the DEAD/H proteins eIF4-AI (M. musculus), PRP28 and PRP2 (S.cerevisiae), and 
more recently discovered members of this and other distinct subgroups of the helicase 
protein superfamily. Novel members of this rapidly expanding family including the 
DEAH protein prhl of S.pombe (Inoue et al., 1992) and the human DEAD protein 
p54 (Lu and Yunis, 1991) also show complete conservation of the SAT residues at 
domain ifi. The Kurz gene of D. melanogaster which encodes DEAE at the ATPase 
B site also conserves the downstream SAT sequence. Similarly, the bacterial DNA 
replication factor priA, which is well defined biochemically as a DNA-dependent 
ATPase and has ATP-dependent DNA helicase activity specific for a DNA hairpin 
(for a review see Matson et al., 1990) contains the variant motif DEEH at domain II 
however the SAT motif remains intact (Ouzounis and Blenowe, 1991). Very recently, 
another subfamily containing specific variants of the 7 helicase motifs has been 
delineated, most of which are involved or implicated in transcriptional regulation 
(Bork and Koonin, 1992). These possess the ATPase B motif variant DEGH, and 
interestingly, the signature within domain ifi is either TGT in the case of snF2 
(S.cerevisiae) or SGT for Rad 54 (S.cerevisiae) which although a member of this 
class is known to be involved in excision and recombinational repair (see figure 4.5). 
Therefore, even diverse members of the heicase-like protein superfamily 
conserve a combination of the hydroxyl group side-chains of serine or threonine 
separated by a small inert residue (either alanine or glycine) within the appropriately 
positioned domain ifi. Understanding the functional constraints responsible for the 
rigid structural conservation of this and the other helicase motifs is now a primary 
goal, and will determine the mechanistic similarities shared by these proteins which 
are involved in a wide range of cellular processes. Characterisation of mutants such 
as that isolated in this study will form the framework of this understanding. 
The function of the SAT motif has been probed only for the prototype of the 
DEAD family eIF4-A (Pause and Sonenberg, 1992). Purified mutant forms of this 
ATP-dependent RNA helicase were analysed in vitro with respect to ATP binding, 
ATP hydrolysis and RNA unwinding. The function of the SAT residues in eIF4-A 
was assessed by modifying this sequence to encode AAA, and under the single set of 
assay conditions used, this caused complete abrogation of RNA unwinding however 
the ATP hydrolysis rate was increased 2.4-fold with respect to WT levels. Therefore 
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el F4 - Al VLDEADEML LLSATM 
PRP2 8 VLDEADKMI ....... MFTATM 
p54 VLDEADKLL ....... LYSATF 
PRP2 MIDFIAHERT ....... ISSATM 
pihi ILDEAHERT ....... IMSATL 
KURZ ILDEAEERS ....... IMSAT 
pr iA VIDEEKDSS ....... LGSATP 
Rad3 IFDEAHNI ........ ITSGTI 
Rad54 LADEGHRL ........ ILSGTP 
SNF2 IIDEGRRM........ ILTGTP 
figure 4.5: Helicase motifs II and III from members of 
protein families which form distinct subgroups within a 
superfamily of putative and demonstrated helicases. Highly 
conserved motifs are in bold. See text for references. 
for the prototype helicase, eIF4-A, the SAT residues are critical for RNA unwinding 
but not ATP hydrolysis; the ATPase and the RNA unwinding activities of the mutant 
were uncoupled. 
In the light of this result, and considering that for PRP2 and the other 
DEAD/H splicing factors RNA unwinding has not yet been demonstrated, it will be 
of great value not only to understand the mechanism for the dominant inhibitory 
behaviour exhibited by PRP2', but also to assess the effects of the SAT to LAT 
substitution on the catalytic activities of this RNA-dependent ATPase. Potentially 
important analogies between PRP2 and the prototype eIF4-A could be revealed. Thus 
a substantial part of this thesis shall be concerned with these areas of interest. 
Intriguing parallels can be made between the results presented so far in this 
thesis and those obtained through analysis of spontaneous mutants of the RAD3 gene 
of S.cerevisiae which encodes a well-studied ATP-dependent DNA:DNA and 
DNA:RNA helicase (reviewed in Deschavanne and Harosh, 1993). RAD3 is a 
multifunctional protein involved in the DNA excision repair process and as a member 
of the helicase superfamily H contains the 7 conserved domains including signatures 
II and ifi which encode DEAR and SGT respectively as shown in figure 4.5. 
(Gorbalenya et al., 1989). One mutant allele rad3-2 which causes a UV-sensitive 
phenotype was cloned by gap repair and sequence analysis revealed a single point 
mutation causing the amino acid substitution G461R (Naumovski and Friedberg 
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1986). Unknown to the authors at that time, the glycine to arginine substitution falls 
within the conserved SXT motif (Gorbalenya et al., 1989); SGT was changed to SRT. 
Significantly, overexpression of the mutant rad3-2 protein rendered WT yeast cells 
partially UV-sensitive. Similar to the dominant negative PRP2 mutants isolated in this 
study, the inhibitory phenotype caused by increased levels of rad3-2 is best explained 
in terms of the rad3-2 protein retaining its affinity for damaged DNA or other 
substrates but being impaired in a catalytic activity required for DNA repair. The 
apparent susceptibility of the motif ifi sequence to dominant inhibitory mutations once 
again demonstrates the functional importance of this motif and it is tempting to 
speculate that this function might be conserved throughout the helicase superfamily. 
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CHAPTER 5. 
Effects of other Amino Acid Substitutions at the PRP2 
SAT Motif. 
5.1 INTROUCTION. 
A single serine to leucine substitution at amino-acid 378 of PRP21I  has been 
shown to induce a dominant inhibitory effect when the protein is overproduced in a 
WT yeast strain. This substitution causes at least three obvious molecular changes at 
the first residue of the SAT motif: 
(i)Size: the leucine side-chain is much larger than that of serine. 
Loss of a hydroxyl group: unlike serine, leucine does not provide a 
hydroxyl group. 
Hydrophilicity to hydrophobicity: serine is hydrophillic whereas leucine 
is hydrophobic. 
In an attempt to dissect and identify which of these changes induced by the 
replacement of serine by leucine are important for the dominant inhibitory behaviour 
of PRP2", a number of PRP2 mutants encoding one or two amino-acid substitutions 
at the SAT motif were created using site-directed mutagenesis. The four mutants 
generated initially encoded the following amino acid substitutions: S3781 (SAT to 
JAY), S378C (SAT to CAT), S378A (SAT to AAT) and as an internal control S378L 
(SAT to LAT). For simplicity, the proteins encoded by the mutated PRP2 genes have 
been named ppIAT ppCAT pRp2AAT and ppLkT  respectively. 
Interesting results obtained from analysis of these mutants, led to the 
generation of three other PRP2 mutants encoding T380A (SAT to SAA), 
S378L/T380A (SAT to LAA), and S378A/T380A (SAT to AAA) and the proteins 
produced by these genes will be referred to as PRP2T  PRP2' and PRP2 
respectively. 
The phenotypes of these mutants were explored in vivo with respect to 
functional activity and effect on cell growth when overexpressed from the GALl 
inducible promoter. 
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5.2 METHODS AND MATERIALS. 
Table 5.1 Oligodeoxynucleotides Used for Site-Directed 
Mutagenesis of the PRP2 gene. 
Name of Sequence (5' to 3') Amino Acid Amino Name of 
Oligo Substitution(s) Acids at Mutant 
Introduced the SAT Protein 
Motif 
924V CATTGFGCTAATGAT S378L LAT PRP2 T 
ATAAGC 
921V CATFGTFGCTATTGAT S3781 IAT PRP2T 
ATAAGC 
922V CATFGTFGCACATGAT S378C CAT PRP2CAT 
ATAAGC 
923V CATFGTFGCTGCTGAT S378A AAT PRP2T 
ATAAGC 
911X GCGFCATGCTGCTG S380A SAA ppSAA 
ATGATATAAGC 
912X GCGTFCATFGCTGCTA S378L/T380A LAA 
 
LAA I 913X GCGrICATFGCTGCTG S378A/T380A AAA AAA PRP2 
CTGATATAAGC 
NB: All mutant PRP2 genes were reconstituted using an N-terminally polyhistidine-
tagged vector (described in chapter 7) facilitating future purification of mutant 
proteins. For simplicity, plasmids carrying the genes encoding PRP2T, ppLkT 
ppCAT ppAAT, pRp2SAA PRP2' PRP2W  will be referred to as pBMPRP2 T , 
pBMPRP2 T , pBMPRP2' T , pBMPRP2 T , pBMPRP2, pBMPRP2', and 
pBMPRP2 respectively. 
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5.2.1 Generating the PRP2 SAT Motif Mutants. 
PRP2 mutants were generated using site-directed mutagenesis as described in 
section 2.4.5. The Hind ffl-XbaI fragment of the PRP2 gene was subcloned into the 
vector pTZ18R producing the construct pTZP2H-X which was used as a template for 
the reactions. Synthetic oligodeoxynucleotides complementary to the PRP2 sequence 
spanning the region encoding the SAT residues and carrying the desired mutation 
were annealed to the template acting as primers for the elongation reaction. The 
oligonucleotides used are listed in table 5.2. Positive clones containing the expected 
mutation(s) were identified directly by sequencing using oligonucleotide 385V. 
Nucleotide sequence of the region encoding the altered SAT residues for the 7 
mutants generated is shown in figure 5.1 (showing the sequence of the non-coding 
strand) and includes the WT sequence of this region for reference. To reconstitute 
mutant PRP2 genes, the mutated PRP2 Hindffl-XbaI fragments were cloned into the 
polyhistidine-tagged PRP2 deletion construct pBMP2AH-)& replacing the short, 
Hindffl-XbaI linker. [The N-terminally histidine-tagged version of pBMP2H-X was 
used to facilitate purification of mutant proteins. Construction of the polyhistidine-
tagged vector and purification of PRP2 protein will be described in chapter 7]. 
5.3 RESULTS AND DISCUSSION. 
5.3.1 pp2LAT pRp2IAT and ppCAT  but not pfflAAT  Cause a Dominant 
Inhibitory Growth Defect when Overproduced in S150-2B. 
In order to assess the growth phenotype of WT cells overproducing pplAT 
ppCAT ppAAT and ppLAT  the corresponding pBMPRP2-derived mutant 
plasmids were introduced into the strain S150-2B and transformants spotted onto both 
YMGCas and YMGRCas plates. To permit the identification of any temperature-
dependent effects, all transformants were incubated on both types of media at 23 0C, 
300C 340C and 360C for three days and at 18 0C for 5 days. As a positive control, 
cells harbouring pBMPRP2 and were included on the test plates. As temperature-
dependent effects were not displayed by any of the transformants, the result of this 
growth assay is shown only for cells grown at 30 °C (figure 5.2A). 
As expected, the gene encoding PRP2T  was dominant when overexpressed. 
This mutant, originally isolated by random mutagenesis, acted as an internal control 
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FIGURE 5.1 Other Amino Acid Substitutions at the PRP2 SAT Motif. 
Nucleotide sequence of the region encoding the altered SAT residues for the 7 
mutants generated by site-directed mutagenesis of pTZP2H-X is shown. Sequencing 
of the single-stranded DNA templates was carried out using the primer 385V. The 
mutated nucleotides are underlined, and the sequence is that of the non-coding strand. 
The WT sequence of this region is included for reference. 
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FIGURE 5.2A Overproduction of WT PRP2, PRP2LAT, PRP2 1AT, PRP2CAT, and 
ppAAT in S150-2B. 
S150-2B transformants carrying pBMPRP2 (WT), pBMPRP2T (LAT), pBMPRP2T 
(IAT), pBMPRP2T  (CAT), or pBMPRP2T  (AAT), were grown overnight in 
selective YMGCas at 30°C, harvested by centrifugation and resuspended in dH 20 to 
an approximate concentration of 106  cells/mi. 15ti drops of these cultures were 
spotted onto either selective YMGRCas (Galactose) or selective YMGCas (Glucose) 
plates. The plates were incubated for 3 days at 30 °C. 
FIGURE 5.2B Overproduction of WT PRP2, PRP2 11T, PRP2AAT, PRP2S, and 
PRP2 in S150-2B Grown at Various Temperatures. 
S150-2B transformants carrying pBMPRP2 (WT), pBMPRP2T (LAT), 
pBMPRP2T (AAT),  pBMPRP2S  (SAA), pBMPRP2 IA  (LAA), and pBMPRP2W 
(AAA) were grown overnight in selective YMGCas at 30 0C, harvested by 
centrifugation and resuspended in dH 20 to an approximate concentration of 10 6 
cells/mi. 151d drops of these cultures were spotted onto either selective YMGRCas 
(Galactose) or selective YMGCas (Glucose) plates. The plates were incubated at 
230C, 300C, 340C, and 360C for three days and at 18 1C for 5 days as indicated. 
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confirming the mapping and sequencing data by demonstrating that the S378L 
substitution was indeed responsible for the galactose-sensitive phenotype. 
Both ppIAT  and ppCAT caused galactose-sensitivity when overproduced, 
however PRP2T did not. This indicated that the loss of a hydroxyl group at amino 
acid 378 was not the sole determinant of dominance as an alanine residue at this 
position, providing only a methyl group, had no effect. That the large size of the 
leucine side-chain was the sole cause of dominance was also ruled out; a cysteine 
residue at amino acid 378 also caused a dominant effect despite the size similarity of 
senne (present in WT PRP2) and cysteine, (differing only in terms of the increased 
size of a sulphur atom of cysteine compared to an oxygen atom of serine). In 
addition, the simple hypothesis by which substitution of a hydrophiffic serine residue 
with a hydrophobic residue determined the dominant effect was also ruled out. 
Although the three tested residues that caused dominance (L, I, and C) are 
hydrophobic, alanine, which is also hydrophobic (or at least significantly more 
hydrophobic than serine) had no effect. It must be considered however that the small 
size of the A side-chain may also have contributed to the absence of a dominant 
phenotype when ppAAT  was overproduced. 
In summary, of the very limited number of substitutions made during this 
study, residues that were more hydrophobic and either similar in size or larger than 
S produced a dominant negative effect when used to replaced S378 of PRP2. It might 
be predicted that the hydrophobic L, I, and C side-chains caused steric interference, 
disrupting the conserved structure of the SAT residues whereas the small, inert A 
residue did not. In the absence of crystallographic data to provide an understanding 
of the structure of the SAT domain, interpretation of these results remains highly 
speculative. 
5.3.2 PRP2AAT  is Functional in vivo. 
That the overproduction of ppAAT  protein did not cause cell growth 
inhibition indicates that this form of the protein does not interfere with the activity 
of WT PRP2. There are two possible explanations that can account for this: 
The mutation causing the S378A substitution is recessive, possibly 
rendering PRP2T  protein incapable of interacting with spliceosomal components. In 
this case, the defective polypeptide would not compete with WT PRP2 for binding to 
essential splicing factors. 
The S378A substitution is tolerated therefore PRP2T  is functional (or at 
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least partially functional). 
In order to establish which of these explanations was correct, the ability of the 
gene encoding ppAAT  to permit growth of a haploid yeast cell when present in 
single-copy under the control of its own promoter was tested. One-step gene 
replacement (Rothstein, 1983) was carried out to replace one of the PRP2 loci of a 
diploid strain with the gene encoding ppAAT  This strain was then sporulated, and 
tetrad analysis performed to assess the viability of the four haploid products of 
meiosis. Linear DNA fragments containing the entire mutant PRP2 gene encoding 
ppAAT were used to transform the diploid strain EFY2 in which one copy of the 
PRP2 gene has been disrupted by the removal of the central Hindffl-XbaI region, and 
insertion of the URA3 selectable marker at this site (thus the disrupted gene, referred 
to as PRP2::URA3, does not contain the region of PRP2 encoding SAT). Selection 
for ura3 transformants in which a gene conversion event had led to the replacement 
of the PRP2::URA3 gene with the gene encoding PRP2 T was carried out by plating 
cells on 5-fluoro-orotic acid (5-FOA) plates. 5-FOA is toxic for WT cells as these 
convert 5-fluoro-orotic acid to fluorodeoxyuridine, a potent inhibitor of thymidylate 
synthetase. In contrast, ura3 auxotrophs fail to utilise orotic acid, and therefore 
growth of these mutants is selected on this medium (Boeke et al., 1984). 
To ensure that the ura3 auxotrophs obtained were a result of the appropriate 
gene replacement event, total yeast DNA was isolated from these strains, digested 
with Ba,nHI, and subjected to Southern blot analysis using a 32P-labelled DNA probe 
carrying the entire PRP2 gene. The result of the Southern blot analysis is shown in 
figure 5.3. Lanes 1 and 2 were included as controls showing respectively, DNA 
prepared from the diploid strain EFY2 prior to and following replacement of the 
PRP2::URA3 locus with a PRP2 gene containing a single point mutation. This was 
carried out previously by E.Flinn (this lab.). The two bands of similar intensity 
detected in lane 1 represented the 3.2kb WT PRP2 locus and the 3.6kb PRP2::URA3 
locus. Following replacement of the disrupted locus with a PRP2 gene containing only 
a single point mutation, the 3.6kb band had disappeared (lane 2). DNA prepared from 
a ura3 strain following replacement of the PRP2:: URA3 gene of EFY2 with the gene 
encoding PRP2T  is shown in lane 3. As expected, the 3.6kb band corresponding to 
the disrupted locus was undetectable, and only the 3.2kb band was present (that the 
3.2kb band was less intense than that in lane 2 wa due to uneven loading of DNA). 
This indicated that the gene encoding PRP2T  was present on the genome and had 
replaced the disrupted PRP2 locus. The diploid strain generated was named EFY2 1 . 
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FIGURE 5.3 Southern Blot: Replacement of the Disrupted PRP2::UR43 locus of 
the diploid strain EFY2 with the Gene Encoding PRP2AAT. 
Total genomic DNA was prepared from the PRP21PRP2:. URA3 diploid strain EFY2 
(lane 1) and two derivatives of this strain EFY2A1T  (lane 2), and EFYAAT  (lane3). The 
genomic DNA was restriction digested with BamHI, electrophoresed through a 0.8 % 
agarose gel, blotted onto Hybond-N and hybridised to a 3.2kb 32P-labelled DNA 
BamHI fragment isolated from the plasmid pBMPRP2 carrying the entire PRP2 gene. 
The probe was made by labelling the restriction fragment by the random priming 
method. Maps show the location of the BamHI sites flanking the PRP2 and disrupted 
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EFY2T was sporulated at 30°C, and dissection of tetrads yielded, in each 
case, four viable spores indicating that activity of the PRP2T  protein was sufficient 
to permit cell growth. 
5.3.3 Overproduction of pJp21 PRP21  ppSAA and PRP2 in S150-.2B. 
Since PRP21  was shown to function in vivo, it was predicted that the SAT 
motif of PRP2 may only require one of the two hydroxyl groups to function ie. if 
AAT was tolerated, perhaps SAA would also be tolerated. This was tested by 
generating a mutant encoding SAA, and as a control, a mutant encoding AAA at the 
SAT motif. 
Plasmids carrying the mutant genes encoding ppLkT ppAAT ppSAA 
and PRP2 were introduced into S150-2B and transformants spotted onto both 
glucose- and galactose-containing media to compare growth phenotypes. In order to 
detect any temperature-dependent effects all transformants were incubated on both 
types of media at 23 °C, 30°C and 340C for three days and at 18 0C for 5 days. As a 
positive control, cells harbouring WT pBMPRP2 and were included on the test plates. 
The result of the growth assay is shown in figure 5.2B. 
As expected, at each temperature, all transformants grew on glucose-
containing medium. Cells harbouring the WT plasmid pBMPRP2 also grew on 
galactose-medium, whereas growth inhibition was displayed by cells overproducing 
the ppLkT  protein. Transformants overproducing either the active PRP2T  protein 
or the ppSAA  protein grew on both types of media at all temperatures demonstrating 
that the ppSAA  protein does not compete with its WT counterpart, and therefore 
may actually be functional in vivo, mimicking the behaviour of the reciprocal mutant 
protein PRP2 T. This would agree with the theory that the SAT motif of PRP2 can 
function even in the absence of one of the hydroxyl side-chains. In order to test this, 
the functional activity of the PRP2, and PRP2 proteins was assessed, the results 
being described in the following section. 
An intriguing phenotype was displayed by cells overproducing PRP2. 
Growth of the transformants on galactose was restricted, but only at temperatures 
below 23°C. At 18°C, cell growth was completely inhibited, however the defect was 
alleviated as the growth temperature was increased. Partial inhibition was displayed 
at 23°C, and growth behaviour at 300C was restored to that of the WT control cells. 
Therefore the PRP2 protein behaved in a heat-sensitive manner, causing a 
dominant inhibitory phenotype when overproduced at 18 °C. This is reminiscent of the 
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behaviour of a mutant form of the DEAH protein PRP16. Overproduction of the 
prpl6-1 protein also causes cell growth inhibition at 18 °C but not at higher 
temperatures (Schwer and Guthrie, 1992a). It is possible that this reflects participation 
of these mutant proteins in the formation of hyperstabilised complexes at low 
temperatures, disassembly being permitted only when temperatures are increased. 
5.3.4 PRP2, ppSAA  PRP2 but not pfflLAT  Complement a Temperature-
sensitive p,p2-1  Defect in vivo. 
To assess the ability of the ppLkT ppAAT PRP2, and PRP2 mutant 
proteins to complement a heat-sensitive pip2-1 defect in vivo, plasmids carrying the 
mutant genes were introduced into the temperature-sensitive pip2-1 strain DJY36 and 
transformants were incubated at the permissive and non-permissive temperatures of 
23°C and 36°C respectively. The strain DJY36 facilitates regulated gene expression 
from the GALl promoter, therefore transformants were spotted onto both glucose 
(GLU) and galactose-containing media (GAL) to assess the effects of both repressed 
and induced expression of the genes encoding mutant and WT forms of the PRP2 
protein. DJY36 transformants carrying WF pBMPRP2 and pBMP2iH-X were 
included as positive and negative controls respectively. The results are summarised 
in table 5.2. 
Table 5.2 Growth of DJY36 Transformants on Glucose- and Galactose-containing 
Media at 23°C and 36°C 
Plasnild Used to 
Transform DJY36 
23°C 36°C 
GLU GAL GLU GAL 
pBMPRP2 + + + + 
pBMP2âH-X + + - - 
pBMPRP2 T + - - - 
pBMPRP2 T + + - + 
pBMPRP2 + + - + 
pBMPRP2 AAA + - - + 
1- mciicates growm, - inaicates no growm. 
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As expected, all DJY36 transformants grew at the permissive temperature, 
except for those harbouring either pBMPRP2' T or pBMPRP2 grown on inducing 
medium. This demonstrates that the dominant inhibitory effect caused by ppLAT  and 
PRP2 overproduction was not a strain-specific phenomenon; both DJY36 and 
S150-2B were affected (in addition, several other WT yeast strains exhibit a growth 
inhibitory phenotype when induced to overexpress PRP2T  M. Cooper pers. comm.). 
At the non-permissive temperature (36 0C), cells carrying the WT plasmid 
pBMPRP2 were able to grow on both glucose- and galactose-containing media. The 
observed complementation even when PRP2 expression was repressed on glucose 
probably reflects a combination of the "leakiness" of the GALl promoter, and the 
high specific activity of the PRP2 protein. Protein produced from the deletion mutant 
carried by pBMP2H-X did not provide complementation even when cells were 
grown on galactose. Similarly, transformants carrying pBMPRP2lAT  were also unable 
to grow at 36°C on glucose- or galactose-containing media. In contrast, the PRP2T, 
ppSAA and PRP2AAA proteins did complement the heat-sensitive defect however only 
when overproduced. This indicated that the activity of the mutant proteins compared 
to that of WT PRP2 was reduced as overproduction was necessary for 
complementation of the pip2-1 defect. Although it would be expected that the defect 
caused by the double amino acid substitution would cause a more severe defect than 
either of the single amino acid substitutions, the in vivo complementation assay used 
was not amenable to quantitation of activity and therefore this remains unresolved. 
Considering the rigid conservation of the SAT residues at helicase domain Ill 
of related helicase-like proteins, the partial redundancy of the serine and threonine 
residues is rather unexpected. Hydroxyl groups are frequently found in reactive sites 
of enzymes, and often coordinate interactions with other molecules through hydrogen 
bonding. The results presented here show that replacement of threonine or serine or 
both of these residues with an A residue decreases but does not completely abolish 
the activity of the PRP2 protein. Therefore, it is likely that these residues do not play 
a central role in catalysis or in ligand binding, but are perhaps employed for a more 
subtle nevertheless important function. The results of Pause and Sonenberg, (1992) 
are consistent with this proposal. They generated a mutant form of the prototype 
helicase eIF-4A changing the SAT residues to AAA. Assaying the mutant protein at 
30°C, they showed that ATPase and RNA unwinding activities were uncoupled; 
ATPase activity was increased but RNA unwinding was abolished. This suggests that 
the SAT residues might be involved in the transduction of energy derived from ATP 
hydrolysis to drive the RNA unwinding event. In the light of the results presented 
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here, it would be valuable to reassess the behaviour of the eIF-4A mutant protein at 
a range of temperatures (Pause and Sonenberg carried out assays only at 30 1C). 
5.3.5 Both the pffl}LAT  and PRP' Proteins cause Growth Inhibition when 
Overproduced in S150-2B. 
If the temperature-independent inhibitory behaviour of PRP21T  is conditional 
upon the integrity of the T residue, it could be speculated that this third residue of 
SAT is important for the interaction of PRP2 with spliceosomal factors ie. loss of the 
T residue might prevent the mutant protein from sequestering essential factors 
indicated by loss of the inhibitory phenotype. Alternatively, it could be predicted that 
such a mutant (encoding LAA at the SAT domain) might behave in a temperature-
dependant manner similar to the AAA mutant; hyperstabilisation of defective 
complexes at low temperatures might be required to facilitate a dominant inhibitory 
phenotype if the threonine residue is involved in a stabilising interaction. 
This theory was disproved; a mutant encoding LAA was generated and its 
behaviour was identical to that of the LAT mutant; overproduction of PRP2' - in 
S150-2B also caused cell growth inhibition in a temperature-independent manner (not 
shown). Therefore, presence of the L residue caused the dominant defect even in the 
absence of the 'r residue. 
It would be interesting to observe the effects of leucine at other positions of 
the SAT motif by creating mutants encoding SAL and SLT; the latter indicating 
whether a dominant effect would be achieved even in the presence of both -OH side 
chains. 
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5.4 SUMMARY OF RESULTS AND CONCLUSIONS. 
The results presented and discussed in this chapter are summarised in table 5.3 
below. 
Table 5.3 Summary of Results. 
Mutant Protein Growth Inhibitory when Functional in vivo? 
Overproduced 
ppIAT YES NO 
ppLAT YES Not tested 
ppCAT YES Not tested 
ppAAT NO Function reduced but 
sufficient for cell viability 
(see 5.3.2) 
ppSAA NO Function reduced at 36 0C, 
not tested below 36°C 
PRP2 AAA YES at or below 231C Function reduced at 36 °C, 
NO at or above 30°C not tested below 360C 
PRP2 LAA YES Not tested 
An attempt was made to determine the properties of leucine that were required 
to cause a dominant inhibitory phenotype when this residue replaced serine at the 
PRP2 SAT motif. A simple conclusion could not be made, however, in light of the 
limited number of substitutions tested it was shown that a dominant inhibitory 
phenotype was induced when S378 of PRP2 was replaced with a residue that was 
either similar in size or larger, and was more hydrophobic than serine. 
Surprisingly, the genes encoding PRP2AAT ppSAA and PRP21 were all 
capable of complementing the heat-sensitive defect of a prp2-1 strain however only 
when expression was induced by growth of cells on galactose. This indicated that, at 
360C, although the activity of the mutant proteins was not abolished, it was reduced 
compared to that of WT PRP2; the latter could complement the prp2-1 defect even 
when cells were grown on glucose. This partial redundancy of the highly conserved 
S and T residues is likely to reflect the nature of the SAT motif function. Although 
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S and T residues often play critical roles in catalysis and molecular interactions, for 
those of the SAT domain, a less stringent role is suggested. One possibility, 
considering studies of eIF-4A by Pause and Sonenberg, (1992), might be a role in the 
harnessing of energy derived from ATP hydrolysis to drive a coupled event proposed 
to be RNA unwinding. 
Phenotypes of cells overexpressing PRP2LT  PRP21 and PRP21 provided 
clues concerning the mechanism for dominance exerted by the leucine residue. Both 
ppLkT and PRP21 caused dominant inhibitory effects in a temperature-
independent manner indicating that the L and T residues did not in any way 
cooperate. Interestingly, PRP2 overexpression was also inhibitory however only 
at or below 23°C. Therefore, replacement of L by A induced a low-temperature 
requirement for exertion of a dominant negative phenotype. As cold-sensitive defects 
in multi-component systems are often explained in terms of hyperstabilised complex 
formation (for example see Shannon and Guthrie, 1991), a similar mechanism might 
explain the inhibitory phenotype of PRP2. The results are consistent with the 
following scenario: the leucine residue of PRP21T  participates in a strong, stable 
interaction with essential spliceosomal components causing a temperature-independent 
dominant phenotype. For the PRP2 mutant, the interaction is no longer secured, 
thus to compensate, low temperatures are required to aid the stabilisation of the 
interaction. Alternatively, and perhaps more likely, the substitutions may confer their 
effects indirectly by differentially affecting the two activities hypothesised to be 
important for PRP2 function; ATP hydrolysis and RNA unwinding. The defect(s) of 
ppLAT may be more severe than for PRP2. Thus, an activity of PRP2, perhaps 
responsible for a conformational change in the spliceosome which is required for 
PRP2 release, might be completely abolished by the S378L substitution but only 
reduced in the case of PRP2. This would explain the low temperature-requirement 
for dominance observed for PRP2, and the temperature-independent dominant 
phenotype of ppLkT 
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CHAPTER 6. 
In vitro Characterisation of PRP2'. 
6.1 INTRODUCTION. 
The preceding chapters have described the isolation of a PRP2 mutant which 
encodes the residues LAT rather than SAT at the conserved helicase motif ifi, and 
consequently, causes an in vivo splicing defect when overexpressed in a wild-type 
strain. Subsequent in vivo experiments suggested that this dominant phenotype is due 
to competition between mutant and WT forms of PRP2 protein for binding to 
essential splicing factors. In order to assess the potential use of this mutant as a tool 
for studying the normally transient interaction(s) of PRP2 with spliceosomes it is 
essential to study the mechanism of the dominant effect on splicing in vitro. 
The development of systems which allow labelled transcripts to be efficiently 
spliced in vitro have provided an opportunity to study the mechanism of splicing, the 
components required for the reaction, and also the ordered pathway of spliceosome 
assembly (Kole and Weissman, 1982; Kramer et al., 1984; Lin et al., 1985). 
Experiments described in this chapter employ such a system and involve the analysis 
of cell-free splicing extracts prepared from cells induced to overproduce either WT 
PRP2 or the dominant negative protein. The ability of these in vitro extracts to splice 
primary transcripts is assessed, and the complexes assembled during these reactions 
are analysed by native gel electrophoresis. Competition between mutant and WT 
molecules for interaction with splicing complexes is explored using a splicing extract 
mixing experiment. Finally, immunoprecipitation with anti-PRP2 antibodies is 
exploited to approach the central question: Is PRP2" strongly associated with splicing 
complexes throughout the in vitro splicing reaction? In parallel, the nature of the 
interaction of PRP2" with splicing complexes is compared to that of the heat-
inactivated prp2 and WT PRP2 proteins. The molecular mechanism for the dominant 
inhibitory behaviour of PRP2 is revealed and presented in the form of a model. 
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6.2 METHODS AND MATERIALS. 
6.2.1 Preparation of Yeast Splicing Extracts. 
Yeast splicing extracts were prepared from the strain Si 50-2B harbouring the 
plasmid pBMPRP2 grown in either YMGCas (repressing conditions) or in 
YMGRCas (inducing conditions) after initial growth to mid-log phase in YMGCas at 
30°C. These will be referred to as PRP2-GLU or PRP2"-GAL extracts 
respectively. Splicing extracts were also prepared from S 150-2B carrying the plasmid 
pBMPRP2 grown in YMGRCas (inducing conditions) following initial growth in 
YMGCas at 30°C and will be referred to as PRP2-GAL extracts. For use in 
complementation experiments, extracts were prepared from the pip2-1 temperature-
sensitive strain DJY85 grown in YMGCas at 23 °C. Extracts were prepared as 
described in section 2.5.5.1. 
6.2.2 Heat-inactivation of pip2-1 Heat-sensitive Extracts. 
Heat-sensitive extracts prepared from the pip2-1 mutant strain DJY85 grown 
at the permissive temperature of 23 °C were heat-inactivated in vitro by simply 
incubating 40d aliquots at 32 0C-350C for 1-1.5 hours, cooling on ice, and snap 
freezing for use in in vitro splicing assays. The temperature and length of incubation 
required for complete inactivation was strongly extract dependent. 
6.2.3 In vitro Splicing Reactions. 
The radiolabelled RNA substrates used in the in vitro splicing reactions were 
produced by in vitro transcription from pTZrp28s and pSM8 with bacteriophage T7 
RNA polymerase (2.4.12). Standard splicing reactions (10d volumes), carried out to 
assay for the production of splicing intermediates and products or for the analysis of 
splicing complex formation, contained a single splicing extract present at 50% (v/v) 
in the total reaction. These were assembled exactly as described in section 2.5.5.2. 
The following modifications were carried out for the assembly of splicing reactions 
performed for immunoprecipitation experiments or to assay the complementation of 
prp2-1 heat-inactivated extracts: 
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Heat-inactivated prp2-1 Complementation/Inhibition Reactions: 
For each 101 reaction, prp2á spliceosomes were pre-formed in a pp2-1 heat-
inactivated splicing extract by incubating 4d pip2-1 heat-inactivated extract with 4141 
splicing mix containing labelled rp28 transcript at 25°C for 15 minutes. Splicing mix 
was prepared exactly as in section 2.5.5.2. Meanwhile, 241 samples of 
complementation or complementation/inhibition extracts were pre-incubated at 25°C 
for 10 minutes prior to their addition to each of the 81 prp2A spliceosome aliquots: 
complementation extract contained 1d of a 1/20 dilution of PRP2-GAL extract mixed 
with 1d buffer D; complementation/inhibition extract contained 1l of a 1/20 dilution 
of PRP2-GAL extract mixed with 1l PRP2'-GAL extract which was either 
undiluted, or diluted to 1/10, 1/20 or 1/60. Buffer D was used for the dilution of 
splicing extracts. Following the addition of complementation or 
complementation/inhibition extracts to prp2A spliceosomes, reactions were allowed 
to proceed for a further 25 minutes at 25 °C and then cooled on ice. RNA from Sizl 
of each reaction was analysed by denaturing polyacrylamide gel electrophoresis. 
Splicing Reactions for Immunoprecipitation Experiments: 
201d reactions were assembled by mixing 81d PRP2'-GLU extract with either 4d 
PRP2-GAL or 4d PRP2'-GAL extract which were diluted by a factor of 2 using 
buffer D (the latter was just sufficient to inhibit the activity of the PRP2'-GLU 
extract) and pre-incubating at 25 0C for 10 mins prior to the addition of 8d splicing 
mix which was prepared precisely as in section 2.5.5.2. except that dH20 was added 
up to 40d rather than 50d (to allow 121d of splicing extracts to be added to 8l 
splicing mix for each reaction). Reactions were allowed to proceed for 20 mins at 
250C and then stopped by cooling rapidly on ice. Immunoprecipitation was carried out 
from 101d of each reaction. 51 was used to analyse the splicing intermediates and 
products by denaturing polyacrylaniide-gel electrophoresis, the remaining 5d being 
subjected to native gel electrophoresis for the analysis of splicing complexes. 
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6.3 RESULTS. 
6.3.1 Overproduction of PRP2d1l  Inhibits Splicing in vitro causing the 
Accumulation of Inactive Splicing Complexes. 
To establish that the in vivo splicing defect caused by overproduction of 
PRP2d1 I was also observed in vitro, splicing assays were carried out using extracts 
prepared from S150-2B cells in which expression of PRP2" was induced or 
repressed, and as a positive control, from cells overexpressing WT PRP2. The 
splicing products and intermediates formed during the reactions were analysed by 
denaturing polyacrylamide gel electrophoresis and the result is shown in figure 6. 1A. 
Consistent with the in vivo data, splicing extracts prepared from cells in which 
expression of PRP2-dnl was repressed (PRP2 1-GLU extracts) were active in the 
presence of ATP (lanes 1 and 2), whereas those prepared from the same strain grown 
under inducing conditions (PRP2'-GAL extracts) were inactive (lane 3). As 
expected, overproduction of WT PRP2 had no effect on in vitro splicing; extracts 
prepared from cells overproducing the WT protein (PRP2-GAL extracts) were active 
in the presence of ATP (lanes 4 and 5). This assay demonstrates that high levels of 
PRP2(hl abolish splicing in vitro whereas increased amounts of the WT protein are 
in no way detrimental. Confirmation was obtained from experiments described later 
which demonstrate that the activity of WT splicing extracts are completely abolished 
by the addition of a diluted PRP2-GAL extract. 
In order to assess the effects of PRP2" overproduction on spliceosome 
assembly, in vitro splicing reactions carried out in overproducing PRP2 or PRP2(bI 
extracts were stopped after 2, 5, 10, 20, or 30 minutes and the complexes were 
analysed by native gel electrophoresis (Figure 6. 1B). The gel system used was based 
on that described by Pikielny et al., (1986) which resolves three discrete complexes 
designated I, II and III in order of increasing electrophoretic mobility. In this system, 
the order of complex assembly is ifi, I, II. The final complex, II, has been shown to 
contain the products and intermediates of the reaction and therefore represents the 
active spliceosome. 
A typical time course of complex assembly during a WT reaction is shown in 
lanes 1 to 4. The kinetics of the time course were similar to those observed by 
Pikielny et al., (1986). At 2 minutes only complex ifi was observed, at 5 minutes 
however, all three complexes were detected indicating the conversion of complex ifi 
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FIGURE 6.1 The effects. of Overexpressing PRP2-dnl on pre-mRNA Splicing in 
vitro and on the Assembly of Splicing Complexes. 
In vitro Splicing Assays. 
Splicing reactions (101.d) containing radiolabelled rp28 pre-mRNA and 50% (v/v) 
splicing extract were incubated for 30 mins at 25°C either in the presence or absence 
of ATP (+ATP, -ATP). RNA was recovered and electrophoresed through a 6% 
(w/v) denaturing polyacrylamide gel. The splicing extracts were prepared from the 
strain S 150-213 carrying either pBMPRP2'' grown under repressing conditions (diii 
GLU, lanes 1 and 2) or inducing conditions for 6 hours (diii GAL, lane 3) or from 
S 15072B carrying pBMPRP2 grown under inducing conditions for 6 hours (WT GAL, 
lanes 4 and 5). IVS.E2, lariat intron-exon 2 intermediate species; IVS, lariat excised 
intron; pre-mRNA, rp28 substrate; M, spliced mRNA product. 
Analysis of Splicing Complexes by Native Gel electrophoresis - Time Course. 
5.d aliquots of the dnl GAL or WT GAL (+ATP) splicing reactions shown in figure 
5. 1A (lanes 3 and 4) incubated for the times indicated (2, 5, 10, 20 and 30 mins) 
were electrophoresed through a composite 0.25% (w/v) agarose, 3% (wlv) 
polyacrylamide non-denaturing gel. Complexes were designated I, II and III according 
to Pikielny et al., (1986). 
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to the intermediate complex I which became rapidly converted to the active 
spliceosome (complex II). At 10 minutes, production of the active spliceosome 
reached a peak (lane 3), and later time points, (in this case 20 minutes, lane 4) 
indicated a marked decrease in all three species presumably due to the conversion of 
complexes I and ifi to band II which finally became disassembled. 
Lanes 5 to 9 demonstrate the striking effect of PRP2' overproduction. 
Differences between the WT and mutant reactions were first observed at 5 minutes 
(compare lanes 2 and 6): complexes ifi and I formed during the mutant reaction, 
however conversion to the active spliceosome was completely blocked. This resulted 
in the excessive accumulation of the inactive complex I throughout the incubation 
(lanes 6 to 9). Unlike the WT reaction, there were no signs of complex disassembly 
or instability (even after 30 minutes, lane 9), thus the release of spliceosomal 
components assembled into this inactive dead-end complex (complex 1) was either 
inhibited or at least severely delayed. 
6.3.2 WT PRP2 and PRP2" Compete for Interaction with Spliceosomes In Vitro. 
Competition between PRP21' and WT PRP2 for binding to splicing complexes 
was demonstrated by carrying out a splicing extract mixing experiment that exploited 
an assay for functional PRP2 protein developed by Lin et al., (1987). The assay 
involves formation of splicing complexes in heat-inactivated prp2-1 extracts (termed 
prp2A complexes) which are functional intermediates of the splicing pathway and can 
be complemented by the addition of WT PRP2-containing fractions. This system was 
used to assess the ability of a diluted PRP2-GAL extract to inhibit the 
complementing activity of a diluted PRP2-GAL extract. 
Initially a PRP2-GAL extract was diluted to a point at which although it could 
not itself promote splicing, could complement prp2A spliceosomes which were pre-
formed in a heat-inactivated pip2-1 extract. The effect of mixing increasing dilutions 
of a PRP2'-GAL extract with the WT complementing fraction was assessed and is 
shown in figure 6.2. The levels of PRP2 and PRP2d1ZI  proteins in the two extracts 
were estimated to be similar using quantitative Western blot analysis and probing with 
anti-PRP2 antibodies (not shown). 
Prp2A spliceosomes were prepared by incubating heat-inactivated pip2-1 
extract with labelled rp28 transcript under splicing conditions for 15 minutes. These 
spliceosomes were then mixed with either diluted splicing extracts being tested for 
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FIGURE 6.2 PRP2"' Inhibits Complementation of a prp2-1 Heat-Inactivated 
Extract by WT PRP2. 
Splicing reactions (51d) were carried out using rp28 transcript with splicing extract 
prepared from S150-2B induced to overexpress WT PRP2 diluted to 115 or 1/200 in 
the total reaction (lanes 1 and 2 respectively), or with prp2-1 temperature-sensitive 
heat-inactivated extract incubated under splicing conditions for 15 mins and then 
incubated for a further 25 mins following the addition of splicing buffer (lane3), 
overexpressing WT extract diluted to 1/200 in the total reaction volume (lane 4), or 
overexpressing PRP2!12I  extract also diluted to 1/200 (Lane 5). Lanes 6-9; prp2-1 
heat-inactivated extract incubated under splicing conditions for 15 mins and then 
incubated for a further 25 mins following the addition of overexpressing WT extract 
diluted to 1/200, mixed with overexpressing PRP2t2I  extract diluted to 1/10 (lane 6), 
1/100 (lane 7), 1/200 (lane 8), and 1/600 (lane 9) in the total reaction volume. 
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complementation (lanes 4-9), or as a negative control, buffer D (lane 3). A 200-fold 
dilution of extract prepared from cells overproducing PRP2 (PRP2-GAL) could not 
itself promote splicing (lane 2), but could complement the prp2A spliceosomes 
indicated by the conversion of pre-mRNA to the lariat RNA species shown in lane 4. 
In contrast, a PRP2-GAL extract also present at an overall dilution of 1/200 could 
not complement prp2A spliceosomes (lane 5) indicating that the mutant protein was 
functionally inactive. When overproducing PRP2" extract was mixed with the WT 
complementing extract to a dilution of 1/10, complementation was completely 
inhibited (lane 6). This inhibition was alleviated by titrating the amount of mutant 
extract to 1/100, 1/200, and 1/600 in the total reaction (lanes 7, 8 and 9). Therefore, 
PRP2" protein blocked the complementing activity of its WT cellular counterpart. 
When the PRP2 1-GAL extract was diluted to 1/600, the complementing activity of 
the WT PRP2-GAL fraction was completely restored (lane 9). 
The most feasible explanation for this result is that the two forms of PRP2 
compete for binding to the prp2A spliceosomes. When the WT form binds, an active 
complex is formed and splicing proceeds whereas if PRP21I  interacts the complex is 
inactivated. If the mutant protein is present at levels similar to or greater than that of 
WT protein, a reduction in splicing activity is detected due to a decrease in the 
number of active spliceosomes. This model suggests that although the mutant protein 
is unable to perform its activity required for the first step of splicing, it retains the 
ability to interact with spliceosomes. This was tested in the following experiment. 
Although the levels of PRP2 and PRP2(b  protein in the complementing and 
inhibiting fractions were judged to be similar using Western blot analysis, the limited 
sensitivity of the assay requires that this experiment is considered qualitative rather 
than quantitative. It is noteworthy however that when the complementing and 
inhibiting activities were introduced at approximately equal levels (lane 8, both at a 
dilution of 1/200 in the total reaction), a decrease in splicing activity was clearly 
detected (compare the intensity of the lariat species in lanes 2 and 8). This is 
reminiscent of the in vivo competition experiment described in section 3.3.3 in which 
the growth defect conferred by PRP2d?I  overproduction could not be completely 
rescued by the simultaneous overproduction of WT PRP2. Taken together these in 
vivo and in vitro results suggest that the PRP2-dnl mutation might act in a co-
dominant (or at least partially dominant) manner in single copy. This would imply 
that the mechanism for the dominant phenotype involves irreversible sequestration or 
at least hindered release of essential spliceosomal components. Such a mechanism is 
also suggested by the excessive accumulation of complex I during mutant splicing 
reactions. The experiment described in the following section aims to verify this 
theory. 
6.3.3 Release of PRP2dhl  from Splicing Complexes is Impeded. 
The interaction of PRP2" with splicing complexes was examined directly 
by immunoprecipitation using anti-PRP2 antibodies (Figure 6.3B). Previously, similar 
experiments have demonstrated that WT PRP2 interacts transiently with spliceosomes, 
and that the recessive heat-sensitive prp2 protein fails to associate with complexes 
following heat-inactivation (King and Beggs, 1990). If PRP2(hI,  in contrast to its WT 
counterpart, is indeed retained in "stalled" complexes, thus denying entry of WT 
PRP2, P32-labelled pre-mRNA should be strongly co-immunoprecipitated from mutant 
splicing reactions using PRP2-specific antibodies. In contrast, precipitation of PRP2-
associated complexes from WT reactions should be relatively inefficient due to the 
transient nature of this interaction. Therefore the levels of RNA co-precipitated 
following incubation in a WT extract and an extract in which activity was inhibited 
by the presence of PRP2(hI  protein were compared. As an additional control, 
immunoprecipitation was also performed from a heat-inactivated prp2-1 extract 
incubated under splicing conditions. 
In order to optimise immumoprecipitation efficiency, WT and dominant 
negative splicing reactions both contained active PRP2''-GLU extract however for 
the dominant negative reaction, a minimum volume of PRP2-GAL extract shown 
by titration experiments to inhibit the activity of the PRP2'-GLU extract was added. 
For the WT reaction, the same volume of overexpressing extract, in this case PRP2-
GAL was added to the PRP2-GLU extract. This avoided saturation of anti-PRP2 
antibodies by superfluous PRP2 or PRP2dII  molecules. An example of a titration 
experiment carried out to determine the minimum volume of PRP2"-GAL extract 
required to inhibit activity of the PRP2'-GLU extract is shown in figure 6.3A. 
PRP2'"-GLU extract showed strong splicing activity when incubated with buffer D 
alone (lane 8), however, when buffer D was replaced with dilutions of a PRP211-
GAL extract ranging from 1/5 to 1/200 in the total reaction volume, this activity was 
either reduced or abolished (lanes 2-7). When the PRP2-GAL extract was added at 
a dilution of 1/10, splicing was completely inhibited (lane 3), however, when present 
at a dilution of 1/15 (lane 4), splicing activity was detectable, and inhibition was 
further reduced as the dilution factor was increased (lanes 5, 6, and 7). Therefore the 
conditions shown in lane 3 were used for the dominant negative reaction; PRP2 1 - 
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FIGURE 6.3 Analysis of the Interaction of PRP2"' with Splicing Complexes. 
Titration Experiment - To Determine the Minimum Volume of PRP2"-
containing Extract Required to Inhibit Splicing Activity of a WT Extract. 
In vitro splicing reactions (201.d) contained rp28 transcript and 8l splicing extract 
prepared from S150-2B extract plus 41Ll of extract prepared from S150-2B cells 
induced to overexpress PRP2" which was either undiluted (1/5 in the total reaction, 
lane 2), or diluted by a factor of 2 (1/10 in the total reaction, lane 3), a factor of 3 
(1/15 in the total reaction, lane 4), a factor of 4 (1/20 in the total reaction, lane 5), 
a factor of 10 (1150 in the total reaction, lane 6) or a factor of 40 (1/200 in the total 
reaction) using buffer D. RNA was extracted from Spi of each reaction and analysed 
by denaturing-gel electrophoresis. IVS.E2; lariat intron-exon 2 intermediate species, 
IVS; lariat excised intron product, El .E2; spliced mRNA product. 
Immunoprecipitation Experiment. 
In vitro splicing reactions (20141) were carried out using rp28 transcript plus an 
intronless control transcript in either 811 of splicing extract prepared from S150-2B 
cells mixed with 4il of extract prepared from S 150-213 induced to overexpress either 
PRP2" (dnl) or WT PRP2 (WT) which had been diluted by a factor of 2 using 
buffer D (WT), or in a heat-inactivated extract prepared from a temperature-sensitive 
prp2-1 strain (2-1). Reactions were stopped after 20 mins. Total RNA was extracted 
from 31 of each reaction (lanes 7, 8 and 9), and immunoprecipitation was carried out 
from 101d of each reaction using excess a-PRP2 antiserum (90141 of a-55 anti-serum, 
see figure 2. 1), (lanes 1, 2, 4 and 6), pre-immune serum (90il) (lane 3), or a-M 3G 
antibodies (10jd) (lane 5). Sjl of each reaction was analysed by native gel 
electrophoresis (lanes 10-13) and splicing complexes formed are designated I II and 
III according to Pikielny et al., (1986). Lane M; markers, end-labelled fragments of 
pBR322 plasmid DNA that had been digested with MspI and AvaI+NheI and then 
mixed, IVS.E2; lariat intron-exon 2 intermediate species. IVS; lariat excised intron 
product, El.E2; spliced mRNA product. 
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GAL extract was added to the PRP2''-GLU extract at a dilution of 1/10 in the total 
reaction. Similarly, for the WT splicing reaction PRP2-GAL extract was added to the 
PRP2'"-GLU extract at a dilution of 1/10. In addition to employing using these 
optimised splicing reaction conditions, excess anti-PRP2 antibodies were used. 
Analysis of the RNA species (Figure 6.3B lanes 7, 8, and 9), and the splicing 
complexes formed during the reactions (lanes 10-13) indicated that for the dominant 
negative reaction, splicing was inhibited due to a block in the transition of complex 
Ito the active spliceosome (complex II of Pikielny et al., (1986)), whereas in the WT 
reaction, active spliceosomes were assembled and reaction products and intermediates 
yielded. Analysis of the splicing complexes formed during incubation with heat-
inactivated pip2-1 extract revealed a similar pattern to that of the dominant inhibitory 
reaction; complexes were stalled prior to the formation of the active spliceosome (lane 
13). Therefore active PRP2 protein was essential for the first step of the splicing 
reaction, and conversion of complex I to the active spliceosome; both recessive and 
dominant mutations led to complete abrogation of step one and a block in progression 
of complex I to complex H. 
Anti-PRP2 antibodies strongly immunoprecipitated pre-mRNA-associated 
complexes from the dominant negative splicing reaction (lane 1) indicating that 
PRP2(bI protein was indeed stably associated with spliceosomes. As expected, 
precipitation was dependent on the formation of complexes demonstrated by the minus 
ATP control (lanes 2 and 11), and on the use of PRP2-specific antibodies indicated 
by the pre-immune serum control (lane 3). That the RNA precipitated was indeed 
specifically associated with splicing complexes rather than non-specifically bound to 
free PRP2 or to protein A-sepharose was shown by including an intronless control 
transcript which would not be assembled into spliceosomes. Under no circumstances 
was the control transcript precipitated. 
In contrast, WT PRP2 had a weak or highly transient association; precipitation 
of labelled RNA species from the WT splicing reaction using anti-PRP2 antibodies 
was almost undetectable (lane 4), whereas strong precipitation of pre-mRNA was 
achieved using anti-M 3G antibodies which precipitate spliceosomes. Consistent with 
the observation of King and Beggs, (1990), co-precipitation of RNA from the prp2-1 
reaction was undetectable. They showed that this was due to the failure of the prp2 
protein to interact with complexes. Therefore, although both the dominant and 
recessive mutations caused complexes to be stalled prior to the formation of the active 
spliceosome, the protein of the dominant mutant was capable of entering complexes, 
whereas heat-inactivated prp2 protein was not. 
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6.4 DISCUSSION. 
In this chapter, the dominant negative effect on splicing caused by 
overproduction of the PRP2' protein in a WT yeast strain was reproduced in an in 
vitro splicing system. The behaviour of the PRP21I  protein in vitro was shown to be 
consistent with previous observations made in vivo and this model system was then 
exploited to reveal the molecular basis for the dominant inhibitory phenotype. 
In vitro splicing extracts prepared from cells induced to overproduce PRP2(hl 
were inactive whereas overproduction of WT PRP2 showed no deleterious effect on 
splicing. Thus the splicing defect shown to cause growth inhibition in vivo was 
observed in the in vitro system. Using native gel electrophoresis, the complexes 
assembled during incubations with these extracts were analysed; overexpression of 
PRP21' was shown to inhibit formation of the active spliceosome, (complex II, 
according to Pikielny et al., 1986) and caused the accumulation of a slowly migrating 
complex resembling complex I of Pikielny et al. 
Evidence to support a model in which mutant and WT molecules compete for 
binding to spliceosomes was obtained by challenging PRP2-deficient spliceosomes 
(prp2A spliceosomes) pre-formed in a heat-inactivated prp2-1 extract with fractions 
containing various ratios of PRP2 and PRP2' protein. The inactive prp2 
spliceosomes were complemented by the additon of a WT PRP2-containing fraction, 
and PRP2" protein was shown to be inactive as addition of a PRPZ"-containing 
fraction did not complement prp2A spliceosomes. The complementing activity of WT 
PRP2 was completely inhibited when PRP2(hI  and PRP2 proteins were presented 
together at a ratio of approximately 20:1. To facilitate complete restoration of 
activity, a three-fold excess of WT PRP2 was required, and when the complementing 
and inhibiting fractions were present at similar levels only partial activity was 
detected. This co-dominant phenotype was observed previously in cells simultaneously 
overproducing both WT and mutant forms of PRP2 and is consistent with the 
following scenario: PRP2" and WT PRP2 compete for entry into spliceosomes 
however as release of the mutant polypeptide is retarded, entry of the WT form is 
denied and a population of stalled complexes containing inactive PRP211  accumulates. 
This mechanism would explain the progressive accumulation of inactive complex I 
observed during the incubations with mutant extract. 
The definitive experiment designed to test this model involved co-
immunoprecipitation of pre-mRNA-associated complexes from in vitro splicing 
reactions using PRP2-specific antibodies. PRP2 protein was indeed shown to be 
strongly associated with inactive spliceosomes whereas both WT and heat-inactivated 
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prp2 proteins were not. King and Beggs, (1990) showed that pre-mRNA and the 
intermediate RNA species were weakly precipitated from a WT splicing reaction 
indicating a transient association of WT PRP2 at step one of the reaction. The fact 
that precipitation of RNA from the WT splicing reaction in this study is almost 
undetectable reflects the short exposure time used relative to that of King and Beggs 
(1990), as weak precipitation can be detected following longer exposure times. They 
also showed that heat-inactivated prp2 protein fails to assemble into complexes. 
Another less favourable interpretation of the results presented by King and 
Beggs, (1990) is that the interaction of PRP2 with splicing complexes is weak rather 
than transient. Recently, this possibility has been ruled out using a system developed 
by M.McGarvey (this lab.) which involves the formation of spliceosomes in heat-
inactivated p,p2-1 extracts which are subsequently isolated and ATP-depleted. These 
are referred to as ATPá prp2A spliceosomes, and can be complemented by the 
addition of both purified PRP2 protein and ATP (purification of WT and dominant 
negative forms of PRP2 protein accomplished during the course of this PhD. will be 
described in chapter 7). When purified PRP2 protein is added back to ATPA prp2i 
spliceosomes, labelled pre-mRNA is strongly co-immunoprecipitated indicating a 
strong association of PRP2 with complexes in the absence of ATP. Upon subsequent 
addition of ATP however, co-precipitation of labelled pre-mRNA is no longer 
detectable indicating that PRP2 is released from complexes in an ATP-dependent 
manner (M.McGarvey unpublished results). The equivalent experiment was also 
carried out using purified PRP2(hI  protein, and the result confirms the findings 
presented in this chapter. Using this system, PRP2(h  protein was not released from 
complexes even upon addition of ATP. As PRP2 is known to possesss an RNA-
dependent ATPase activity (Kim et al., 1992), it will be of great interest to assess the 
effect(s) of the dominant negative mutation on this activity, thus this is the focus of 
the following chapter. 
Figure 6.4 shows a schematic summary of the results presented in this chapter 
together with the relevant information from Pikielny et al., (1986) and King and 
Beggs (1990). The model shows the complexes (defined by Pildelny et al.) which 
were shown to assemble during the reactions (from which immunoprecipitations were 
carried out). In the WT reaction, all three complexes, ifi, I, and the active complex 
II are observed. King and Beggs demonstrated that PRP2 protein does not associate 
with early complexes, but interacts prior to step one, and is present throughout this 
step being released prior to completion of step two. PRP2 protein is assembled into 
complex I, which houses pre-mRNA, and is also shown in association with the 
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FIGURE 6.4 Schematic Summary of the Interactions of WT PRP2, PRP2" 
and Heat-Inactivated prp2 Proteins with Splicing Complexes throughout In vitro 
Splicing Reactions. 
The complexes formed during wild type (WT), Dominant Negative mutant (DN1), 
and heat-inactivated pip2-1 (2-1) in vitro splicing reactions are designated III and III 
after Pikielny et al., (1986). Arrows indicate the conversion of complex I (the pre-
spliceosome) into complex II which is then (in the WT reaction) rapidly converted to 
complex III (the active spliceosome). The question mark indicates the fact that it is 
unclear which complex is the site of the first step. 














intermediates of the reaction within complex H. Although complex II may represent 
the conformational change associated with the presence of the intermediates, it is not 
clear whether band I or band II is the site of step one in this system. Therefore PRP2 
may dissociate prior to or simultaneous with conversion of complex I to II (this 
disparity is represented by the question mark). The undetectable co-precipitation of 
RNA from the WT reaction in this study can be explained by the very rapid 
dissociation of the PRP2 protein from spliceosomes. During incubations with either 
the dominant or recessive mutant extracts, complex assembly is stalled with 
accumulation of complex I, however, PRP2(bI  protein is tightly associated with this 
complex whereas the heat-inactivated prp2 protein is not. 
Thus the molecular basis for the dominant phenotype was confirmed; PRP2 11  
enters complexes in competition with WT PRP2 and is either retained, or the 
interaction is prolonged delaying access of WT PRP2. In contrast, the recessive 
nature of the prp2-1 mutant observed in vivo, can be explained by failure of the heat-
inactivated prp2 molecules to associate with complexes leaving the PRP2 binding-site 
available for entry of the WT protein. 
These in vitro studies also ruled out other less interesting mechanisms for 
dominance which could not be discounted by information obtained from in vivo 
experiments. One example is internal dominance, involving the formation of 
homodimers or multimers by the PRP2 protein which might be inactivated by 
incorporation of a single mutant polypeptide; WT molecules might be sequestered 
outwith the spliceosome and in this case the mutant protein would not be strongly 
associated with splicing complexes. In contrast, the formation of mixed homodimers 
which bind more strongly to complex I remains a possibility. That the phenotype 
observed was due simply to a reduction in the levels of WT PRP2 caused by 
overproduction of PRP2(bJ  was ruled out. 
The dominant negative PRP2 mutant isolated provides a powerful genetic tool 
for studying the interactions of the PRP2 protein with its spliceosomal ligands. As 
release of the PRP2dII  protein from spliceosomes is retarded, its interactions can be 
probed using either genetic or biochemical techniques. In addition, the putative 
helicase motif, SAT, has been shown to be both functionally important, and required 
for the release of PRP2 from complexes. An understanding of the biochemical 
defect(s) responsible for the dominant inhibitory phenotype could shed light on the 
role of PRP2 in splicing. Such knowledge could be extended to four other members 
of the putative RNA helicase family which like PRP2 have been proposed to drive 
RNA unwinding events at critical points throughout the splicing reaction. 
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CHAPTER 7. 
Purification and Biochemical Analysis of PRP2" 
Protein. 
7.1 INTRODUCTION. 
Random mutagenesis has identified the highly conserved SAT sequence of 
PRP2 as a motif important for both the function and the release of PRP2 protein from 
splicing complexes. In addition to the dominant negative mutation which caused a 
serine to leucine substitution at the SAT domain, other changes at this motif 
introduced, by site-directed mutagenesis, also induce dominant antagonistic 
phenotypes when the altered proteins are overexpressed. Analysis of the biochemical 
defect(s) of these mutants will not only complete our understanding of their dominant 
effect on splicing, but might also elucidate the function(s) of the SAT motif for PRP2, 
allowing informative analogies to be drawn between this and other members of the 
putative RNA helicase family. 
For the prototype of the DEAD family of putative helicases, the eukaryotic 
translation initiation factor eIF-4A, the SAT motif has been shown to be required for 
RNA unwinding (Pause and Sonenberg, 1992). Despite predictions that PRP2 function 
might also involve the unwinding of RNA helices (Wasserman and Steiz, 1991), 
attempts to demonstrate an RNA unwinding activity for PRP2 in vitro have so far 
failed (Kim et al., 1992). It is likely that this reflects stringent substrate specificity 
of the PRP2 protein and/or the requirement for other trans-acting factors, after all, 
eIF-4A requires the co-factor eIF-4B to permit unwinding (Rozen et al., 1990). 
Therefore, although it is tempting to speculate that the PRP21I  protein might be 
defective in its ability to unwind RNA helices, a simple assay to test this prediction 
is currently unavailable, and the development of such an assay is not a trivial task. 
In contrast, the effects of dominant negative mutations on RNA-dependent ATP 
hydrolysis can be explored, and an essential prerequisite for such experiments is the 
attainment of purified WT and mutant forms of the PRP2 protein. 
This chapter describes the modification of the PRP2 gene to encode a 
recombinant polyhistidine-tagged form of PRP2 assisting the development of a simple 
2-step system for the purification of PRP2 protein from yeast extracts. Subsequent 
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biochemical analysis of essentially purified WT and mutant forms of the protein are 
described. Results are interpreted in the light of current knowledge concerning the 
behaviour of mutant forms of the DEAD/DEAH proteins eIF-4A and PRP16. 
7.2 METHODS AND MATERIALS. 
7.2.1 Synthetic Oligodeoxynucleotides. 
All oligonucleotides were synthesised at the OSWEL DNA service, Edinburgh. 
Table 7.1 Oligodeoxvnucleotides used to Polyhistidine-Tag the PRP2 gene. 
Name Sequence (5' to 3') and Information 
810P AATFCGGATCCATA1TATG(CAT) 6GGTACCATCGAGGGCC 
Sense-strand. Complementary to oligonucleotide 811P. 810P and 811P 
anneal to form a linker used to polyhistidine-tag the PRP2 gene. See 
figure 7.1 for a more detailed description of the linker. 
81 1P GATCGGCCCTCGATGGTACC(ATG)6CATAATATGGATCCG 
Anti-sense strand complementary to the above. 
574S GACATGCGGACTCGGCCCTCG 
Anti-sense strand. Used for site-directed mutagenesis of the N- 
terminal region of the polyhistidine-tagged PRP2 gene. Inserts a single 
nucleotide 5 bases upstream of the PRP2 initiating ATG, placing the 
histidine tag sequence in frame with the sequence of the PRP2 gene 
(see figure 7.3). 
866R GTAACTFCATACGTFCG 
Anti-sense strand. For sequencing upstream from nucleotide 40 of the 
PRP2 gene through the initiation codon of PRP2 into the promoter 
region. Used to screen for the presence, and determine the orientation 
and sequence of the N-terminal polyhistidine-tag. 
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7.2.2 Purification of Polyhistidine-Tagged PRP2, PRP2' and PRP2 AAA Proteins 
from Yeast Extracts. 
Polyhistidine-tagged WT and mutant forms of PRP2 protein were purified 
from cell extracts prepared from the strain S 150-2B induced to overproduce 
recombinant PRP2 proteins. The method used, which was developed during the 
course of this PhD. is presented in the form of a detailed step-by-step protocol in 
section 2.5.8. Details of the development and a visual profile of the 2-step procedure 
are presented in the following results sections. Essentially purified protein eluted from 
the polyuridilic acid agarose column was used directly in in vitro splicing assays and 
ATPase assays. 
7.2.3 In vitro Splicing Reactions. 
In vitro splicing reactions (1041) contained the radiolabelled substrate rp28 
produced by in vitro transcription from pTZrp28s with bacteriophage 17 RNA 
polymerase (2.4.12) and were carried out in order to assess the activity of purified 
forms of PRP2 protein. WT PRP2 activity was assayed by functional 
complementation of the step-one defect in heat-inactivated pp2-1 extracts. The 
dominant negative effect on splicing exhibited by the PRP2 1 ' protein was assayed by 
inhibitio$he splicing activity of a WT extract. These splicing assays will be 
considered separately. 
In vitro Complementation reactions: 
For each 101 reaction, 4141 splicing extract prepared from the pip2-1 strain DJY85 
which had been previously heat-inactivated (6.2.2) was mixed with 1i1 purified WT 
PRP2 protein, which was either undiluted or diluted with buffer BP containing 
250mM KC1 (the buffer with which the PRP2 protein was eluted). Following 
incubation at 25 °C for 5 mins, 541 splicing mix (prepared precisely as in section 
2.5.5.2) was added and reactions incubated at 25 °C for 25 mins and then stopped on 
ice. RNA was extracted from 5il of each sample and analysed by denaturing 
polyacrylamide gel electrophoresis. 
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In vitro Inhibition Reactions: 
For each 101d reaction, 41 splicing extract, prepared from S150-2B was mixed with 
2d purified PRP2(hI  protein which was either undiluted or diluted with buffer BP 
containing 250mM KC1 (the buffer with which the PRP2 protein was eluted). 
Following incubation at 251C for 5 mins, 4l splicing mix was added and reactions 
incubated at 25 0C for a further 25 mins. Splicing mix was prepared precisely as in 
2.5.5.2 except that dH 20 was added up to 40d rather than 50141 to allow a ratio of 
6d splicing extract:4zl splicing mix. RNA was extracted from 511 of each sample 
and analysed by denaturing polyacrylamide gel electrophoresis. 
7.2.3 ATPase Assays. 
Release of [32P]-Pi from ['y-32P]ATP following hydrolysis catalysed by WT or 
mutant forms of purified PRP2 protein was measured using a method adapted from 
Iggo and Lane (1989). In a total volume of 20d, purified PRP2 protein was incubated 
in the presence of 50mM triethanolamine (pH 8.2), 75mM potassium acetate, 1.25 
MgC12, 1mM ATP, 1Ci ['y-32P]ATP (10 Ci/mmol) and 1.25mM DTF (as DTr was 
present in PRP2 protein samples at 5mM, the concentration of DTJ' was always 
adjusted to 1.25mM after dilution of the protein sample in reaction buffer). Where 
indicated, the stimulatory factor poly-U RNA was added at a concentration of 5zg/l. 
The amount of enzyme, and the incubation times are indicated in the text and figure 
legends. 
Reactions were stopped on ice and acid-washed Nont charcoal added up to 
200d (5% in 20mM phosphoric acid) to precipitate the unreacted ATP. Samples were 
incubated on ice for 10 mins, spun in a microcentrifuge for 10 mins, and the 
supernate was analysed for free [32P]-Pi by Cerenkov counting. The background 
resulting from incubation in the absence of enzyme was subtracted from each value. 
Each result was obtained by calculating the average of two independent reactions 
which did not vary by more than 20%. 
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7.3 RESULTS. 
7.3.1 Development of a 2-Step System for the Purification of PRP2 Protein. 
As previous attempts to purify PRP2 protein using an E. coli expression system 
proved unsuccessful (King D. Ph]) thesis this lab.), it was decided to purify PRP2 
from the yeast strain S150-2B containing the plasmid pBMPRP2. A protocol for the 
purification of PRP2 protein from yeast has been published recently by Kim et al., 
(1992) which involves a complicated multistep procedure utilising multiple ammonium 
sulphate precipitations, size fractionation columns, and finally binding to a 
polyuridilic acid agarose column. 
To obviate the requirement for so many procedures, the polyhistidine-tagging 
method was utilised involving the modification of the PRP2 gene to encode a fusion 
protein containing (at the N-terminus) a run of six histidine residues followed by a 
factor Xa cleavage site. Recombinant protein was purified under native conditions, 
by immobilised metal affinity chromatography (IMAC) which exploits the high 
affinity of adjacent histidine residues for NV' (Arnold, 1991). 
Unfortunately, only partial purification of tagged PRP2 protein could be 
achieved using this method alone; two highly abundant yeast proteins also bound to 
the NV' chelating resin with high affinity, therefore another purification step was 
required. For this second step, the RNA binding properties of the PRP2 protein were 
exploited; a poly-U RNA agarose column was used, as in Kim et al., (1992). 
This section describes the procedure used to polyhistidine-tag the PRP2 and 
PRP2-dnl genes, and provides a detailed account of the 2-step purification method. 
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7.3.1.1 Polyhistidine-Tagging the PRP2 Gene. 
The cloning strategy adopted to tag the PRP2 gene at the N-terminus is shown 
diagrammatically in figure 7.2 and details are given in the legend. The tag used was 
formed by annealing the oligonucleotides 810P and 811 P (see table 7. 1), the sequence 
and features of which are shown in figure 7.1 below: 
BamHI 
lop: 5'AATTCGGATCCATATTATG (CAT) 6GGTACCATCGAGGGCC 3 
lip: 	3'GCCTAGGTATAATAC (GTA) 6CCATGGTAGCTCCCGGCTAG5 ' 
mino acids: 	 M (H) 6 G T I E G R 
KpnI Factor Xa 
Cleavage Site 
Figure 7.1: Sequence and features of the polyhistidine tag. 
It contains its own initiation codon and encodes a run of six histidine residues 
followed by a factor Xa protease recognition site (IEGR). It is flanked by EcoPJ and 
Ba,nHJ compatible ends respectively, and a second BamHl recognition site is located 
just inside the EcoRI compatible end. A diagnostic KpnI site was also included to aid 
the cloning procedure. 
The tag was positioned between the GALl promoter sequence and the initiation 
site of the PRP2 gene by cloning the EcoRI-Hindffi fragment from pBMPRP2 
(containing the GALl promoter linked to the first 800bp of the PRP2 gene) into the 
polylinker of pTZ18R. This construct has been named pTZP2E-H. The polyhistidine 
tag (described in figure 7.1) was cleaved to give BamHI compatible ends, and then 
cloned into the BamHI site of pTZP2E-H forming a histidine-tag-truncated PRP2 
fusion under the control of the GALl promoter. Clones carrying the histidine tag were 
identified by diagnostic restriction digestion using the enzyme KpnI (a site for which 
is present in the tag but not in the vector). Single-stranded template DNA was then 
prepared from tag-containing clones, and single isolates carrying one copy of the tag 
placed in the correct orientation were identified by sequencing using oligonucleotide 
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FIGURE 7.2 Polyhistidine-Tagging the PRP2 Gene. 
The 1.6Kb EcoRI-HindIII fragment from pBMPRP2 which contains the GAL] 
promoter and the first 800bp of the PRP2 gene was cloned into the polylinker of 
pTZ18R producing the construct pTZP2E-H (A) which was linearisd with BamHI (B). 
Oligos 810P and 006P were annealed to form the polyhistidine tag (C) which was 
cleaved with BamHI to yield a fragment possessing 2 BamHI compatible ends (D). 
Linearised pTZP2E-H and the histidine tag were ligated (E), and ligation products 
used as templates for preparation of single-stranded DNA for sequencing (F). 
Sequencing was used to identify clones containing a single tag in the correct 
orientation, and one of these was used as a template for site-directed mutagenesis to 
place the sequences of the polyhistidine tag and the PRP2 gene in-frame yielding the 
construct pTZP2E-H' (G). In order to reconstitute the entire histidine-tagged PRP2 
gene, the tag-containing EcoRI-HindIII fragment from pTZP2EHu  was used to 






I (C) Oligos 810P and 006P annealed to form tag. 
(A) Cut with EcoRi and HIndUl to release a 1.6kb 
fragment (containing GALl promoter and the first 
800bp of PRP4 which was cloned into the 




) pTZP2E-H linearised 
th BamHI. 
__ 	 BE 	 H B EBB 	 BB 
 (E) LIGATION with BamHl. TAG 





DNA prepared for 
sequencing to 
check orientation 




mutagenesis used to place 
& 
E/ 0  
(H) His tagged PRP2 
gene reconstituted by 
replacing the 
corresponding region of 







rnr 	IIU "Isudine, Lag 	 his sequences in frame. pTZP2E-H -11111. 
866R (see table 7.1). 
Since the oligonucleotides 810P and 81 1P used to form the tag were designed 
originally for the modification of another gene studied in this lab. (the DED1 gene), 
it was necessary to carry out site-directed mutagenesis to place the histidine tag and 
PRP2 gene sequences in-frame. The mutagenesis procedure was carried out by 
E. Flinn (this lab.) using oligonucleotide 574S (see table 6.1) to add a single C.G 
base-pair 5 nucleotides upstream of the PRP2 initiating ATG. The sequence of the 
histidine tag cloned into the BamHI site of pTZP2E-H and adjacent nucleotides both 
prior to and after site-directed mutagenesis is shown in figure 7.3. below. This 
construct containing the histidine tag and PRP2 sequences in-frame was named 
pTZP2E-H. 
ore Mutagenesis: * 
ATC CAT ATT ATG (CAT) 6 GGT ..... GGC CGA TCC GCA TG 
TAG GTA TAA TAC (GTA) 6 CCA ..... CCG GCT AGG CGT AC * 
ter Mutagenesis: * 
G ATC CAT ATT ATG (CAT) 6 GGT ..... GGC CGA CTC CGC ATG 
C TAG GTA TAA TAC (GTA) 6 CCA .... CCG GCT GAG GCG TAC * 
olyhistidine tag sequence is shown in bold. * marks th 
nitiation codon of the PRP2 gene. .....indicates codons o 
he tag which are not shown. Nucleotides introduced b 
utagenesis are underlined. 
'imir 7.. 	Site-directed mutaaenesis is used to i1ace the 
polyhistidine-tag and PRP2 sequences in-frame. 
Finally, in order to reconstitute the entire tagged PRP2 gene, the EcoRI-
Hind ifi fragment from pTZP2E-I& containing the histidine tag flanked by the GALl 
promoter and the N-terminal PRP2 sequence was cloned back into pBMPRP2 
replacing the corresponding EcoRI-Hindffi region. This construct was named 
his pBMPRP2. 
In addition, the same tag-containing EcoRI-Hindffi fragment from pTZE-H 
was also used to replace the corresponding region of the deletion construct 
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pBMP2iIH-X producing pBMP2H-3" (carried out by S.Anderson, this lab.). By 
replacing the short Hind ffi-XbaI linker of pBMP2AH-XI with the Hind ffl-XbaI 
fragment of the PRP2" gene, a polyhistidine-tagged version of pBMPRP2" 1 was 
generated and named pBMPRP2'". 
7.3.1.2 Tagged PRP2 is Functional in vivo. 
The factor Xa cleavage site positioned between the six adjacent histidine 
residues and the start of the PRP2 protein was included to allow the histidine tail to 
be detached if it interfered with PRP2 activity. To test the function of the his-PRP2 
fusion protein, pBMPRP2 was introduced into the temperature-sensitive pip2-1 
mutant strain DJY36, and transformants incubated at the permissive and non-
permissive temperatures of 23 °C and 36°C respectively on either glucose or galactose-
containing selective media (not shown). pBMPRP2 and pBMP2H-X were also used 
to transform DJY36 acting as positive and negative controls respectively. As 
expected, all transformants grew at the permissive temperature. At 36 °C however, 
cells harbouring pBMP2H-X were unable to grow on either media due to the 
deletion of the central region of the PRP2 gene, whereas those containing either 
pBMPRP2 or pBMPRP2 grew on both types of media and produced colonies of a 
similar size. Therefore, the tagged form of PRP2 protein was shown complement the 
prp2-1 defect even when expression from the inducible promoter was repressed. As 
mentioned in section 5.3.4 such complementation achieved on glucose medium is 
probably due to "leakiness" of the GALl promoter and the high specific activity of 
the PRP2 protein. The apparent WT behaviour of the recombinant PRP2 protein 
indicated that cleavage of purified protein with factor Xa was likely to prove 
unnecessary. 
7.3.1.3 Tagged PRP2" Inhibits Splicing when Overexpressed in vivo. 
To ensure that the polyhistidine tag did not interfere with the dominant 
negative phenotype of PRP2(bI,  pBMPRP2' was introduced into S150-2B and 
transformants were plated on selective YMGRCas and YMGCas. As expected, a 
dominant negative phenotype was observed; cells grew on glucose but not on 
galactose-containing media. This indicated that the activity of recombinant PR2" 
protein was apparently unaffected by the tag. 
7.3.1.4 Step I - Tagged PRP2 is Partially Purified using a Nickel Chelating 
Column. 
The fully optimised procedure used for this first step of the purification system 
is described in detail in section 2.5.8, and is based on the method used by Hoffman 
and Roeder (1991). Extracts prepared from S150-2B cells induced to overproduce his-
tagged PRP2 protein were passed over a Ni" chelating column facilitating binding 
of tagged PRP2 to the resin. Comparison of equal volumes of input and run-through 
samples by Western blotting and probing with anti-PRP2 antibodies demonstrated that 
the lOOkD tagged PRP2 protein bound strongly to the column and that the efficiency 
of binding was increased by circulating the extract over the resin rather than passing 
it over only once (not shown). Efficiency of binding was also improved by omitting 
reducing agents from buffers and the extract itself. Hoffman and Roeder use 5mM 
DTT throughout in extracts and buffers, however this was found to severely reduce 
efficiency of binding recombinant PRP2 protein to the resin. Presumably this is due 
to reduction of the Ni2 rendering it incapable of binding histidine residues. In fact, 
EDTA gradients can be used to elute his-tagged proteins from the column. Since the 
association of histidine residues with nickel ions is resistant to high salt, it was 
possible to load the column in the presence of 500mM NaCl assisting purification by 
disrupting interactions between recombinant PRP2 and other proteins which might 
otherwise be indirectly co-purified. 
Following binding to the column, the lOOkD recombinant PRP2 protein was 
successfully eluted in a partially pure form using a step gradient of imidazole which 
competes for binding to nickel (the functional group of histidine is an imidazole ring). 
A typical profile of the N?'-NTA purification system is shown in figure 7.4A. 
Aliquots of crude extract, flow-through and of the lml elution fractions collected 
from the column were analysed by polyacrylamide gel electrophoresis and silver 
staining. Most of the cellular polypeptides passed over the column unhindered 
(compare extract and flow-through tracks 2 and 3), unfortunately however, two highly 
abundant proteins with approximate apparent molecular weights of 45kD and 50kD 
bind the resin and were present in the 20mM and 49mM wash samples, and extend 
into the 150mM and 200mM elution fractions (tracks 5-10). Attempts to eliminate 
these contaminants prior to elution of the lOOkD PRP2 protein at 200mM inüdazole 
(shown in tracks 6-9) failed even with extended 150mM washes. 
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FIGURE 7.4 Two-Step Purififcation of Polyhistidine-Tagged PRP2 Protein. 
Aliquots of fractions from the two-step purification of polyhistidine-tagged PRP2 
protein were analysed by electrophoresis through a 7.5% SDS-polyacrylamide gel 
followed by silver staining. 
Step I: Nickel Chelating Column. 
Lane 1, marker proteins with sizes indicated in kD; lane 2, unfractionated extract 
(fraction I) prepared from the strain S150-2B induced to overproduce polyhistidine-
tagged PRP2 protein diluted 1:1 with sample buffer (lid); lane 3, run-through sample 
following passage of fraction I over the column (lid); lane 4, first imi fraction of 
20mM imidazole wash (3041); lanes 5 and 6, first and final imi fractions of 49mM 
imidazole wash respectively (3041); lanes 7 and 8, elution fractions 4 and 5 
respectively (150mM imidazole) (301zl); lanes 9, 10, 11, and 12; elution fractions 6, 
7, 8 and 9 respectively (301d) (200mM imidazole). 
Stepil: Polyuridylic Acid Agarose Column. 
Lane 1, marker proteins with sizes indicated in kD; lane 2, pooled fractions 5-12 
from nickel-chelating column (fraction II) (301d), lane 3, run-through sample 
following passage of fraction II over poly-U RNA column (301d), lanes 4 and 5, first 
and final lml fractions of 100mM KC1 wash samples respectively (301d); lanes 6 and 
7, 0.45ml elution fractions 11 and 12 (250mM KC1) (301Ll). 
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7.3.1.5 Step II - Essentially Pure PRP2 elutes from a Poly-U RNA Agarose 
Column. 
In order to purify PRP2 protein away from the abundant 45kD and 50kD 
contaminating proteins, fractions 5-12 from the nickel chelating column were dialysed 
against a suitable buffer and loaded onto a poly-U RNA agarose column. A profile 
of this second purification step is shown in figure 7.4B. All PRP2 protein became 
bound to the poly-U RNA agarose (compare input and run-through samples lanes 2 
and 3) however the 45kD contaminating species did not bind. The SOkD protein, 
which did show affinity for the column, was removed by washing with buffer 
containing increasing concentrations of KC1 (100mM lanes 4 and 5, 150mM and 
200mM not shown). Essentially purified recombinant PRP2 protein was finally eluted 
in a sharp lml peak using 250mM KC1 (lanes 6 and 7). The sharpness of the peak 
was found to be dramatically affected by the speed at which elution buffer was passed 
over the column; slow elution (4m1/hr) provided the best result. 
To demonstrate that the lOOkD protein yielded at each step of the purification 
was indeed PRP2, elution samples were analysed by SDS-PAGE and Western blotting 
using anti-PRP2 antibodies. This is demonstrated in figure 7.6 which shows 
quantitative Western blot analysis of purified WT PRP2 and PRP2dII  which was used 
to confirm that the concentration of the two proteins was similar prior to their use in 
assays and will be discussed in section 7.3.2.4. 
The identity of the purified protein, shown to react with anti-PRP2 antibodies 
was confirmed using a functional assay for PRP2 protein. This involved 
complementation of a heat-inactivated extract prepared from a temperature-sensitive 
pip2-1 strain and is described in section 7.3.2.1. 
7.3.1.6 Mock Purification to Obtain a Negative Control for Assays. 
Since crude yeast extracts contain a vast number of diverse and highly efficient 
enzymes, it was important to demonstrate that any observed catalytic activity of 
purified PRP2 fractions was due specifically to the presence of functional PRP2 
protein rather than contaminants. The ideal negative control for enzyme assays would 
be a purified mutant form of the PRP2 protein that lacked the activity of interest. 
Attempts to purify the heat-sensitivepip2-1 protein (carried out by M.McGarvey; this 
lab.) which could be tested for this purpose were unsuccessful due to instability of the 
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prp2-1 polypeptides during the purification process. Therefore an alternative strategy 
was used; a "mock" purification was carried out from crude yeast extract prepared 
from the strain S150-213 carrying the vector pBM125 alone (ie. without a histidine 
tagged PRP2 gene) grown in YMGRCas. Analysis of the purification fractions from 
step one of the procedure (Figure 7.5A) showed that each sample contained 
contaminating bands of the same apparent molecular weight as those observed during 
purification of WT PRP2 (compare figure 7.5A lanes 5-12 with figure 7.4A lanes 5-
12) however, as expected, the lOOkD band corresponding to recombinant PRP2 
protein was not present. Fractions 5-12 from this mock nickel column purification 
were pooled dialysed and passed over a poly-U RNA agarose column being treated 
in exactly the same way as for the WT purification. The 0.5m1 fractions 11 and 12 
that corresponded to the peak PRP2-containing samples from the WT purification 
were pooled for use as a negative control sample in assays. As expected, analysis of 
this fraction by SDS-PAGE and silver staining demonstrated that bands corresponding 
to PRP2 protein or trace contaminants were undetectable (figure 7.5B lane 8). 
7.3.1.7 Summary of the Purification Procedure and Estimation of Purification 
Yield. 
Following optimisation of the 2-step purification procedure, both PRP2 1' and 
WT PRP2 proteins were purified on separate occasions twice and three times 
respectively. This demonstrated that the method is highly reproducible and that the 
behaviour of mutant and WT recombinant proteins throughout the procedure is similar 
with respect to stability, yield, and binding/elution properties. This suggests that the 
serine to leucine substitution at the SAT motif of PRP2" does not affect binding of 
the protein to single-stranded RNA. 
The full purification strategy showing the crude extract (fraction I), the pooled 
samples from the nickel chelating column (fraction II), and the essentially purified 
PRP2, PRP2' proteins and the mock sample from the poly-U RNA agarose column 
(fraction ifi) are summarised in figure 7.513. 
In order to calculate the specific activity of each of the purification fractions 
I, II, and ifi, the highly sensitive functional assay for PRP2 protein described 
previously in section 6.4 was used. This involved complementation of prp2i 
spliceosomes which were assembled onto labelled pre-mRNA in heat-inactivated pip2-
1 extracts and were subsequently ATP-depleted by gel filtration. The minimum 
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FIGURE 7.5 Mock PRP2 Purification and Summary. 
Mock PRP2 purification. 
Aliquots of fractions from a nickel chelating column mock purification procedure 
using an S150-2B extract that did not contain polyhistidine-tagged PRP2 protein were 
analysed by electrophoresis through a 7.5% SDS-polyacrylamide gel followed by 
silver staining. Lane 1, marker proteins with sizes indicated in kD; Lane 2, 
unfractionated extract prepared from the strain S 150-2B carrying the vector pBM 125 
grown in YMGRCas diluted 1:1 with sample buffer (lid); lane 3, run-through sample 
following passage of fraction I over the column (lid); lane 4, first lml fraction of 
20mM imidazole wash (301d); lanes 5 and 6, first and final lml fractions of 49mM 
imidazole wash respectively (301.&l); lanes 7 and 8, mock elution fractions 4 and 5 
respectively (150mM imidazole) (30id); lanes 9, 10, 11, and 12; mock elution 
fractions 6, 7, 8 and 9 respectively (30141) (200mM imidazole). 
Summary of 2-Step purification procedure. 
Aliquots of fractions from the two-step purification of WT polyhistidine-tagged PRP2 
protein, and final purification fractions (fraction III) of WT PRP2, PRP2', and mock 
sample eluted from the poly-U RNA column were analysed by electrophoresis through 
a 7.5% SDS-polyacrylamide gel followed by silver staining. Lane 1, marker proteins 
with sizes indicated in kD; lane 2, unfractionated extract (fraction I) prepared from 
the strain S150-2B induced to overproduce polyhistidine-tagged PRP2 protein diluted 
1:1 with sample buffer (lid); lane 3, run-through sample following passage of 
fraction I over the column (1d); lane 4, peak PRP2-containing fractions (pooled) 
from nickel-chelating column (fraction II) (3041); lane 5, run-through sample 
following passage of fraction II over poly-U RNA column (30/Ll); lanes 6, 7 and 8, 
pooled, peak PRP2 and PRP2'-containing fractions, or the corresponding fractions 
from the mock purification respectively, from poly-U RNA agarose columns (fraction 
ifi) (41d). 
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volume of each purification fraction required to chase labelled transcripts into reaction 
products and intermediates upon the audition of ATP to ATPL, prp2A spliceosomes 
incubated under standard conditions was determined (carried out by M.McGarvey; 
this lab.) Data obtained from these assays were used to estimate the overall yield of 
the purification procedure which is shown in table 7.2. 
















I 7 210 20000 140000 100 667 1 
II 8 Ø•2b 2500 20000 14 100000 150 
ifi 0.9 1 	0.018" 1 20000 18000 13 1000000 1 1500 
Table 7.2: (a) Protein concentrations were determined by using the Bradford colour 
assay with BSA as a standard. (b) Estimated from the intensity of bands in an SDS-
PAGE gel following either Coomassie blue or silver staining. c) One unit is the 
minimal amount of each fraction required to complement prp2A spliceosomes isolated 
from 5d heat-inactivated prp2-1 splicing extract incubated under standard splicing 
conditions (10141 reactions). 
Table 7.2 demonstrates that the purification procedure is extremely efficient; 
13 % of the active PRP2 protein present in the crude extract is recovered in an 
essentially purified form (the PRP2 purification method published by Kim et al., 
(1992) yields 1.9%). The polyhistidine-tagging step facilitates a massive 150-fold 
purification; most contaminating proteins being removed at this first step. A 10-fold 
purification at the final step is sufficient to remove all visible contaminating bands, 
and this step acts to efficiently concentrate PRP2 protein; only 1 % of PRP2 is lost 
at this step, and the remaining PRP2 protein (13% of that present in the crude 
extract) is eluted in a concentrated form in 0.9 ml. 
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7.3.2 Analysis of Purified PRP2 and PRP2' Protein. 
7.3.2.1 Purified PRP2 is Functional in vitro. 
As demonstrated in section 6.3.2, splicing extracts prepared from the 
temperature-sensitivepip2-1 mutant strain DJY85 can be heat-inactivated in vitro, and 
the activity restored by addition of WT PRP2-containing fractions. This in vitro 
complementation assay was used to assess the functional activity of the WT purified 
PRP2 protein (figure 7.6A). A heat-inactivated pip2-1 extract incubated in the 
presence of buffer alone was inactive (lane 1) however when the buffer was replaced 
with purified WT PRP2 protein at a dilution of 1/10 in the total volume, strong 
complementation was observed indicated by conversion of pre-mRNA to reaction 
intermediates and products (lane 2). The efficiency of complementation was directly 
proportional to the quantity of WT PRP2 added to the inactive extract; conversion of 
pre-mRNA to intermediates and products was reduced as the dilution factor of the 
PRP2 protein was increased (compare lanes 2 and 3). When PRP2 protein was diluted 
to 1/5000 complementation was undetectable. This confirmed that the purified lOOkD 
protein was indeed PRP2, and that it was functional in vitro. 
As this assay was found to be less sensitive and less amenable to quantitation 
than the assay involving complementation of ATP, prp2z spliceosomes developed 
by M.McGarvey (this lab.), the latter was used to quantify the activity of purification 
fractions. 
7.3.2.2 Purified PRP2' Inhibits Splicing in vitro. 
The ability of purified PRP2(hJ  protein to inhibit pre-mRNA splicing and cause 
the accumulation of inactive splicing complexes was assessed by mixing an active 
splicing extract with various dilutions of PRP2' protein and incubating in the 
presence of labelled transcript under splicing conditions. Analysis of both the RNA 
species and the splicing complexes formed during reactions (figure 7.6B) showed that 
WT splicing extract mixed with buffer alone was active (lane 1) and produced the 
active spliceosome complex II according to Pikielny et al., (1986). When, however, 
the buffer was replaced by purified PRP2" protein at a dilution of 1/5, splicing was 
completely abolished and inactive splicing complexes corresponding to complex I of 
Pikielny et al. accumulated. The inhibitory activity was titrated out as the dilution of 
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FIGURE 7.6 In vitro Assay System for Purified forms of PRP2 Protein. 
Complemention of a Heat-Inctivated pip2-1 Extract by Purified WT PRP2 
Protein. 
In vitro splicing reactions (10d) were carried out using rp28 transcript, and contained 
4l heat-inactivated splicing extract prepared from the prp2-1 strain DJY85 mixed 
with either 1l buffer BP containing 250mM KC1 (lane 1), or ljzl purified WT PRP2 
protein (10ng/41) that was either undiluted (1/10 in the total reaction; lane2), or 
diluted with buffer BP containing 250mM KC1 to 11500 (lane 3) or 1/5000 (lane 4) 
in the total reaction volume. Reactions were incubated at 25°C for 25 mins, stopped 
on ice, and RNA was extracted from 51d of each sample and analysed by denaturing 
polyacrylamide gel electrophoresis. IYS. E2, lariat intron-exon 2 intermediate species; 
IVS, lariat excised intron; pre-mRNA, rp28 substrate; M, spliced mRNA product. 
Splicing Inhibition by Purified PRP2' protein in vitro. 
In vitro splicing reactions (101d) were carried out using rp28 transcript, and contained 
4/Ll splicing extract prepared from the strain S150-2B (WT extract), mixed with either 
2l buffer BP containing 250mM KCL (lane 1), or 2d purified PRP2' protein 
(10ng/141) that was either undiluted (1/5 in the total reaction; lane 2), or diluted with 
buffer BP containing 250mM KC1 to 1/20 (lane 3), 1/50 (lane 4), or 1/500 (lane 5) 
in the total reaction volume. Reactions were incubated at 25°C for 25mins and 
stopped on ice. RNA extracted from 5141 of each was analysed by denaturing 
polyacrylamide gel electrophoresis, and 5d aliquots of reaction samples analysed in 
lanes 1, 2, 4, and 5 were also analysed by native gel electrophoresis (lanes 6-9 
respectively). Splicing complexes formed are designated I II and ifi according to 
Pikielny et al. (1986). IVS.E2, lariat intron-exon 2 intermediate species; IVS, lariat 
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purified protein was increased (lanes 3, 4 and 5) and conversion of complex I to the 
active spliceosome was resumed accordingly (lanes 8 and 9). Even when PRP2" was 
diluted to 1/500 in the total reaction volume, WT levels of splicing and of complex 
II formation were not achieved (compare lane 1 with 5 and lane 6 with 9 
respectively). 
7.3.2.3 Purified PRP2 is an RNA Stimulated ATPase. 
To establish that the purified WT PRP2 protein possessed RNA-dependent 
ATPase activity as reported by Kim et al., (1992), 5iJ aliquots of essentially pure 
PRP2 protein (equivalent to bOng) were incubated in the presence of 100mM ATP 
plus 14Ci [-y-32P]ATP either in the presence or absence of the stimulatory factor poly-
U RNA (used at a saturating concentration of 5g/l). Poly-U RNA was used as this 
was shown to be the most effective of four homopolymers tested by Kim et al., 
(1992). After incubation at 25 °C for 30 mins, release of ['y- 32P] was measured by 
precipitating unreacted ATP and analysing the supernate by Cerenkov counting. To 
assess the activity of trace contaminants which might be present in the purification 
fractions, 5d aliquots of the mock purification fraction were also assayed and the 
result is presented in figure 7.7. 
ATPase activity of purified PRP2 was stimulated 10-fold by the addition of 
poly-U RNA whereas the mock purification fraction possessed negligible activity and 
this was not RNA stimulated. The experiment also demonstrated that the purified 
PRP2 protein possessed some activity in the absence of RNA thus, as for PRP16 
(Schwer and Guthrie, 1992), PRP2 possessed RNA-stimulated rather than RNA-
dependent ATPase activity in this system. This was not detected by Kim et al., (1992) 
using a thin layer chromatography detection system for ATPase assays. The unlikely 
possibility that some of the observed activity was due to proteins which remained very 
tightly associated to PRP2 during the purification and which were undetected by the 
SDS-PAGE and silver-staining procedure cannot be ruled out. 
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FIGURE 7.7 RNA-Dependent ATPase Activity of Purified WT PRP2. 
100 nanograms of purified WT PRP2 protein, and the equivalent volume (51il) of 
mock purification fraction was incubated in the presence or absence of poly-U RNA 
in 201.d reaction mixes (541 poly-U RNA and 1mM ATP), at 25°C for 30 mins. The 
release of Pi from [-y- 32P]ATP was measured. 
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7.3.2.4 PRP2" has Reduced ATPase Activity. 
In order to compare the ATPase activities of the purified PRP2 and PRP21 , 
it was crucial to establish that the concentration of the two proteins was equal. As the 
concentrations of purified proteins were too low for the use of standard colourmetric 
quantification, it was decided to compare the intensities of bands corresponding to 
PRP2 protein in SDS-PAGE gels that were detected by silver staining or Western 
blotting and probing with anti-PRP2 antibodies. An example of such a quantitative 
Western blot is shown in figure 7.8 in which duplicate samples of both WT and 
mutant proteins were analysed. The blot was scanned using a Millipore Visage 
Scanner (version 4.6 N), and the integrated optical density of the peak signal in each 
track corresponding to PRP2 protein is presented in table 7.3. 
Readings obtained for duplicate samples did not differ by more than 13% (0% 
in the case of 4l of PRP2' lanes 5 and 6) attesting to the efficacy of this method. 
Comparison of signals obtained from WT and mutant samples indicated their relative 
concentrations; signals obtained from loading 31d of each differed by 17%, and those 
obtained from loading 41 of each differed only by 2%. The relatively large variation 
of 17% obtained by loading 3&l samples is most likely due to loading inacurracy; 3l 
duplicates were considerably more variable than 4l duplicates (11 and 13% 
compared to 4 and 0% respectively). The average difference in optical density 
detected between loading 3l and 4d samples was 38%, therefore, as equal volumes 
differed by much less than this (only 2% in the case of 4d samples, and 17% in the 
case of 3zl samples), the concentrations of WT and mutant proteins did not differ by 
more than 25%, and comparison of differences between samples loaded in lanes 5-8 
implies that the two proteins were of approximately equal concentration. 
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FIGURE 7.8 Quantitative Western Blot Analysis. 
3jd aliquots (lanes 1-4) and 4d aliquots (lanes 5-8) of WT PRP2 protein (lanes 1,2,5 
and 6) and PRP2" protein (lanes 2,3,7 and 8) were electrophoresed through a 7.5% 
SDS-polyacrylamide gel and Western blotted. The blot was probed with a-PRP2 







Table 7.3 quantitative Western Blot Analysis: Comparing Relative Concentrations of 
Purified PRP2 and PRP2" Protein, 
Lane Protein Vol. Integrated % % % 
(ud) Optical Difference Difference Difference 
Density between between between 
duplicates mutant loading 3l 
and WT and 4d 
1 PRP2 3 0.16 
11 2 PRP2 3 0.18 
17 
3 PRP2' 3 0.13 
13 
4 PRP2' 3 0.15 
5 PRP2 4 0.24 
6 PRP2 4 0.23 
2 
7 PRP2" 4 0.24 
8 PRP2" 4 0.24 
To compare ATP hydrolysis rates of purified WT PRP2 and ppthI,  ATPase 
activities of 60ng of each protein (31d) was measured over a period of 90 minutes 
(figure 7.9). The ATPase activity of the mutant was shown to be reduced, but not 
abolished. ATP hydrolysis by PRP2 was stimulated 10-fold at 60 mins by the addition 
of poly-U RNA whereas the mutant was stimulated 5-fold. In this experiment, the 
overall ATP hydrolysis rate of PRP2(bI  was reduced 2.8-fold compared to that of WT 
PRP2. Identical time course experiments were repeated on two other occasions, and 
in these cases the observed decrease in ATP hydrolysis rate was 2.2- and 2.5-fold. 
Therefore, on average, the PRP2-dnl mutation conferred a 2.5-fold reduction in ATP 
hydrolysis. 
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FIGURE 7.9 ATPase Activity of PRP2 and PRP2" 
Time course of ATPase activity. 60 nanograrns of enzyme was incubated in the 
presence (+) or absence (-) of poly-U RNA in 20d reaction mixes (5/LI poly-U RNA, 
1mM ATP), at 25°C for increasing times. The release of Pi from ['y- 32P]ATP was 
measured. 



















7.3.3 Purification and Preliminary Analysis of PRP2. 
For the prototype helicase eIF-4A, alteration of the SAT residues to encode 
AAA caused complete abrogation of RNA unwinding activity, however ATPase 
activity was increased 2.4-fold (Pause and Sonenberg, 1992). It would be intriguing 
therefore, to determine the effects of these amino acid substitutions on the behaviour 
of the putative RNA helicase PRP2. By analogy, it was hypothesised that the 
corresponding amino acid substitutions in PRP2 may induce a similar phenotype ie, 
unlike PRP2dII,  the dominant inhibitory behaviour of PRP2 might not be 
accompanied by a decrease in ATPase activity (but perhaps by an increase). This 
would provide evidence to suggest that the dominant phenotype exhibited by the PRP2 
SAT mutants was not simply due to a reduction in ATP hydrolysis rate, but was due 
to a defect in another activity that was linked to ATP hydrolysis; observed changes 
in ATPase activity being a secondary effect. The most obvious candidate for this ATP 
hydrolysis-linked activity is RNA unwinding. 
A mutant form of PRP2 encoding AAA at the SAT domain was generated 
(described in chapter 5), and two attempts were made to purify the protein from the 
strain S150-2B. Unfortunately, on both occasions, PRP2 protein was unstable 
throughout the purification procedure, being extremely prone to degradation (even in 
the presence of a cocktail of protease inhibitors; not shown). Consequently, in each 
case, the purification yield was approximately 15% that of WT protein causing 
problems for accurate quantification and allowing only a small number of assays to 
be carried out. It is likely that this reflects the temperature-sensitivity of the protein; 
PRP21 was shown to be cold-sensitive in vivo, and active at 36 1C (Chapter 5). 
Interestingly, the properties of PRP2 that hindered the purification procedure were 
reminiscent of those of the heat-sensitive protein prp2-1. 
Consistent with the instability of PRP2 protein in vitro, ATPase activity of 
the protein varied between batches. ATPase activity of the first batch made was 
similar to that of WT PRP2 (measured at 23 °C for 30 minutes). Unfortunately 
however, this was not reproducible; the activity of the second batch was drastically 
impaired; ATP hydrolysis increased only two-fold after incubation for 1 hour in the 
presence of poly-U RNA (data not shown). 
Because of the importance of this experiment, and the exciting preliminary 
result suggesting that PRP21 does indeed retain the ability to hydrolyse ATP, this 
work is being continued by M.McGarvey. It is possible that stability of the protein 
could be improved by increasing the temperature at which the cells are induced to 
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overproduce PRP2. This has only been carried out at the non-permissive 
temperature 23 1C; 30°C or 34°C might be more suitable. Running purification 
columns at room temperature rather than 4 °C might also improve stability and yield. 
Using the first, active, batch of purified PRP2 protein prepared, Margaret 
McGarvey carried out in vitro experiments to determine the nature of the temperature-
dependent inhibitory effect on splicing. The functional activity of PRP2 at various 
temperatures was probed by assaying complementation of ATP-depleted prp2i 
spliceosomes prepared in heat-inactivated pip2-1 extracts. Purified PRP2 mimicked 
the temperature-sensitive behaviour observed in vivo; at 18°C PRP2 was incapable 
of complementing the pip2-1 defect (WT PRP2 showed strong complementation at 
180C), however weak complementation was observed at 23 1C, and at 30°C 
complementation activity was similar to that of WT PRP2. By conducting 
immunoprecipitations from mutant reactions using anti-PRP2 antibodies, Margaret 
also demonstrated that PRP2 protein has a strong interaction with splicing 
complexes, and analysis of the complexes by native gel electrophoresis showed that 
spliceosome assembly was stalled prior to the formation of the active spliceosome; 
complex I of Pikielny et al. accumulated. Thus the mechanism for dominance 
exhibited in a temperature-dependent manner by PRP2 was shown to be the same 
as that displayed by PRP2(hI. 
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7.4 DISCUSSION. 
In order to assess the biochemical/enzymatic defect(s) caused by the PRP2 
SAT to LAT substitution, it was necessary to obtain purified WT and mutant forms 
of the PRP2 protein. A simple 2-step purification strategy was developed in which 
polyhistidine-tagged PRP2 protein, overproduced in yeast, was affinity-purified using 
a nickel-chelating column. This permitted an enormous 150-fold purification in a 
single step, and a further 10-fold purification, to near homogeneity, was achieved by 
subsequent passage over a poly-U RNA agarose column. Using this highly 
reproducible system, PRP2d1  and WT PRP2 proteins were purified with similar 
efficiency; the S378L mutation had no apparent effect on the stability of the protein 
during purification. In contrast, the cold-sensitive dominant negative protein PRP2 
was highly susceptible to degradation throughout both steps of the purification 
procedure, mimicking the behaviour of the heat-sensitive prp2-1 mutant protein. 
Purified PP2'' and WT PRP2' retained their respective biochemical 
activities, as assessed by in vitro splicing inhibition and complementation assays. 
Addition of to WT extracts inhibited splicing and caused the accumulation 
of inactive spliceosomes (complex I according to Pikielny et al., 1986), and the 
activity of heat-inactivated pip2-1 extracts was restored upon addition of WT PRP2. 
This indicated that the polyhistidine tag had no effect on protein activity and thus its 
removal by factor Xa cleavage was unnecessary. 
Considering that the SAT motif has been shown to be critical for the RNA 
unwinding in the prototype helicase eIF-4A (Pause and Sonenberg, 1992), it might 
be predicted that the dominant phenotype of PRP2' is the result of a defect in RNA 
helicase activity. Unfortunately, the development of an assay to test this prediction 
is not a straightforward task. Attempts to demonstrate RNA unwinding activity for 
both PRP2 and PRP16 DEAH proteins have failed (Kim et al., B.Schwer pers. 
comm.). There are two possible explanations for this: (i) DEAH proteins are not 
classical RNA helicases, but perhaps utilise energy derived from ATP hydrolysis for 
an activity that is mechanistically distinct from that exhibited by DEAD protein 
helicases, (ii) DEAH proteins are RNA helicases, however they display stringent 
substrate specificity, acting only on RNA helices with a particular secondary structure 
or sequence, or they require trans-acting auxiliary factors which were not provided 
during assays. There are several lines of evidence in favour of the latter explanation. 
Stringent substrate specificity for helicase activity is not unusual; the well studied 
ATP-dependent DNA helicase priA unwinds a particular DNA hairpin (Matson et al., 
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1990) and stringent substrate specificity has also been noted for the DNA helicase 
RecG (Lloyd and Sharples, 1993). Significantly, the E.coli protein, DbpA, displays 
ATPase activity only in presence of bacterial 23s rRNA (Fuller-Pace and Lane, Pers. 
comm.),In addition, a trans-acting auxiliary factor eIF-4B is required for helicase 
activity of eIF-4A (Rozen et al., 1990). Significantly, RNA helicase activity has been 
demonstrated for the CI protein of the Plumpox potyvirus, a member of the DEXH 
family, whose helicase-like motifs are less well conserved than those of the DEAH 
proteins (Lain et al., 1990). 
In the absence of an RNA unwinding assay, the effect of the PRP2 S378L 
substitution on RNA-dependent ATPase activity was assessed. The mutant displayed 
a partial (2.5-fold) decrease in RNA-dependent ATP hydrolysis rate. It seems unlikely 
that this decrease simply reflects a reduction in RNA binding as PRP2(bI  bound to 
poly-U RNA during the purification, and was eluted from the column with 250mM 
KC1, exactly as for WT PRP2. Although a decrease in ATP binding cannot be ruled 
out, the fact that alteration of the SAT residues of eIF-4A to AAA increased ATP 
binding (Pause and Sonenberg, 1992) suggests that the interaction of ATP at the ATP 
binding domain is not inhibited by mutations within this motif. Thus it is more likely 
that the change in hydrolysis rate is due either to an intrinsic defect in ATP 
hydrolysis itself, or is an indirect result of a fault in the coupled RNA-stimulation of 
ATP hydrolysis. 
Is the modest 2.5-fold decrease in ATP hydrolysis solely responsible for the 
dominant negative effect of PRP2(hI  on splicing, or is another activity of PRP2, 
perhaps one which is coupled to ATP hydrolysis, also affected? Work presented in 
previous chapters has demonstrated that the dominant antagonistic phenotype of 
PRP2" is based on its hindered release from spliceosomes. For PRP16, which shares 
many biochemical characteristics of PRP2, it has been demonstrated that ATP 
hydrolysis is linked to its release from spliceosomes. The mutant prpl6-1 protein 
showed a more substantial, 10-fold decrease in ATP hydrolysis rate and was not 
released from splicing complexes (Schwer and Guthrie, 1992a). In contrast however, 
the PRP2(hI  protein is able to hydrolyse ATP, but at a 2.5-fold reduced rate. That 
some amino acid substitutions at the PRP2 SAT motif were tolerated (see chapter 5) 
implies that the SAT motif does not play a central role in catalysis, but has a more 
subtle/flexible function. This is consistent with the fact that changes at the SAT 
domain of eIF-4A uncoupled ATP hydrolysis from the RNA unwinding activity, 
(unwinding was abrogated but ATP hydrolysis was increased; Pause and Sonenberg, 
1992), suggesting that these residues are involved in the transmission of energy 
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derived from ATP hydrolysis to drive the unwinding event. Therefore it is likely that 
the reduction in ATP hydrolysis caused by the PRP2-dnl mutation is in fact a 
secondary effect of a primary defect in a coupled activity; possibly RNA unwinding. 
The results are consistent with a scenario in which PRP2dII  enters the 
spliceosome, and interacts with its target RNA but is unable to accomplish an 
unwinding event. In 2 ATP is hydrolysed at a slightly reduced rate. 
This inhibits a conformational change required for, or accompanied by, step 1 of the 
splicing reaction, and release of PRP2(hI  from the inactive complex is curbed. In 
order to demonstrate that reduced ATP hydrolysis alone was not the primary cause 
of dominance, a mutant, predicted to hydrolyse ATP with increased or WT 
efficiency, but to be defective in an activity that is normally coupled to ATP 
hydrolysis was generated; PRP2. This mutant is equivalent to that made by Pause 
and Sonenberg for eIF-4A. The elF-4A mutant showed increased ATP hydrolysis, but 
was defective in RNA unwinding. PRP21 caused a dominant negative phenotype 
when overexpressed at or below 23 °C (see chapter 5), and M.McGarvey (this lab.) 
demonstrated that the mechanism for dominance was the same as that for PRP2'; 
retarded release from complexes. Thus, if PRP2 mimicked eIF-4A with respect 
to ATP hydrolysis ie. showed an increase or even retained a WT level of hydrolysis, 
it would indicate that the retarded release of PRP2' from complexes is not primarily 
due to the 2.5-fold decrease in hydrolysis, but due to abrogation of the activity which 
is driven by ATP hydrolysis. Unfortunately, PRP2 protein was unstable during 
purification, and the ATPase activity of purified PRP2 1 protein varied from batch 
to batch thus, no definitive conclusion could be made. The hunt for a stable dominant 
negative PRP2 mutant which retains the ability to hydrolyse ATP continues. 
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Overview and Future Work. 
The ability to couple classical and molecular genetics with biochemical 
approaches in the yeast S. cerevisiae has been invaluable for the rapid progress in our 
understanding of the complex process of pre-mRNA splicing. This thesis documents 
the application of such a combination of techniques to investigate the interactions of 
the putative RNA helicase PRP2 with splicing complexes. Although the ultimate aim 
was to obtain a genetic tool to identify novel splicing factors with which PRP2 
interacts, an important "spin off" of this work, which involved the use of random 
mutagenesis, has been a structure/function study of this member of the rapidly 
growing putative RNA helicase family. Due to the transient nature of the association 
of PRP2 with complexes, (hindering purely biochemical methods), PRP2 mutants 
which are not released from spliceosomes were sought, as these would facilitate the 
use of either genetics or biochemistry to probe this stabilised interaction. Such a 
defect might manifest itself in the form of a dominant inhibitory phenotype; 
overproduction of an inactive form of PRP2 which is not released from complexes, 
would block the entry of WT PRP2 leading to a defect in pre-mRNA splicing. In 
order to obtain such a mutant, a pool of randomly generated PRP2 mutants were 
screened for the ability to inhibit cell growth when overexpressed from an inducible 
promoter. Three putative dominant negative mutants were obtained and subjected to 
further analysis. 
As expected, overproduction of the three mutant forms of PRP2 protein caused 
an in vivo splicing defect resulting in cell growth inhibition. Sequence analysis 
revealed that all three mutants possessed the same single point mutation causing a 
serine to leucine substitution at the highly conserved helicase motif SAT. This was 
particularly exciting as the SAT motif is critical for RNA unwinding in the helicase 
prototype eIF-4A, and this is the first time that the functional importance of these 
same residues in any other member of the DEAD/H family has been demonstrated. 
In order to investigate the cause of the dominant negative effect of the serine to 
leucine substitution (S378L), site-directed mutagenesis was used to assess the outcome 
of other amino acid substitutions at the PRP2 SAT motif. It was established that the 
mutant phenotype caused by S378L was not simply due to the loss of a hydroxyl 
group, or an increase in the size of the residue at this site, or the change from a 
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hydrophilic to a hydrophobic side chain. The effect was more complex; a result of 
a combination of these molecular changes. Surprisingly, several amino acid 
substitutions were tolerated. Mutants encoding SAA or AAT at the SAT domain were 
partially active in vivo. At first sight this suggested that the motif might function with 
only one of the hydroxyl-containing groups, however, a mutant encoding AAA was 
also shown to be partially functional at 36 °C. Interestingly, at lower temperatures 
(23°C and below), this mutant, PRP2, was dominant when overproduced, possibly 
due to hyperstabilisation of complexes at low temperatures. 
Biochemical analysis of yeast splicing extracts prepared from strains induced 
to overproduce the original mutant protein, PRP2 1' (possessing LAT), revealed the 
molecular mechanism for the dominant inhibitory effect on splicing. As predicted, 
PRP2' was shown to compete with its WT counterpart for entry into spliceosomes, 
and was subsequently retained, its overproduction causing the accumulation of 
inactive splicing complexes. Therefore the genetic tool "designed" to facilitate the 
isolation of spliceosomal components with which PRP2 interacts was indeed obtained. 
This system is ideal for the identification of anticipated interactions between PRP2dl 
and one or more of the spliceosomal RNA species, as these are likely to be stabilised 
in stalled spliceosomes. The direct technique of UV crosslinking could be employed 
for this purpose. In addition, the dominant negative mutant can be used as the basis 
for suppressor analyses in order to identify other, perhaps novel, splicing factors 
which genetically interact with PRP2(hI. 
The predicted RNA interactions of PRP2 may involve the pre-mRNA, and/or 
one or more of the spliceosomal snRNAs. PRP2'':pre-mRNA interactions could be 
identified through UV irradiation of stalled complexes containing labelled pre-mRNA 
followed by immunoprecipitation using anti-PRP2 antibodies. The histidine-tagged 
version of PRP2d  could be employed to aid isolation of snRNA molecules 
crosslinked to PRP2'", by passage of UV-irradiated stalled complexes over a nickel-
chelating column. Identification of these unlabelled snRNA molecules could be 
achieved through the use of biotinylated anti-sense oligoribonucleotide probes 
complementary to regions of various snRNAs, and use of a sensitive bioluminescence 
detection strategy utilising streptavidin coupled to horseradish peroxidase. 
The technique of isolating high copy suppressors of conditional dominant 
negative mutants has been used with great success in other systems (for example, 
Powers et al., 1991; Leberer et al., 1992), and is therefore an obvious approach for 
the application of the PRP2-dnl mutant. The theory behind this method is that 
overproduction of factors which bind PRP2, might titrate out toxic PRP2(hI  protein. 
165 
One disadvantage is that certain overproduced PRP2 ligands may not be identified if 
they also sequester, and prevent the activity of, WT PRP2. The method is however 
likely to isolate factors that interact more strongly with dominant negative PRP2 
protein than the WT form. 
An alternative approach is to screen for cold- or heat-sensitive genomic 
suppressor mutations that may for example affect spliceosomal factors that interact 
with PRP2, reducing the affinity of PRP2' with complexes. Dominant suppressors 
might also be sought through the use of a diploid strain induced to overproduce 
PRP2'. This would obviate the requirement for an additional phenotype such as 
temperature-sensitivity, as the dominant suppressor could be cloned by making a 
genomic DNA library from the suppressor strain which could then be screened in a 
haploid induced to overproduce PRP21 . 
Currently, a central question in the field of nuclear pre-mRNA splicing is, do 
the helicase-like splicing factors, (PRP2, PRP5, PRP16, PRP22 and PRP28) act to 
unwind double stranded helices? Unwinding activity in vitro has not yet been 
demonstrated, however the biochemical analysis of mutants such as those isolated in 
this study may shed light on this issue. The effect of the PRP2 S378L substitution on 
its RNA-dependent ATPase activity was assessed using purified PRP2 and PRP2" 
protins obtained through the development of a simple two-step purification procedure. 
The mutant showed a 2.5-fold reduction in ATP hydrolysis rate. As substitutions at 
the SAT motif of the prototype helicase eIF-4A abolished RNA unwinding activity 
(Pause and Sonenberg, 1992) then by analogy, the primary defect of PRP2dI  might 
not be the observed reduction in ATP hydrolysis rate, but a defect in an activity 
which is coupled to ATP hydrolysis, presumed to be RNA unwinding. 
The prediction that PRP2" will be defective in its ability to unwind RNA 
helices should be testable through the development of an RNA helicase assay which, 
for the DEAH proteins, has so far failed. Using the simple purification strategy as 
a source of enzyme, trans-acting factors which may be required for the unwinding 
event could be sought through biochemical fractionation and complementation 
procedures. The problem of stringent RNA substrate specificity might be overcome 
by challenging the putative helicase with a wide range of RNA helices for example 
certain snRNA:snRNA and snRNA:pre-mRNA duplexes. Clues as to the natural 
substrate for PRP2 helicase activity might be obtained by simply screening a range 
of RNA substrates for those that give increased stimulation of ATP hydrolysis. In 
parallel, substrates that increase the ATP hydrolysis rate of PRP2' to WT levels 
might be revealed, demonstrating that indeed, the dominant negative defect is not 
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simply a direct result of lowered ATP hydrolysis rate. 
The dramatic effect of PRP2d?I  protein on complex formation during in vitro 
splicing provides a novel method for probing other systems for the existence of PRP2 
homologues. A presumptive PRP2 homologue has been isolated from Hela extracts 
(Kramer et al., 1987; Utans and Kramer, 1990), therefore to assess the extent of 
mechanistic similarity between yeast and mammalian PRP2 equivalents, the effects 
of PRP2(hI  protein on spliceosome formation in Hela extracts could be monitored. 
In summary, this study has provided the means to identify splicing factors that 
interact with PRP2. The development of a system for the purification of mutant and 
WT forms of PRP2 protein provides the opportunity to study the biochemical 
properties of this presumptive RNA helicase. This will further our understanding of 
its role in splicing. Such information might also be extended to other members of the 
putative helicase family. 
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